Australian Government
Australian Institute of Health and Welfare

Alcohol and other drug treatment services in Australia annual report

Web report | Last updated: **14 Jun 2024** | Topic: Alcohol & other drug treatment services

About

In 2022–23, around 131,500 people aged 10 and over received treatment from alcohol and other drug treatment services. The 4 most common drugs that led clients to seek treatment were alcohol (43% of episodes), amphetamines (24%), cannabis (17%) and heroin (4.5%). The median age of all clients was 36 years.

This report has been updated with financial year data for 2022–23 and is updated on an annual basis.

Cat. no: HSE 250

- State and territory summaries
- Data

Findings from this report:

- Treatment agencies provided around 235,500 treatment episodes to an estimated 131,500 people aged 10 and over
- 3 in 5 people who received treatment were male (60%) and half (50%) were aged 20–39
- Of the 235,500 AOD treatment episodes provided, counselling was the most common treatment (34%)
- Alcohol remains the most common principal drug of concern for which clients received treatment

Related reports

Explore featured data

Clients

People may receive treatment for their own or someone else's alcohol or drug use (see Key terminology and glossary). Characteristics of all clients are described below, including clients' principal drugs of concern by age group and new and returning clients in the current collection year.

The Alcohol and Other Drug Treatment Services (AODTS) collection captures information on treatment services clients received. It does not measure the underlying need for treatment or level of alcohol or drug use in the community. Changes in client numbers over time may be due to clients' access to treatment, treatment availability, differences in counting methodologies, and/or funding available for alcohol and other drug treatment services.

Key findings

In 2022–23:

- Around 131,500 people aged 10 and over received treatment for their own or someone else's alcohol or drug use from publicly funded alcohol and other drug (AOD) treatment services. This equates to 568 clients per 100,000 people.
- Around 235,500 treatment episodes were provided to clients.
- An average of 1.7 treatment episodes were provided to people receiving treatment for their own alcohol or drug use.
- 6 in 10 people receiving treatment were male (60%), and half (50%) were aged 20–39.
- One in 6 (18%) people aged 10 and over identified as Aboriginal and Torres Strait Islander (First Nations) people.
- Of the clients receiving treatment in 2022–23, 54% previously received AOD treatment from a service at some point since 2013–14.

In the 10 years to 2022–23:

- There has been a 15% increase in client numbers since 2013–14, from around 114,400 to 131,500 in 2022–23.
- Adjusting for population growth, this equates to a modest increase in the rate of service use over this period from 564 to 568 clients per 100,000 people.

Characteristics of clients

The number of people treated by publicly funded alcohol and other drug treatment agencies increased by 15% in the last 10 years, from 114,436 in 2013–14 to 131,516 in 2022–23.

When taking population growth into consideration, the rate of people receiving services over the past decade has fluctuated, rising from 564 clients per 100,000 people in 2013–14 to peak at 623 in 2018–19 and 2019–20 before falling to 568 clients in 2022–23.

Of the clients receiving treatment in 2022–23:

- 54% had previously received treatment at least once since 2013–14 when client reporting was enabled
- 46% had not previously received treatment since 2013–14.

In 2022–23:

- 125,948 people received treatment for their own alcohol or drug use and 11,072 received treatment in relation to someone else's alcohol or drug use.
- Around 1 in 20 (4.9% or 6,561) clients received treatment for their own as well as someone else's alcohol or drug use (Table SCR.27).

Figure CLIENTS 1: AODTS clients and treatment episodes, by state and territory, 2013–14 to 2022–23

The line chart shows that there were 568 clients per 100,000 population in Australia in 2022–23, decreasing from 576 clients per 100,000 population in 2021-22. Across the period 2013–14 to 2022–23, the rate of clients was highest in the Northern Territory (1,424 per 100,000 in 2022–23) and lowest in New South Wales (384 per 100,000 in 2022–23). A filter allows the user to view by rate of clients, number of clients or number of treatment episodes.



Figure CLIENTS 1: AODTS clients and treatment episodes, by state and territory, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SCR.21.
http://www.aihw.gov.au

See notes >

Client profile

In 2022–23:

- Most people (94% or 123, 744 clients) received treatment for their own alcohol or drug use. These clients were more likely to be male (61% or 75,267).
- In contrast, of the 5.9% of people (or 7,772 clients) who received treatment for someone else's alcohol or drug use, close to half were female (47% or 3,631 clients) (12% or 968 reported not stated for sex) (tables SC.1–2).
- The rate of all clients receiving AOD services was highest for those that lived in *Very remote* areas (1,412 per 100,000 people) and lowest for those in *Major cities* (487 per 100,000, Table SCR.29).
- Almost 4 in 5 (79% or 104, 452 clients) received treatment at a single agency, 14% (18,345) attended 2 agencies, and 6.6% (8,719) of clients received treatment at 3 or more agencies (Table SCR.23).

See Key terminology and glossary for further information on how clients are counted in this report.

Age and sex

Clients who received treatment for their own alcohol or drug use tended to be younger than those who received treatment for someone else's alcohol or drug use.

In 2022–23, client characteristics revealed:

- The majority of all clients were male (60% or 78,392 clients) and half (50% or 66,106 clients) of all clients were aged 20–39.
- 3 in 5 (60% or 74,376 clients) of people receiving treatment for their own alcohol or drug use were aged under 40.
- Almost 1 in 10 (9.3% or 11,541 clients) of people receiving treatment for their own alcohol or drug use were 10–19 years of age.
- People aged 60 and over accounted for 5.9% (or 7,287) of clients who received treatment for their own alcohol or drug use.
- Over half (51% or 3,929 clients) of those who received treatment for someone else's alcohol or drug use were aged under 40.
- Over 1 in 8 (12% or 916) clients who received treatment for someone else's alcohol or drug use were aged over 60 (Figure CLIENTS 2, tables SC.2-4).

Figure CLIENTS 2: Proportion of clients by client type, sex, and age group, 2013–14 to 2022–23

The butterfly bar chart shows that, among all clients, the most common age group for both male and female clients in 2022–23 was 30–39 (27.3% of males and 26.1% of females), followed by 20–29 (23.2% of males and 22.8% of females). A filter allows the user to view data for all clients, clients seeking treatment for their own drug use, or clients seeking treatment for someone else's drug use. Buttons allow the user to navigate to bar charts presenting trend data disaggregated by sex, age group and client type.



Figure CLIENTS 2: Number and proportion of clients by client type, sex, and age group, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC.2, SC.3 and SC.4.
http://www.aihw.gov.au

See notes >

Profile of new and returning clients

AOD use is often complex and clients accessing AOD treatment services may return to receive further support and treatment over one or more years to achieve their goals. In 2022–23:

- Nationally, over half (54% or 70,602) of all clients had previously received AOD treatment from a service at some point since 2013–14 when client reporting was enabled (see Key terminology and glossary). This proportion of returning clients ranged from 60% (or 2,073) in the Australian Capital Territory to 50% (or 18,145) in Queensland. Of these clients:
  - Over 3 in 5 of returning clients were male (63% or 44,511).
  - Over half (55% or 38,977) were aged 30–49.
  - Almost all received treatment for their own alcohol or drug use (95% or 67,268).
- Over 2 in 5 (46% or 60,914) clients had not previously received treatment since 2013–14 (see Key terminology and glossary) (Table SCR.28). This proportion of new clients ranged from 50% in Queensland to 40% in the Australian Capital Territory. Of these clients:
  - 3 in 5 (61% or 37,451 clients) of new clients were aged under 40, with 1 in 7 (15% or 9,111 clients) aged 10–19.
  - Over half (56% or 33,881) of new clients were male.
- Nearly 3 in 5 clients (57% or 4,458) who received treatment for someone else's alcohol or drug use were new clients (Figure CLIENTS 3, Table SCR.28).

Figure CLIENTS 3: Number and proportion of new and returning clients by sex, client type and age group, 2022–23

The pie chart shows in 2022–23, most new and returning clients were male (55.6% and 63.0% respectively) and most new and returning clients sought treatment for their own drug use (92.7% and 95.3% respectively). The bar chart displays in 2022–23, the most common age groups for new clients were 20–29 (23.5%) followed by 30–39 (23.0%). The most common age groups for returning clients

were 30–39 (30.7%) followed by 40–49 (24.5%). A filter allows users to toggle between measures of per cent and number of clients.



Figure CLIENTS 3: Number and proportion of new and returning clients by sex, client type and age group, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SCR.28.
http://www.aihw.gov.au

See notes >

Clients and drugs of concern

AOD treatment services provide treatment for the drug that is of most concern to the client, which is referred to as their principal drug of concern.

Different age groups received treatment for different principal drugs of concern. For people who received treatment for their own alcohol or drug use in 2022–23:

- Alcohol was the most common principal drug of concern in the older age groups: just under two-thirds of people aged 50–59 (63%) and over three-quarters of people aged 60 and over (77%) received treatment for alcohol as a principal drug of concern.
- Amphetamines were the most common principal drug of concern for those aged 30–39 and 40–49 (32% and 25%, respectively).
- Cannabis was the most common principal drug of concern in younger clients, for almost 2 in 3 people aged 10–19 (64%), 1 in 3 people aged 20–29 (30%), and 13% of people aged 30–39.

Figure CLIENTS 4: Clients who received treatment for their own drug use, by age group and principal drug of concern, 2013–14 to 2022–23

The stacked horizontal bar chart shows that the most common principal drug of concern (PDOC) differed with age in 2022–23. Cannabis was the most common PDOC for clients aged 10–19 (64.4% of clients) or 20–29 (29.9%). Amphetamines was the most common PDOC for clients aged 30–39 (32.3%), and alcohol was the most common principal drug of concern among clients aged 40–49 (48.2% of clients), 50–59 (62.5%) or 60+ (76.6%). A filter allows the user to view different years of data.



Figure CLIENTS 4: Clients who received treatment for their own drug use, by age group and principal drug of concern, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SC.10.
http://www.aihw.gov.au

See notes >

The age and sex profiles of the clients varied by principal drug of concern. For people who received treatment for their own alcohol or drug use in 2022–23 (123,744):

- For clients who received treatment where heroin (5,573) was the principal drug of concern, the majority (83%) were aged 30 and over (32% were aged 30–39 and 33% were aged 40–49) (Table SC.10).
- Over half (56%) of all people receiving treatment for codeine (247) as the principal drug of concern were female.
- For clients who received treatment for cocaine (1,564) as a principal drug of concern, males were nearly 6 times (83%) more likely to receive treatment for cocaine than females (12%) (Table SC.9).
- Nearly 7 in 10 (68%) clients receiving treatment for volatile solvents (226) as a principal drug of concern were Aboriginal and Torres Strait Islander (First Nations) people (Table SC.11).

Usual accommodation type for client

The collection of information about a person's usual type of accommodation where they lived prior to the start of their AOD treatment enables AOD services to identify people who may be vulnerable, such as those from custodial settings or people at risk of homelessness. This information may help identify people living in a public place or experiencing homelessness, supporting the 'no exit to homelessness' policy where agencies can only discharge a client to safe, stable housing (Department of Social Services 2020).

Usual accommodation type for the client prior to treatment is reported for selected jurisdictions: New South Wales, Queensland, Western Australia, South Australia, Australian Capital Territory and the Northern Territory. As data quality improves additional jurisdictional data will be reported. The following analysis therefore includes 59% of all treatment episodes (139,037) nationally (Figure CLIENTS 5, Table OV.13).

In 2022–23, treatment episodes reporting the usual accommodation type for AOD clients from selected states and territories revealed:

- The most common accommodation prior to the start of treatment was independent residential accommodation (e.g., private residence, boarding house, private hotel or informal housing) which ranged from 45% in the Northern Territory to 90% in Western Australia.

- The Northern Territory reported the highest proportion of episodes with usual accommodation types as custodial (prison/remand centre/youth training centre) (21%) and supported independent living (18%).
- South Australia reported the highest proportion of episodes with usual accommodation types as none/homeless/public place (10%) (Figure CLIENTS 5, Table OV.13).

Figure CLIENTS 5: Treatment episodes by client's accommodation type prior to treatment service, selected states and territories, 2017–18 to 2022–23

The stacked horizontal bar chart shows client accommodation type prior to treatment service for New South Wales, Queensland, Western Australia, South Australia and the Northern Territory in 2022–23. Independent residential accommodation was the most common accommodation type prior to treatment service across all included states/territories, ranging from 45.2% of clients in the Northern Territory to 89.6% in Western Australia. A filter allows the user to view different years of data.



Figure CLIENTS 5: Treatment episodes by client's accommodation type prior to treatment service, selected states and territories, 2017–18 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment National Minimum Data Set. Table OV.13.
http://www.aihw.gov.au

See notes >

References

DSS (Department of Social Services) 2020. National Housing and Homelessness Agreement - external site opens in new window. Canberra: DSS. Viewed 1 July 2020.

Aboriginal and Torres Strait Islander (First Nations) people

In 2022–23, Aboriginal and Torres Strait Islander (First Nations) people accounted for 18% (23,928) of people aged 10 and over who received treatment or support for their own or someone else's alcohol or drug use (Table SCR.26).

Nationally, the rate of First Nations people who received treatment remains high:

- The rate of First Nations people who received treatment for alcohol or drug use has increased over time, from 2,829 per 100,000 people in 2013–14 to 3,373 in 2022–23 (crude rate for clients aged 10 and over).
- In 2022–23, First Nations people were more than 6 times as likely to receive treatment for alcohol or drug use as non-Indigenous Australians after adjusting for differences in age structure (3,370 per 100,000 people compared with 496 per 100,000, age standardised rates for clients aged 10 and over) (Figure FIRST NATIONS 1, Table SCR.26).

Figure FIRST NATIONS 1: Estimated number and rate of clients, by Indigenous status, 2013–14 to 2022–23

The line graph shows that between 2013–14 to 2022–23, the age-standardised rate of clients was consistently higher for First Nations people than non-Indigenous Australians. In 2022–23, the age-standardised rate of clients was 3,370 per 100,000 population for First Nations people, compared with 496 per 100,000 for non-Indigenous Australians. A filter allows the user to view data for age-standardised rate, crude rate or number of clients.



Figure FIRST NATIONS 1: Estimated number and rate of clients, by Indigenous status, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SCR.26.
http://www.aihw.gov.au

See notes >

Client profile

In 2022–23, among First Nations clients aged 10 and over:

- Close to 1 in 5 (18% or 22,371) received treatment for their own alcohol or drug use.
- Around 1 in 10 (11% or 887) received treatment for someone else's alcohol or drug use.

- Around 3 in 5 (59%) were male and close to 2 in 5 (38%) were female.
- 7 in 10 (70%) were aged 10 to 39 years.
- Indigenous status was not reported for 2.8% (3,675) of clients (Figure First Nations 2, tables SC.5–SC.8).

Figure FIRST NATIONS 2: Proportion of First Nations clients by Indigenous status, sex and age group (10 years and over), 2022–23

The butterfly bar chart shows that the most common age group for both male and female First Nations clients in 2022–23 was 30–39 (29.0% of males and 30.1% of females), followed by 20–29 (28.6% of males and 28.0% of females). Buttons allow the user to navigate to a stacked bar chart presenting trend data disaggregated by Indigenous status and client type.



Figure FIRST NATIONS 2: Proportion of First Nations clients by Indigenous status, sex, age group (10 years and over) and client type, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SC.8 and SC.5.
http://www.aihw.gov.au

See notes >

Profile of new and returning First Nations clients

AOD use is often complex and clients accessing AOD treatment services may return to receive further support and treatment over one or more years to achieve their goals. In 2022–23:

- 3 in 5 (60% or 13,968) of First Nations people had previously received alcohol and other drug treatment from a service at some point since 2013–14 when client reporting was enabled.
- Around 2 in 5 (40% or 9,327) of First Nations people were new clients, who had not previously received treatment since 2013–14 (Table SCR.28) (see Key terminology and glossary).

Principal drug of concern

The main principal drugs of concern that First Nations people received treatment for were alcohol (37% of clients), amphetamines (25%), cannabis (23%), and heroin (5.2%) (Figure FIRST NATIONS 3, Table SC.11).

National trends in the main drugs of concern have changed over time:

- The crude rate of First Nations people who received treatment for alcohol has fluctuated but has risen steadily from 1,072 per 100,000 people in 2015–16 to 1,270 in 2022–23.
- The rate of First Nations people who received treatment for amphetamines more than doubled, from 399 per 100,000 people in 2013–14 to 909 per 100,000 people in 2022–23, after peaking in 2019–20 at 1,054 (Table SCR.26).

In 2022–23, after adjusting for differences in age-structure, First Nations people were:

- Nine times as likely to receive treatment for heroin (age standardised rate ratio) as non-Indigenous Australians (214 per 100,000 compared with 23 per 100,000).
- Seven and 8 times as likely to receive treatment for alcohol or amphetamines (respectively) as non-Indigenous Australians.
- Seven times as likely to receive treatment for cannabis as non-Indigenous Australians (702 per 100,000 compared with 102 per 100,000) (Figure FIRST NATIONS 3, Table SCR.26).

Figure FIRST NATIONS 3: Proportion and rate of First Nations AODTS clients, by Indigenous status and principal drug of concern, 2013–14 to 2022–23

The visualisation includes 2 charts. The top chart is a stacked horizontal bar chart that shows the most common principal drug of concern among First Nations clients in 2022–23 was alcohol (36.8%), followed by amphetamines (24.7%). The bottom chart is a line chart that shows that alcohol has remained the most common principal drug of concern among First Nations clients across the period 2013–14 to 2022–23. Two filters for the bottom chart allow the user to view data for First Nations people or non-Indigenous Australian clients and as a crude or age-standardised rate.



Figure FIRST NATIONS 3: Proportion and rate of First Nations AODTS clients, by Indigenous status and principal drug of concern, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC.11 and SCR.26.
http://www.aihw.gov.au

See notes >

Main treatment

For the 22,371 First Nations people who received treatment for their own alcohol or drug use, counselling was the most common main treatment type (38% of clients), followed by assessment only (26%). Similarly, for First Nations people who received treatment for another person's alcohol or drug use (887), counselling was the most common treatment type (41%), followed by support and case management (39%, Table SC.20). Clients can also receive one or more treatment episodes within the reference year.

The referral into treatment and the setting for treatment varied by treatment type for First Nations clients:

- Most referrals for First Nations clients into treatment were from a family member or a self-referral (32%).
- Over one-quarter (27%) of all referrals for First Nations clients into treatment were from a health service.
- First Nations clients who received either withdrawal management (54%) or pharmacotherapy (62%) as a treatment type were most likely to be referred by a family member or a self-referral.
- The majority of First Nations clients received counselling (87%) or pharmacotherapy (95%) in a non-residential setting.

- Nearly 4 in 5 (79%) of First Nations clients received rehabilitation and 3 in 4 (74%) received withdrawal management in residential settings (Figure FIRST NATIONS 4 and FIRST NATIONS 5, tables SC.21 and SC.22).

Figure FIRST NATIONS 4: Proportion of First Nations AODTS clients, by Indigenous status, main treatment type and referral source for all clients, 2022–23

The stacked horizontal bar chart shows that the 2 most common sources of referral for First Nations AODTS clients were self/family and health service. This was consistent across all main treatment types. The proportion of clients who were referred via self/family ranged from 20.9% of clients receiving information and education as the main treatment type to 61.7% for clients receiving pharmacotherapy. The proportion of clients who were referred via a health service ranged from 17.8% for clients receiving pharmacotherapy to 49.1% for clients receiving information and education.



Figure FIRST NATIONS 4: Proportion of First Nations AODTS clients, by Indigenous status, main treatment type and referral source for all clients, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SC.21.
http://www.aihw.gov.au

See notes >

Figure FIRST NATIONS 5: Proportion of First Nations AODTS clients, by Indigenous status, main treatment type and delivery setting for all clients, 2022–23

The stacked horizontal bar chart shows that non-residential treatment settings were the most common delivery setting among First Nations clients receiving counselling, support and case management, assessment only, pharmacotherapy, information and education, or 'Other' as the main treatment type in 2022–23 (ranging from 45.8% to 94.9% of clients). Residential treatment settings were the most common delivery setting for clients receiving withdrawal management or rehabilitation (73.9% and 79.3% of clients, respectively).



Figure FIRST NATIONS 5: Proportion of First Nations AODTS clients, by Indigenous status, main treatment type and delivery setting for all clients, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SC.22.
http://www.aihw.gov.au

See notes >

Australian Government-funded First Nations AOD reporting

The Australian Government funds primary healthcare services and substance use services specifically for First Nations people. These services may be in scope for the AODTS NMDS, but the majority of the services currently do not report to the NMDS. Substance use services previously reported via the First Nations Online Services Report (OSR) data collection up to 2017–18 (AIHW 2024). The substance use services program was transferred to the Indigenous Affairs Group within the Department of Prime Minister and Cabinet in September 2013 and then to the National Indigenous Australians Agency in July 2019 (Australian National Audit Office 2017, National Indigenous Australians Agency 2024). Since the cessation of substance use services data being collected by the OSR, the number of substances use services for First Nations people in-scope and reporting to the AODTS NMDS has gradually increased.

The National Agreement on Closing the Gap - external site opens in new window noted that funding for Aboriginal and Torres Strait Islander (First Nations) Alcohol and Other Drugs (AOD) services and support will increase by up to $66 million to 2024–25, in addition to current funding. First Nations' AOD Treatment Services funded under the Indigenous Advancement Strategy (IAS) currently assists more than 65 providers to deliver AOD activities (Department of Prime Minister and Cabinet 2024). The Commonwealth also provides AOD treatment services and prevention, research and communication activities through the Drug and Alcohol Program (DAP) and funding to Primary Health Networks (PHNs), with nearly 30% of PHN funding allocated for First Nations specific treatment services (National Indigenous Australians Agency 2022).

References

AIHW (Australian Institute of Health and Welfare) (2024). Online Services Report (OSR) for Aboriginal and Torres Strait Islander specific primary health care organisations, 2022–23: Quality Statement - external site opens in new window, AIHW METEOR Metadata Online Registry website, accessed 6 March 2024.

ANAO (Australian National Audit Office) (2017). Indigenous Advancement Strategy: Department of the Prime Minister and Cabinet - external site opens in new window, ANAO, Australian Government, accessed 6 March 2023.

Department of Prime Minister and Cabinet (2024), Funding boost for First Nations Alcohol and Other Drug treatment services - external site opens in new window, Department of Prime Minister and Cabinet website, accessed 8 April 2024.

NIAA (National Indigenous Australians Agency) (2022). Commonwealth Closing the Gap Annual Report 2022 - external site opens in new window, NIAA, Australian Government, accessed 6 March 2023.

NIAA (2024). *Our Business* - external site opens in new window, NIAA, Australian Government, accessed 6 March 2024.

Drugs of concern

People may receive alcohol and other drug (AOD) treatment services for use of one or several substances. The principal drug of concern (PDOC) is the main substance that the client stated led them to receive treatment. Clients can also nominate up to 5 additional drugs of concern, though these are not necessarily the subject of any treatment within the episode.

This section presents information on treatment episodes provided to clients for their own AOD use only. It is assumed that only the person using a substance themselves can accurately report their principal drug of concern. Therefore, these data are not collected for people who received treatment for someone else's drug use.

This section focuses on treatment episodes provided for alcohol, amphetamines, cannabis and heroin as the PDOC. These 4 drugs were consistently the most common principal drugs of concern across Australia in the 10-year period up to 2022–23. For detailed information on each drug of concern, refer to the technical notes.

Key findings

In 2022–23:

- The most common principal drug of concern was alcohol (43% or 92,000 episodes), followed by amphetamines (24%), cannabis (17%) and heroin (4.5%).
- Over 4 in 5 treatment episodes for amphetamines were for methamphetamine as the principal drug of concern (82% or 42,000 episodes).

Over the 10-year period to 2022–23:

- The top 4 principal drugs of concern have remained consistent with amphetamines replacing cannabis as the second most common principal drug of concern from 2015–16.
- Alcohol remains the most common principal drug of concern, increasing from 69,000 to 92,000 episodes over this period.
- Treatment episodes for amphetamines as the principal drug of concern almost tripled between 2013–14 and 2019–20 (29,000 to 61,000) and has subsequently declined (52,000 in 2022–23).
- Treatment episodes for heroin as a principal drug of concern fell from 7.0% to 4.5% over this period (12,000 to 9,700 episodes).

Drugs of concern and treatment provided

In 2022–23, 217,303 (or 92%) treatment episodes were provided to 123, 744 clients for their own AOD use (Table OV.1). Among these episodes:

- The most common principal drugs of concern were alcohol (43% of treatment episodes), amphetamines (24%), cannabis (17%) and heroin (4.5%) (Table Drg.1).
- Clients reported at least 1 additional drug of concern in over one quarter of treatment episodes (26%).
  - The number of additional drugs reported was most commonly 1 (17% of episodes) or 2 drugs (6.0%).
  - Cannabis (10% of episodes), nicotine (7.8%) and alcohol (6.0%) were the most common additional drugs of concern (tables Drg.1, Drg.2, Drg.3).
- For the 4 most common principal drugs of concern, the most common treatment setting was non-residential treatment facilities (ranging from 62% to 71%) (Table Drg.8).

In the 10 years to 2022–23, the total number of treatment episodes for clients' own drug use increased from 171,828 to 217,303 episodes (Table OV.1), while the number of clients receiving treatment increased from 108,449 to 123,744.

Among these episodes across the period:

- Alcohol remained the most common principal drug of concern each year, and treatment episodes increased by 33% over this period (from 69,491 to 92,417 episodes).
- The proportion of treatment episodes for alcohol in relation to all other drugs of concern fluctuated, falling from 40% in 2013–14 to 32% in 2015–16, before rising to 43% in 2022–23.

- Treatment episodes for amphetamines as a principal drug of concern almost doubled since 2013–14 (28,919 to 51,902 episodes), although this has declined since 2019–20 (60,987 episodes).
  - Over 4 in 5 (82%) episodes for amphetamines were for methamphetamine as the principal drug of concern, increasing from 25% since 2013–14 (from 7,168 to 42,380 episodes).
- Treatment episodes for heroin as the principal drug of concern fell from 7.0% to 4.5% (12,000 to 9,745 episodes).
- Treatment episodes for cannabis fluctuated, peaking at 45,043 episodes in 2015–16.
- In relation to all other drugs of concern, cannabis treatment episodes were most prominent between 2013-14 to 2014–15 when they constituted 24% of all episodes (Table Drg.5).

Fluctuations in certain principal drug treatment episodes in particular years may be due to administrative anomalies in the data. For example, the drop in all treatment episodes in the 2014–15 and 2016–17 collection years may be partly related to system changes resulting in under-reporting or partial reporting of the number of episodes in some jurisdictions (See the Data quality statement - external site opens in new window for further details).

Explore drugs of concern

- Alcohol
- Amphetamines
- Cannabis
- Heroin
- Pharmaceuticals
- Selected other drugs

Alcohol

Alcohol: client demographics and treatment

On this page:

In 2022–23, alcohol was reported as a drug of concern (either principal or additional) in almost half of all treatment episodes (49% or 105,451 episodes) (Table Drg.5).

Alcohol has remained the most common principal drug of concern (PDOC) since the beginning of the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) in 2002–03.

- Over 2 in 5 treatment episodes (43% or 92,417 episodes) were for alcohol as a principal drug of concern in 2022–23 (Table Drg.5).
- Alcohol-related treatment episodes increased from 69,491 in 2013–14, to 92,417 in 2022–23.
- The proportion of treatment episodes for alcohol in relation to all other drugs of concern fluctuated over time, falling from 40% in 2013–14 to 32% in 2015–16, before rising to 43% in 2022–23 (Table Drg.1).

In 2022–23, around 1 in 5 (21% or 19,502 episodes) alcohol-related treatment episodes reported at least one additional drug of concern (Table Drg.2).

The most common additional drugs of concern were cannabis (39% or 10,292 episodes), nicotine (27% or 7,182 episodes) and amphetamines (18% or 4,648 episodes) (Table Drg.3). Clients can nominate up to 5 additional drugs of concern: these drugs may not have been the subject of any treatment in the episode.

Figure ALCOHOL: Closed treatment episodes for own alcohol or drug use by alcohol as a principal drug of concern and top 5 additional drugs of concern, 2022–23



Note: Diagram presents the top 5 additional drugs of concern for a principal drug of concern. Totals do not add to 100%.

For information on alcohol use and harms, please see:

- Tobacco, alcohol and other drugs in Australia: Alcohol
- National Drug Strategy Household Survey 2022–2023: Alcohol consumption

Client demographics

In 2022–23, 50,106 clients received treatment for their own use of alcohol as a principal drug of concern. Of these clients:

- 3 in 5 were male (60% of clients) (Table SC.9).

- 1 in 2 were aged either 30–39 (25% of clients) or 40–49 (26%) (Table SC.10). This was consistent for both males and females (Figure ALCOHOL 1).
- One in 6 were Aboriginal and Torres Strait Islander (First Nations) people (16% of clients) (Table SC.11). This represents a crude rate of 1,270 First Nations clients per 100,000 people (crude rate) (Table SCR.26).

Figure ALCOHOL 1: Clients with alcohol as the principal drug of concern, by sex and age group, 2022–23
The butterfly bar chart shows that in 2022–23, male clients receiving treatment for alcohol as the principal drug of concern were most likely to be aged 40–49 (26.0%) or 30–39 (25.2%). This was similar for female clients (26.2% aged 40–49 and 23.8% aged 30–39).



Figure ALCOHOL 1: Clients with alcohol as the principal drug of concern, by sex and age group, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set.Tables SC.9 and SC10.
http://www.aihw.gov.au

See notes >

Treatment

In 2022–23, 92,417 treatment episodes were provided to clients for alcohol as the principal drug of concern (Table Drg.5).

Among alcohol-related treatment episodes in 2022–23:

- The most common source of referral into treatment was self or family (41% or 37,667 episodes), followed by health services (37%) (Figure ALCOHOL 2, Table Drg.13).
  - Across the 10 years to 2022–23, health service referrals increased while referral from the criminal justice system (diversion) fell.
- The most common main treatment type was counselling (33% or 30,491 episodes), followed by assessment only (23%) and withdrawal management (14%) (Figure ALCOHOL 2, Table Drg.18).
  - Counselling, withdrawal management, and assessment only remained the most common treatment types across the 10 years to 2022–23, although the proportion of episodes for each treatment type varied over time.
- 2 in 3 episodes were provided in non-residential treatment settings (66% of episodes). A further 19% were provided in residential treatment settings and 5.6% were provided in outreach settings (Table Drg.20).
- The median duration of treatment episodes was just under 4 weeks (27 days) (Table Drg.21).
- Over 1 in 3 (36%) treatment episodes lasted 2–29 days, and 26% lasted 1–3 months (Table OV.12).
- Over 3 in 5 episodes ended with a planned completion (63% of episodes), while 19% ended unexpectedly (that is, the client ceased to participate against advice, without notice or due to non-compliance) (Figure ALCOHOL 2, Table Drg.19).

Figure ALCOHOL 2: Treatment episodes with alcohol as the principal drug of concern, by main treatment type, reason for cessation or source of referral, 2013–14 to 2022–23

The line graph shows that counselling was the most common main treatment type among treatment episodes for alcohol across the 10 years to 2022–23, accounting for 30,491 episodes in 2022–23. Assessment only and withdrawal management remained the second and third most common main treatment types across the period. Filters allow the user to view data as the number or proportion (per cent) of episodes for main treatment type, reason for cessation or source of referral.



Figure ALCOHOL 2: Treatment episodes with alcohol as the principal drug of concern, by main treatment type, reason for cessation or source of referral, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables Drg.12, Drg.13 and Drg.18.
http://www.aihw.gov.au

See notes >

Amphetamines

Amphetamines: client demographics and treatment

On this page:

In 2022–23, amphetamines were reported as a drug of concern (either principal or additional) in 3 in 10 treatment episodes (30% or 64,528 episodes) (Table Drg.5).

Classification of amphetamines in the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS)

AODTS NMDS data for amphetamines correspond to the Australian Standard Classification of Drugs of Concern (ASCDC) for the general 'amphetamines' classification, in which methamphetamine is a sub-classification (ABS 2011).

The ASCDC is set up with 3 levels of classification which includes the broad group (e.g., Stimulants and hallucinogens), narrow group and base-level categories (which are the most detailed). Data available in the AODTS NMDS report the narrow group 'amphetamines' classification. Base-level categories within this narrow group include:

- Amphetamine
- Dexamphetamine
- Methamphetamine
- Amphetamine analogues
- Amphetamines, not elsewhere classified (n.e.c)
- Amphetamines not further defined (n.f.d).

Changes to coding for methamphetamines has been difficult due to jurisdictional differences in client management systems, and the use of only broad or narrow group coding by some agencies. This has improved over time due to advancements in workforce training, agency coding practices and new system updates.

Data on different forms of amphetamines – methamphetamine specifically – have not been separately reported over time due to the nature of the classification structure used in this collection. Information on methamphetamines as a principal drug of concern was reported for the first time in the 2019–20 Alcohol and Other Drug Treatment Services in Australia annual report.

Amphetamines were the second most common principal drug of concern, recorded in almost 1 in 4 treatment episodes (24% or 51,902 episodes) (Table Drg.4).

Amphetamines have remained the second most common principal drug of concern:

- Since 2015–16, when it surpassed cannabis for the first time (Table Drg.5).
- With treatment episodes almost doubling since 2013–14 (28,919 to 51,902 episodes), although this has declined since 2019–20.
- In relation to all other drugs of concern, treatment episodes for amphetamines steadily rose between 2013–14 (17%) and 2019–20 (28%) but declined in 2020–21 to 24% where is has remained since (Table Drg.1).

In 2022–23, around 1 in 3 (33% or 16,958) amphetamine-related treatment episodes reported at least one additional drug of concern (Table Drg.2). The most common additional drugs of concern were cannabis (37% or 9,104 episodes), alcohol (22% or 5,480 episodes) and nicotine (18% or 4,411 episodes) (Table Drg.3). Clients can nominate up to 5 additional drugs of concern: these drugs may not have been the subject of any treatment in the episode.

Figure AMPET: Closed treatment episodes for own alcohol or drug use by amphetamines as a principal drug of concern and top 5 additional drugs of concern, 2022–23



Note: Diagram presents the top 5 additional drugs of concern for a principal drug of concern. Totals do not add to 100%.

For information on amphetamine use and harms, please see:

- Tobacco, alcohol and other drugs in Australia: Meth/amphetamine and other stimulants
- National Drug Strategy Household Survey 2022–2023: Methamphetamine and amphetamine in the NDSHS

Client demographics

In 2022–23, 27,974 clients received treatment for amphetamines as the principal drug of concern. Of these clients:

- 3 in 5 were male (61% of clients) (Table SC.9).
- Almost 2 in 3 were aged either 20–29 (26% of clients) or 30–39 years (39%) (Table SC.10). This was consistent for both males and females (Figure AMPHET 1).
- 1 in 5 were Aboriginal and Torres Strait Islander (First Nations) people (20% of clients) (Table SC.11). This represents a crude rate of 909 First Nations clients per 100,000 people (crude rate) (Table SCR.26).

Figure AMPHET 1: Clients with amphetamines as the principal drug of concern, by sex and age group, 2022–23
The butterfly bar chart shows that in 2022–23, clients receiving treatment for amphetamines as the principal drug of concern were most likely to be aged 30–39 (38.5% of male clients; 39.5% of female clients).



Figure AMPHET 1: Clients with amphetamines as the principal drug of concern, by sex and age group, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC.9 and SC10.
http://www.aihw.gov.au

See notes >

Treatment

In 2022–23, 51,902 treatment episodes were provided to clients for amphetamines as the principal drug of concern (Table Drg.4).

Among amphetamine-related treatment episodes in 2022–23:

- The most common source of referral into treatment was self/family (36% or 18,938 episodes), followed by health services (26%) (Figure AMPHET 2, Table Drg.37).
- The most common main treatment type was counselling (34% or 17,647), followed by assessment only (23%) (Figure AMPHET 2, Table Drg.36). This is consistent with previous years, although the proportion of counselling episodes has fluctuated in the 10 years to 2022–23.
- Over 3 in 5 treatment episodes took place in a non-residential treatment facility (62% of episodes) (Table Drg.38).
- The median duration of treatment episodes was over four weeks (31 days) (Table Drg.39).
- Episode duration varied by main treatment type, with the longest median duration being around 10 weeks (72 days) for counselling (Table Drg.41). Nearly 3 in 10 (29%) treatment episodes lasted 2–29 days, a further 28% lasted 1 to 3 months (Table OV.12).
- Over 1 in 2 episodes ended with a planned completion (53% of episodes), while 24% ended unexpectedly (that is, the client ceased to participate against advice, without notice or due to non-compliance) (Figure AMPHET 2, Table Drg.38).

Figure AMPHET 2: Treatment episodes with amphetamines as the principal drug of concern, by main treatment type, reason for cessation or source of referral, 2013–14 to 2022–23

The line graph shows that counselling was the most common main treatment type among treatment episodes for amphetamines across the 10 years to 2022–23, rising from 12,969 episodes in 2013–14, peaking at 24,701 episodes in 2019-20 and falling to 17,647 episodes in 2022–23. Assessment only remained the second most common main treatment types across the period, accounting for 12,087 episodes in 2022–23. Filters allow the user to view data as the number or per cent of episodes for main treatment type, reason for cessation or source of referral.



Figure AMPHET 2: Treatment episodes with amphetamines as the principal drug of concern, by main treatment type, reason for cessation or source of referral, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables Drg.12, Drg.13 and Drg.36.
http://www.aihw.gov.au

See notes >

Methamphetamine-related treatment episodes

In 2022–23, 4 in 5 (82%) amphetamine-related treatment episodes were for methamphetamine as the principal drug of concern (Table Drg.5). Methamphetamine episodes increased from 25% to 82% since 2013–14 (from 7,168 to 42,380 episodes) (Figure AMPHET 3).

The rise in reported episodes for methamphetamine may be due to a combination of factors, including improvements in agency coding practices for methamphetamine, treatment system updates and increases in funded treatment services.

Figure AMPHET 3: Treatment episodes with amphetamines as the principal drug of concern, by amphetamine type, 2013–14 to 2022–23

The line graph shows that methamphetamine has remained the most common amphetamine type among treatment episodes for amphetamines since 2015–16, when it overtook 'Amphetamines not further defined'. Methamphetamine accounted for 42,380 treatment episodes in 2022–23. A filter allows the user to view data as the number or per cent of episodes.



Figure AMPHET 3: Treatment episodes with amphetamines as the principal drug of concern, by amphetamine type, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table Drg.5.
http://www.aihw.gov.au

See notes >

Method of use

How does a client's method of use relate to the form of amphetamine used?

A client's usual method of administering their principal drug of concern may indicate the form of drug used, particularly for amphetamines. For example:

- Clients who report smoking or inhaling amphetamines are most likely to be using amphetamines in crystal form.
- Clients who report ingesting or snorting are most likely to be using a powder form.
- Clients who report injecting amphetamines may be using any form of amphetamines, as each form (base, crystal and powder) can be injected. However, recent data from the Illicit Drug Reporting System (an annual survey of people who inject drugs) indicate that crystal and powder are the most common forms used among people who inject methamphetamine (Sutherland et al. 2022).

Among all amphetamine-related treatment episodes in 2022–23, smoking/inhaling was the most common method of use (50% of episodes), followed by injecting (33%) (Figure AMPHET 4, Table Drg.6). This was similar for methamphetamine (52% and 36% for smoking/inhaling and injecting, respectively) (Table Drg.6).

Between 2013–14 and 2022–23:

- The number of episodes where clients reported smoking/inhaling amphetamines increased from 11,963 episodes in 2013–14 to 26,143 episodes in 2022–23 (Figure AMPHET 4, Table Drg.6). This declined from 29,162 episodes in 2020–21, reflecting an overall decline in treatment episodes for amphetamines in the past three years.
- The number of episodes where clients injected amphetamines more than doubled between 2013–14 to 2019–20 (from 12,596 to 22,375 episodes), falling to 16,314 in 2021–22 before increasing to 17,142 in 2022–23 (Figure AMPHET 4, Table Drg.6).

Figure AMPHET 4: Treatment episodes with amphetamines as the principal drug of concern, by method of use, 2013–14 to 2022–23

The line graph shows that 'Smokes or inhales' has remained the most common method of use among treatment episodes for amphetamines since 2014–15, when it overtook 'Injects' for the first time. 'Smokes or inhales' was the method of use in 26,143 episodes for amphetamines in 2022–23, while 'Injects' was the second most common method of use in 17,142 episodes. Buttons allow the user to navigate to a horizontal stacked bar chart presenting trend data disaggregated by amphetamines group and method of use.



The rise in treatment episodes between 2013–14 and 2019–20 where clients report injecting amphetamines may be related to several factors, including increases in treatment episodes overall, and particularly for people who might have been injecting amphetamines and heroin interchangeably (AIHW 2015).

Additionally, increases in treatment episodes for smoking methamphetamine from 2010 onwards are associated with increased importation of high purity crystalline methamphetamine into Australia (Degenhardt et al. 2017). National Drug and Alcohol Research Centre (NDARC) analysis of AODTS NMDS data indicates this greater availability of crystalline methamphetamines is reflected in the increased number of episodes identifying smoking as a method of use (McKetin et al. 2021).

Treatment episodes for methamphetamines where smoking was the method of use were primarily provided to younger clients (median age 30 years). These clients were more likely to receive main treatment types of assessment only or support and case management (McKetin et al. 2021).

References

ABS 2011. Australian Standard Classification of Drugs of Concern, 2011 - external site opens in new window. ABS cat. No. 1248.0. Canberra: ABS.

AIHW 2015. Trends in methylamphetamine availability, use and treatment, 2003–04 to 2013–14. Drug treatment series no. 26. Cat. No. HSE 165. Canberra: AIHW

Degenhardt L, Sara G, McKetin R, Roxburgh A, Dobbins T, Farrell M et al. 2017. Crystalline methamphetamine use and methamphetamine-related harms in Australia. Drug and Alcohol Review 36:160–70.

McKetin R, Chrzanowska A, Man N, Peacock A, Sutherland R & Degenhardt L. 2021. Trends in treatment episodes for methamphetamine smoking and injecting in Australia, 2003–2019. Drug and Alcohol Review.

Sutherland R, Uporova J, King C, Jones F, Karlsson A, Gibbs D, et al. 2022. Australian Drug Trends 2022: Key findings from the National Illicit Drug Reporting System (IDRS) Interviews - external site opens in new window, Sydney: National Drug and Alcohol Research Centre, University of New South Wales, accessed 3 April 2023.

Cannabis

Cannabis: client demographics and treatment

On this page:

In 2022–23, cannabis was reported as a drug of concern (either principal or additional) in nearly 1 in 4 treatment episodes (28% or 60,674 episodes) (Table Drg.4).

Cannabis was the third most common principal drug of concern:

- In nearly 1 in 5 treatment episodes (17% or 37,969 episodes) (Table Drg.4).
- Over 10 years to 2022–23, treatment episodes for cannabis fluctuated, peaking at 45,043 episodes in 2015–16.
- In 2015–16 cannabis was surpassed by amphetamines as the second most common principal drug of concern (PDOC).

In 2022–23, almost 3 in 10 (28% or 10,453 episodes) of cannabis-related treatment episodes reported at least 1 additional drug of concern (Table Drg.2). The most common additional drugs of concern were alcohol (33% or 4,992 episodes), amphetamines (24% or 3,660 episodes) and nicotine (24% or 3,624 episodes) (Table Drg.3). Clients can nominate up to 5 additional drugs of concern: these drugs may not have been the subject of any treatment within the episode.

Figure CANNABIS: Closed treatment episodes for own alcohol or drug use by cannabis as a principal drug of concern and top 5 additional drugs of concern, 2022–23



Note: Diagram presents the top 5 additional drugs of concern for a principal drug of concern. Totals do not add to 100%.

For information on cannabis use and harms, please see:

- Tobacco, alcohol and other drugs in Australia: Cannabis
- National Drug Strategy Household Survey 2022–2023: Cannabis in the NDSHS
- Trends in cannabis availability, use, and treatment in Australia, 2013–14 to 2021–22

Client demographics

In 2022–23, 24,702 clients received treatment for cannabis as the principal drug of concern. Of these clients:

- Nearly 3 in 5 were male (59% of clients) (Table SC.9).
- Around 2 in 3 people were aged either 10–19 (30% of clients) or 20–29 years (35%) (Table SC.10). This was consistent for both males and females (Figure CANNABIS 1).

- Around 1 in 5 were Aboriginal and Torres Strait Islander (First Nations) people (21% of clients) (Table SC.11). This represents a crude rate of 817 First Nations clients per 100,000 people (Table SCR.26).

Figure CANNABIS 1: Clients with cannabis as the principal drug of concern, by sex and age group, 2022–23

The butterfly bar chart shows that male clients receiving treatment for cannabis as the principal drug of concern were most likely to be aged 10–19 (30.5% of clients) or 20–29 (34.6%) in 2022–23. This was similar for female clients (30.6% aged 10–19 and 35.7% aged 20–29).



Figure CANNABIS 1: Clients with cannabis as the principal drug of concern, by sex and age group, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC.9 and SC10.
http://www.aihw.gov.au

See notes >

Treatment

In 2022–23, 37,969 treatment episodes were provided to clients for cannabis as the principal drug of concern (Table Drg.4).

Among cannabis-related treatment episodes in 2022–23:

- The most common referral sources into treatment were health services (28% of episodes) and self/family (27%), followed by diversion referrals from the criminal justice system (21%) (Figure CANNABIS 32 Table Drg.28). For more information on diversion clients, see Source of referral and diversion clients.
- The most common main treatment type was counselling (45% of episodes), followed by assessment only (17%) (Figure CANNABIS 2, Table Drg.27).
- Counselling remained the most common main treatment type between 2013–14 and 2022–23.
- Nearly 7 in 10 treatment episodes took place in a non-residential treatment facility (69% of episodes) (Table Drg.29).
- The median duration of treatment episodes was over 3 weeks (24 days) (Table Drg.30).
- Over 3 in 5 episodes ended with a planned completion (64% of episodes), while 20% ended unexpectedly (that is, the client ceased to participate against advice, without notice or due to non-compliance) (Figure CANNABIS 2, Table Drg.29).

Figure CANNABIS 2: Treatment episodes with cannabis as the principal drug of concern, by main treatment type, reason for cessation or source of referral, 2013–14 to 2022–23 (number or per cent)

The line graph shows that counselling was the most common main treatment type among treatment episodes for cannabis across the 10 years to 2022–23, rising from 16,259 episodes in 2013–14 to 17,192 in 2022–23. Assessment only was the second most common main treatment type in 2022–23 (6,499 episodes), though this fluctuated over time. Filters allow the user to view data as the number or per cent of episodes for main treatment type, reason for cessation or source of referral.



Figure CANNABIS 2: Treatment episodes with cannabis as the principal drug of concern, by main treatment type, reason for cessation or source of referral, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables Drg.12, Drg.13 and Drg.27.
http://www.aihw.gov.au

See notes >

Clients referred via diversion programs

Diversion treatment programs

Throughout Australia, diversion programs have been developed to divert people who were apprehended or sentenced for minor drug offences away from the criminal justice system into drug treatment. Treatment services range from short-term assessment, information or education sessions to longer-term treatments such as counselling and withdrawal management. For more information, refer to Diversion programs in Australia data and the Key terminology and glossary.

Most treatment episodes provided to clients diverted from the criminal justice system are for cannabis, followed by amphetamines. Clients who are referred via diversion may also receive other treatment episodes with a source of referral other than diversion.

In 2022–23, around 1 in 8 clients receiving treatment for their own drug use were referred into treatment via police or court diversion programs (12% or 15,145 clients) (Table SC.13).

Among these clients:

- Around half reported cannabis as the principal drug of concern (47% of clients) (SC.13).
- 19% of these clients also received alcohol and other drug (AOD) treatment following referral through other sources, such as from a health service or self/family (Table OV.14).
- Over 1 in 5 treatment episodes for cannabis as the principal drug of concern were provided to clients who had been referred via diversion programs (21% or 7,990 episodes) (Table Drg.28).

Diversion clients by selected principal drug of concern

Nationally, in 2022–23 treatment referrals via drug diversion programs accounted for a substantial proportion of treatment episodes for clients with a principal drug of concern of cannabis.

Clients who are referred into AOD treatment via diversion may receive multiple treatment episodes during a collection period, including treatment:

- for diversion-related episodes only (diversion episodes)
- for episodes with a non-diversion source of referral (such as a health service), in addition to episodes where they were referred via diversion (combinations of diversion and non-diversion treatment episodes).

In 2022–23, of the total 26,904 diversion-related treatment episodes:

- Cannabis (48%) was the most common principal drug of concern for diversion referrals into treatment, followed by amphetamines (15%).
- Amphetamines (35%) was the most common principal drug of concern for diversion clients who also received non-diversion treatment episodes (Figure CANNABIS 4, Table OV.14).

For clients with no diversion-related referrals, alcohol was the principal drug of concern for nearly half (46%) of the episodes.

Figure CANNABIS 3: Client diversion referrals for own drug use by selected principal drug of concern and client diversion episode type, 2022–23

The stacked horizontal bar graph shows that cannabis was the most common principal drug of concern (PDOC) among treatment episodes provided to clients referred via diversion in 2022–23 (48.2% of episodes). By comparison, amphetamines was the most common PDOC among non-diversion episodes provided to diversion clients (34.5% of episodes) and alcohol was the most common PDOC among non-diversion episodes provided to non-diversion clients (46.4%).



Figure CANNABIS 3: Client diversion referrals for own drug use by selected principal drug of concern and client diversion episode type, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table OV.14.
http://www.aihw.gov.au

See notes >

Heroin

Heroin: client demographics and treatment

On this page:

In 2022–23, heroin was reported as a drug of concern (either principal or additional) in 5.7% of all treatment episodes (12,367 episodes) (Table Drg.4).

Heroin was the fourth most common principal drug of concern:

- In 4.5% of all treatment episodes (9,745 episodes) (Table Drg.4).
- This has remained consistent across the 10 years to 2022–23, although the proportion of heroin-related episodes has declined from a peak of 7.0% (12,000 episodes) in 2013–14 (Table Drg.5).

In 2022–23, over 1 in 3 (35% or 3,424 episodes) heroin-related treatment episodes reported at least 1 additional drug of concern (Table Drg.2). The most common additional drugs of concern were amphetamines (33% or 1,863 episodes), cannabis (20% or 1,134 episodes) and nicotine (13% or 753 episodes) (Table Drg.3). Clients can nominate up to 5 additional drugs of concern: these drugs may not have been the subject of any treatment within the episode.

Figure HEROIN: Closed treatment episodes for own alcohol or drug use by heroin as a principal drug of concern and additional drugs of concern, 2022–23



Note: Diagram presents the top 5 additional drugs of concern for a principal drug of concern. Totals do not add to 100%.

Treatment for heroin use in the AODTS NMDS collection

People who receive treatment for heroin use have several options for treatment, including withdrawal programs (called detoxification) and abstinence-based treatment (for example, residential rehabilitation in a therapeutic community) (O'Brien 2004).

In Australia, one of the most common treatments for heroin use is opioid pharmacotherapy treatment (also known as opioid agonist therapy). Opioid pharmacotherapy involves replacing opioid drugs, including heroin, with a longer-lasting, medically prescribed opioid.

Agencies whose sole function is to prescribe or provide dosing services for opioid pharmacotherapy are excluded from the AODTS NMDS. Data from these agencies are captured in the National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD) collection (AIHW 2024). For more information, please see the 2023 NOPSAD report.

For information on heroin use and harms, please see:

- Tobacco, alcohol and other drugs in Australia: Illicit opioids, including heroin

- National Drug Strategy Household Survey 2022–2023: Low prevalence illicit drugs in the NDSHS

Client demographics

In 2022–23, 5,573 clients received treatment for heroin as the principal drug of concern. Of these clients:

- Over 2 in 3 were male (67% of clients) (Table SC.9).
- Almost 2 in 3 were aged either 30–39 (32% of clients) or 40–49 (33%) (Table SC.10). This was consistent for both males and females (Figure HEROIN 1).
- Over 1 in 5 were Aboriginal and Torres Strait Islander (First Nations) people (21% of clients) (Table SC.11). This represents a crude rate of 195 First Nations clients per 100,000 people (Table SCR.26).

Figure HEROIN 1: Clients with heroin as the principal drug of concern, by sex and age group, 2022–23
The butterfly bar chart shows that in 2022–23, male clients receiving treatment for heroin as the principal drug of concern were most likely to be aged 40-49 (33.9%) followed by 30-39 (30.9%). Female clients were most likely to be aged 30-39 (34.2%) followed by 40-49 (31.3%).



Figure HEROIN 1: Clients with heroin as the principal drug of concern, by sex and age group, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC.9 and SC10.
http://www.aihw.gov.au

See notes >

Treatment

In 2022–23, 9,745 treatment episodes were provided to clients for heroin as the principal drug of concern (Table Drg.4).

Among heroin-related treatment episodes in 2022–23:

- Self/family (42% of episodes) was the most common source of referral into treatment followed by health services (28%) (Figure HEROIN 2, Table Drg.55).
- The most common main treatment type was assessment only (23% of episodes), followed by pharmacotherapy (19%) and counselling (18%) (Figure HEROIN 2, Table Drg.54).

In the 10 years to 2022–23, main treatment types for heroin have fluctuated:

- Treatment episodes for withdrawal management decreased from 18% to 7.8% (or from around 2,141 to 762 episodes).
- Conversely, pharmacotherapy episodes increased from 10% to 19% (or from around 1,230 to 1,807 episodes). Fluctuations in pharmacotherapy treatment episodes over time can be attributed to changes to jurisdictional coding practices and systems, resulting in under-reporting of pharmacotherapy at the national level (Table Drg.54).
- Over 7 in 10 treatment episodes took place in a non-residential treatment facility (71% of episodes) (Table Drg.56).
- The median duration of treatment episodes was around 5 weeks (34 days) (Table Drg.58).
- About 3 in 5 treatment episodes ended with a planned completion (58% of episodes), while 1 in 5 (20%) ended unexpectedly (Figure HEROIN 2, Table Drg.56).

Figure HEROIN 2: Treatment episodes with heroin as the principal drug of concern, by main treatment type, reason for cessation or source of referral, 2013–14 to 2022–23

The line graph shows that counselling has been the most common main treatment type among treatment episodes for cannabis for most of the 10 years to 2022–23. The number of counselling episodes has fallen from 4,169 in 2013–14 to 1,725 in 2022–23. Other treatment types fluctuated across time, with assessment only becoming the most common treatment type in 2022–23 (2,244 episodes). Filters allow the user to view data as the number or per cent of episodes for main treatment type, reason for cessation or source of referral.



Figure HEROIN 2: Treatment episodes with heroin as the principal drug of concern, by main treatment type, reason for cessation or source of referral, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables Drg.12, Drg.13 and Drg.54.
http://www.aihw.gov.au

See notes >

In 2022–23, injecting remained the most common method of use in heroin-related treatment episodes (72% of episodes) (Table Drg.6). Clients reported injecting drugs in the past 3 months in nearly half of treatment episodes (47% of episodes). In a further 11% of episodes, clients reported that they last injected 3–12 months ago (Table Drg.52).

Between 2013–14 and 2022–23 the proportion of treatment episodes where clients receiving treatment for heroin as a principal drug of concern reported that they had never injected drugs increased almost 4-fold, rising from 5.4% (648 episodes) to 19% (1,867 episodes) (Table Drg.52).

References

AIHW (2024) *National Opioid Pharmacotherapy Statistics Annual Data collection*, AIHW, Australian Government, accessed 30 May 2024.

O'Brien S 2004. Treatment options for heroin and other opioid dependence: a guide for families and carers. Canberra: Department of Health and Ageing.

Pharmaceuticals

Pharmaceuticals: client demographics and treatment

On this page:

In 2022–23, pharmaceuticals were reported as a drug of concern (either principal or additional) in 10.0% of all treatment episodes (22,602 episodes) (Table Drg.87).

- Pharmaceuticals were the principal drug of concern in 5.6% of treatment episodes (12,062 episodes) (Table Drg.87).
- As a proportion, relative to all drugs of concern, pharmaceuticals declined from a peak of 6.8% in 2013–14 (11,756 episodes) before steadily increasing from 2019–20.
- In the 10 years to 2022–23, pharmaceuticals were generally more likely to be reported as an additional rather than principal drug of concern. However, in 2022–23 the proportion of episodes with pharmaceuticals as an additional drug of concern has declined to 4.8% while those with pharmaceuticals as a principal drug of concern have increased to 5.6% (Table Drg.87).

The most common additional drugs of concern reported with pharmaceuticals were amphetamines (26% or 1,704 episodes), cannabis (20% or 1,303 episodes) and alcohol (13% or 887 episodes) (Table Drg.88). Clients can nominate up to 5 additional drugs of concern: these drugs are not necessarily the subject of any treatment within the episode.

Classification of pharmaceutical drugs in the AODTS NMDS

Pharmaceuticals are drugs that are available from a pharmacy – over the counter or by prescription – including opioids (such as codeine and oxycodone) and benzodiazepines (such as diazepam). Some pharmaceutical drug use is for non-medical purposes (Department of Health 2017).

Pharmaceuticals are not listed as a broad drug group in the Australian Standard Classification of Drugs of Concern (ASCDC) classification. In the AODTS NMDS report, the 'pharmaceuticals' drug classification includes the following 10 drug types: codeine, morphine, buprenorphine, oxycodone, methadone, benzodiazepines, steroids, other opioids, other analgesics, and other sedatives and hypnotics. Refer to the Technical notes and Key terminology and glossary for more information.

For information on pharmaceutical drug use and harms, please see:

- Tobacco, alcohol and other drugs in Australia: Pharmaceuticals
- National Drug Strategy Household Survey 2022–2023
  - Non-medical use of pain-relievers and opioids in the NDSHS
  - Non-medical use of pharmaceutical stimulants in the NDSHS
  - NDSHS data tables 6. Non-medical pharmaceutical

Pharmaceuticals by drug type

In 2022–23, opioids and benzodiazepines accounted for nearly 3 in 4 episodes provided for a pharmaceutical drug as the principal drug of concern (PDOC) (72% or 8,643 episodes) (Table Drg.87). 'Opioids' includes codeine, morphine, buprenorphine, oxycodone, methadone, and other opioids.

- Opioids as a group were a principal drug of concern in 2.4% of all treatment episodes and an additional drug of concern in 1.1% (5,289 and 2,500 episodes, respectively).
  - Buprenorphine (1,855 episodes), methadone (890) and oxycodone (812) were the most common principal drug types recorded in opioid-related treatment episodes.
- Benzodiazepine was a principal drug of concern in 1.5% of treatment episodes and listed as an additional drug of concern in 2.1% episodes (3,354 and 4,498 episodes, respectively).

Over the 10 years to 2022–23:

- The number of treatment episodes for benzodiazepines while initially decreasing from 2,650 episodes in 2012–13 to 1,727 episodes in 2015–16, has steadily increased reaching its highest level in 2022–23, 3,354 episodes.
- The number of episodes for opioids as a drug group peaked at 7,731 in 2013–14 before falling to 4,722 episodes in 2021–22 then increasing to 5,289 in 2022–23 (Figure PHARMS 1, Table Drg.87).

Figure PHARMS 1: Treatment episodes with pharmaceuticals as the principal drug of concern, by selected principal drugs of concern, 2013–14 to 2022–23

The line graph shows that amongst pharmaceutical drugs, benzodiazepines were the most common principal drug of concern for most years in the 10-year period to 2022–23, increasing from 2,650 episodes in 2013–14 to 3,354 episodes in 2022–23.

Filters allow the user to toggle between viewing episode data on pharmaceutical drugs by pharmaceutical drug type, or in relation to the 5 most common principal drugs of concern in the AODTS NMDS. Filters also allow the user to toggle between the number and proportion of episodes.



Figure PHARMS 1: Treatment episodes with pharmaceuticals as the principal drug of concern, relative to most common principal drugs of concern or by selected pharmaceutical drug type, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables Drg.1 and Drg.87.
http://www.aihw.gov.au

See notes >

Client demographics

In 2022–23, 6,889 clients received treatment for any pharmaceutical drug as the principal drug of concern (Table SC.30). Of these clients:

- 3 in 5 were male (62% of clients). The proportion of male clients receiving treatment for a pharmaceutical principal drug of concern ranged from 42% for codeine to 89% for steroids (Table SC.30).
- 1 in 2 clients were aged either 20–29 (25%) or 30–39 (30%). The proportion of clients in each age group varied by PDOC:
  - Clients receiving treatment for benzodiazepines had the highest proportion of people aged 10–19 (17% of clients).
  - Most clients receiving treatment for opioids were aged either 30–39 or 40–49, ranging from 54% for oxycodone to 66% for buprenorphine (Table SC.31).
- Around 1 in 7 were Aboriginal and Torres Strait Islander (First Nations) people (14% of clients). The proportion of First Nations clients was highest for buprenorphine (27% of clients) (Table SC.32).

Treatment

In 2022–23, around 12,062 treatment episodes were provided to clients for pharmaceuticals as the principal drug of concern (Table Drg.87).

- The most common sources of referral into treatment were self/family (40% of episodes) and health services (39%). This was relatively consistent across drug types, but diversion was the most common referral into treatment for steroid-related treatment episodes (38% of episodes) (Table Drg.90).
- The most common main treatment types were assessment only (31% of episodes) and counselling (19%) (Figure PHARMS 3, Table Drg.89).
- Most episodes took place in non-residential treatment facilities (72% of episodes), this was the most common treatment setting across drug types (Figure PHARMS 3, Table Drg.92).
- Over 3 in 5 treatment episodes ended with a planned completion (62% of episodes, ranging from 57% for morphine as the PDOC to 79% for steroids). Around 1 in 5 episodes ended unexpectedly (18%) (Figure PHARMS 2, Table Drg.91).

Figure PHARMS 2: Treatment episodes with selected pharmaceutical drugs as the principal drug of concern, by main treatment type, treatment delivery setting or reason for cessation, 2022–23

The stacked horizontal bar chart shows that in 2022–23 assessment only was the most common main treatment type among most episodes for pharmaceutical drugs with the exception of benzodiazepines and codeine, ranging from 28.3% for methadone to 53.9% for buprenorphine. Counselling was the most common main treatment type in episodes where benzodiazepines (28.3% of episodes) was the principal drug of concern. Pharmacotherapy was the most common main treatment type in episodes where codeine (28.1% of episodes) was the principal drug of concern. A filter allows the user to view data for main treatment type, reason for cessation or treatment delivery setting.



Figure PHARMS 2: Treatment episodes with selected pharmaceuticals as the principal drug of concern, by main treatment type, reason for cessation or treatment delivery setting, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables Drg.89, Drg.91 and Drg.92.
http://www.aihw.gov.au

See notes >

References

ABS 2011. Australian Standard Classification of Drugs of Concern, 2011 - external site opens in new window. ABS cat. no. 1248.0. Canberra: ABS.

Department of Health 2017. National Drug Strategy 2017–2026 - external site opens in new window. Canberra: Commonwealth of Australia.

Selected other drugs

Selected other drugs: client demographics and treatment

On this page:

In addition to the most common principal drugs of concern, the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) report includes information on selected other drug types: nicotine, ecstasy and cocaine. These drugs may be commonly used in the community or linked to increased risk of harm. Treatment captured through the AODTS NMDS for these drugs may be less prominent than for other drugs as they are relatively uncommon, or people who use them are less likely to receive treatment than people who use other drugs. See the Key terminology and glossary for further information.

Together, nicotine, ecstasy and cocaine have contributed around 1–2% of all treatment episodes each year since 2013–14 (tables Drg.1, Drg.5). Individually, the proportion of treatment episodes for each of these drugs has remained at less than 2% per year across the period (Table SD.9).

Nicotine, ecstasy and cocaine are more likely to be reported as an additional rather than principal drug of concern. For example, nicotine was reported as a principal drug of concern in only 1.1% of treatment episodes in 2022–23 but was an additional drug of concern in 7.8% of episodes (Table Drg.5).

For information on selected other drug use and harms, please see:

- Tobacco, alcohol and other drugs in Australia: Tobacco
- Tobacco, alcohol and other drugs in Australia: Meth/amphetamine and other stimulants
- National Drug Strategy Household Survey 2022–2023:
  - Tobacco and e-cigarettes/vapes
  - Ecstasy in the NDSHS
  - Cocaine in the NDSHS

Nicotine

In 2022–23, nicotine was reported as a drug of concern (either principal or additional) in 8.9% of all treatment episodes (19,257 episodes) (Table Drg.5). In 2022–23:

- Nicotine was the principal drug of concern in just 1.1% of treatment episodes (2,309 episodes) (tables Drg.1, Drg.5). This proportion has remained relatively stable since 2013–14 (1.7% or 2,837 episodes) (Table Drg.5).
- Nicotine was an additional drug of concern in just under 1 in 10 treatment episodes (7.8% or 16,948 episodes) (Table Drg.4). Most treatment episodes with nicotine as an additional drug of concern were for alcohol (42%), amphetamines (26% of episodes) or cannabis (21%) as the principal drug of concern (Table Drg.3).

The low proportion of episodes for nicotine as the principal drug of concern in the AODTS NMDS collection may be due to the existence of numerous alternative support options within the community (for example, general practitioners, pharmacies, helplines, and web services). Additionally, people may view alcohol and other drug (AOD) treatment services as being most appropriate for drug use that is beyond the expertise of general practitioners. However, therapy to quit smoking is becoming an integral part of some AOD services as a parallel treatment with other drugs of concern.

Nicotine treatment provided in AOD treatment services

When considering nicotine treatment in Australia, consultation between a client and a service provider/clinician is an important step in determining a client's treatment plan. Clients may actively seek treatment for nicotine or be offered treatment for nicotine by the service provider/clinician. Nicotine may be nominated as a principal or additional drug of concern by the client. Following consultation, a service provider/clinician will determine a treatment plan with the client.

Clients do not regularly seek (or are referred to) AOD treatment services for nicotine addiction treatment. Clients are more often referred to other avenues of treatment. This is due to the prevalence of other resources for nicotine addiction therapy including helplines and access to nicotine replacement therapy (NRT) via general practitioners.

Client demographics

In 2022–23, 1,728 clients received treatment for nicotine as the principal drug of concern (Table SC.9).

Of these clients:

- Over half were male (53% of clients) (Table SC.9).
- Almost 2 in 3 (64%) were aged either 10–19 (30% of clients), 20–29 (16%), or 30–39 (18%) years (Table SC.10).
- Nearly 1 in 5 were Aboriginal and Torres Strait Islander (First Nations) people (18% of clients) (Table SC.11).

Treatment

In 2022–23, 2,309 treatment episodes were provided to clients for nicotine as the principal drug of concern.

Among nicotine-related episodes in 2022–23:

- The most common source of referral into treatment was health service (32% of episodes), followed by self/family (21%) (Table Drg.46).
- The most common main treatment types were counselling (34% of episodes) and assessment only (29%) (Table Drg.45).
- The median duration of these treatment episodes was 30 days (Table Drg.48). Over half of all episodes (55%) lasted between 2 days and 3 months, while over 1 in 5 (23%) lasted less than 1 day (Table OV.12).
- 7 in 10 episodes ended with a planned completion (70% of episodes), while 17% ended unexpectedly (Table Drg.47).

Ecstasy

In 2022–23, ecstasy was reported as a drug of concern (either principal or additional) in 0.8% of all treatment episodes (1,736 episodes) (Table Drg.4).

In 2022–23:

- Ecstasy was the principal drug of concern in 0.2% of treatment episodes (447 episodes) (Table Drg.5).
- This proportion has remained relatively stable since 2013–14 (0.6% or 974 episodes) (Table Drg.5).
- Ecstasy was an additional drug of concern in 0.6% of treatment episodes (1,289 episodes) this has remained stable since 2013–14 (0.6% or 974 episodes) (tables Drg.4 and Drg.5). Most treatment episodes with ecstasy as an additional drug of concern were for amphetamines (31%), cannabis (28% of episodes) or alcohol (27%) (Table Drg.3).

Client demographics

In 2022–23, 326 clients received treatment for ecstasy as the principal drug of concern. Among these clients:

- 7 in 10 were male (72% of clients) (Table SC.9)
- Around 4 in 5 were aged either 10–19 (23% of clients) or 20–29 (54%) (Table SC.10)
- Less than 1 in 13 were First Nations people (7.7%) (Table SC.11).

Treatment

In 2022–23, 447 treatment episodes were provided to clients for ecstasy as the principal drug of concern (Table Drg.4). The median duration of these treatment episodes was just over 1 week (8 days), the same as the previous year (Table Drg.75). Among ecstasy-related treatment episodes in 2022–23:

- The most common source of referral into treatment was diversion from the criminal justice system (33% of episodes), followed by self/family (31%) (Table Drg.73).
- The most common main treatment types were counselling (47% of episodes) and assessment only (21%) (Table Drg.72).
- Just under 7 in 10 treatment episodes ended with a planned completion (68% of episodes), while 15% ended unexpectedly.
- The proportion of episodes with a planned completion ranged from 48% for episodes with rehabilitation as the main treatment to 86% for information and education (Table Drg.74).

Cocaine

In 2022–23, cocaine was reported as a drug of concern (either principal or additional) in 2.1% of all closed treatment episodes (4,505 episodes) (Table Drg.4).

In 2022–23:

- Cocaine was the principal drug of concern in 1.0% of treatment episodes (2,100 episodes), rising from 0.3% of episodes in 2013–14 (550 episodes) (Table Drg.5).
- Cocaine was an additional drug of concern in 1.1% of treatment episodes (2,405 episodes).
- This has remained relatively stable since 2013–14 (1.4%), with a slight increase in episode numbers from 2,354 to 2,405 across the period (Table Drg.5). Most treatment episodes with cocaine as an additional drug of concern were for alcohol (45% of episodes), amphetamines (27%) or cannabis (15%) (Table Drg.3).

Client demographics

In 2022–23, 1,564 clients received treatment for cocaine as the principal drug of concern (Table SC.12).

Among these clients:

- Over 4 in 5 were male (83% of clients) (Table SC.9).
- Over half were aged 20–29 years (51% of clients) and a further 30% were aged 30–39 (Table SC.10).
- Around 1 in 14 (6.9%) were First Nations people (Table SC.11).

Treatment

In 2022–23, 2,100 treatment episodes were provided to clients for cocaine as the principal drug of concern (Table Drg.4). The median duration of these treatment episodes was just over 5 weeks (37 days), the same as the previous year (Table Drg.84).

Among cocaine-related treatment episodes in 2022–23:

- The most common source of referral into treatment was self/family (35% of episodes), followed by diversion (23%) and health services (15%) (Table Drg.82).
- The most common main treatment types were counselling (50% of episodes) and assessment only (21%) (Table Drg.81).
- 4 in 5 treatment episodes took place in non-residential treatment facilities (80% of episodes) (Table Drg.83).
- Nearly 2 in 3 treatment episodes ended with a planned completion (65% of episodes), while 17% ended unexpectedly.
- Planned completions were most likely where the main treatment type was information and education (91% of episodes) (Table Drg.82).

Treatment provided

There are a number of treatment types available to assist people receiving treatment for alcohol or drug use, most of which aim to reduce the harm of drug use through services such as counselling or information and education. For a subset of people who use alcohol and drugs, treatment and support will be required over the course of their life (consistent with dependence being a chronic condition, like asthma or diabetes). In many cases, people may require ongoing support to achieve long-term change. For other people, early support and treatment will be sufficient to reduce harms and prevent the need for further treatment or they may access treatment intermittently as required (Department of Health and Aged Care 2019).

Key findings

In 2022–23:

- Around 235,500 treatment episodes were provided to around 131,500 clients.
- Clients received an average of 1.8 treatment episodes nationally.
- 92% (around 217,000) of all treatment episodes were provided to people receiving treatment for their own drug use while a further 7.7% (around 18,200) were for someone else's alcohol or drug use.
- Counselling was the most common treatment type provided to all clients (34% of all treatment episodes), followed by assessment only (22%).
- For someone else's alcohol or drug use, the most common treatment type was support and case management (46% of treatment episodes), followed by counselling (34%).

Over the 10-year period to 2022–23:

- Counselling has remained the most common treatment type for all clients, ranging between 43% of episodes in 2013–14 and 34% in 2022–23.
- Withdrawal management treatment episodes for a client's own drug use fell from 15% to 11%, moving from the third to the fourth most common treatment.
- Support and case management has become the third most common treatment for all clients, increasing from 9.3% of episodes in 2013–14 to 15% in 2022–23.

Treatment types

People can receive treatment for their own or someone else's alcohol or drug use (see Key terminology and glossary). Rehabilitation, withdrawal management (detoxification) and pharmacotherapy are not available for people who received treatment for someone else's alcohol or drug use.

In 2022–23, a total of 235,461 closed treatment episodes were provided to 131,516 people for their own or someone else's alcohol or drug use. Clients received an average of 1.8 treatment episodes each (Table SCR.21):

Between 2013–14 and 2022–23:

- Treatment episodes increased by 30% (from 180,783 to 235,461 episodes.
- Between 2021–22 and 2022–23, treatment episodes increased by 3.1%.
- Clients receiving treatment increased from 114,436 to 131,516, peaking in 2020–21 (242,980 episodes or 139,271 clients).
- Between 2021–22 and 2022–23, client numbers increased by 0.8%.

Closed treatment episodes for clients who received treatment for own or other's drug use

In 2022–23:

- Over 9 in 10 treatment episodes (92% or 217,303) were provided for a client's own alcohol or drug use.
- Around 1 in 12 (7.7% or 18,158) treatment episodes were in relation to someone else's alcohol or drug use (Table Trt.2).
- 125,948 people received treatment for their own alcohol or drug use and 11,072 people received treatment in relation to someone else's alcohol or drug use (Table SCR.30).

Among clients receiving treatment for their own alcohol or drug use:

- Counselling was the most common main treatment type across most age groups followed by assessment only, except for clients aged 10–19, where it was support and case management.
- Over 1 in 5 (22%) of clients aged 10–19 received support and case management as a treatment type.
- Older clients aged 40 and over were more likely to receive withdrawal management as a main treatment type (8.4–9.5%) than younger clients.

Among clients who received support for someone else's alcohol or drug use, the age of clients varied by main treatment type:

- Counselling was the most common treatment provided to more than half of clients aged over 40 (51% of clients aged 40–49, 65% of clients aged 50–59, and 72% of clients aged over 60).
- Around 1 in 3 clients aged 10–19 (31%) and 20–29 (37%), received support and case management (Figure TREATMENT CLIENTS 1, Table SC.19).

Figure TREATMENT CLIENTS 1: Clients, by client type, main treatment type and age group, 2022–23

The stacked horizontal bar chart shows that in 2022–23, counselling was the most common main treatment type provided to all clients across all age groups, ranging from 36.1% for all clients aged 60+ years to 49.6% for all clients aged 10–19 years. A filter allows the user to view data for all clients, clients seeking treatment for their own drug use or clients seeking treatment for someone else's drug use.

Figure TREATMENTCLIENTS 1: Clients by client type, main treatment type and age group, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SC.19.
http://www.aihw.gov.au

See notes >

Trends in main treatment types

The types of main treatments clients have received have changed over time, reflecting the changes in service delivery.

For treatment episodes provided for a client's own alcohol or drug use over the 10-year period to 2022–23:

- Counselling has remained the most common treatment type, gradually declining from a high of 41% (70,734) of episodes in 2013–14 to a low of 34% (73,561) in 2022–23.
- The proportion of episodes with withdrawal management as main treatment dropped from 15% (25,613) in 2013–14 to 11% (23,250) in 2022–23.
- The proportion of Assessment only (from 16% to 23%), support and case management (from 9.3% to 13%) and other main treatment (from 1.9% to 8.6%) have increased over this period.

For treatment episodes provided for those who received support for someone else's alcohol or drug use over the 10-year period to 2022–23:

- Until 2022–23, counselling was the most common treatment type, ranging from a high of 73% of episodes in 2016–17 before declining and reaching its lowest level in 2022–23, 34%.
- In 2022–23, support and case management became the most common main treatment, increasing over 8-fold in the 10 years to 2022–23, from 8.0-10% between 2013–14 and 2017–18 before increasing steadily to 46% (8,355) in 2022–23 (Figure TREATMENT CLIENTS 2, Table Trt.3).
  - This increase may be due in part to changes in coding practices for support and case management in 2019–20. The word 'only' was removed (support and case management only) allowing agencies to more accurately capture this treatment type in conjunction with other treatment types.

Trends in main treatment type have changed over time, reflecting in part changing client needs, service delivery practices and expansion, changes in coding practices/methodology in the collection and state and territory policies.

For treatment episodes provided to all clients over the 10-year period to 2022–23:

- Counselling was the most common treatment type, ranging from 77,021 episodes (43%) in 2013–14 to a high of 92,455 (38%) episodes in 2020–21 before decreasing to 79,689 (34%) in 2022–23 (Figure TREATMENT CLIENTS 2, Table Trt.3). The peak recorded in 2020–21 coincided with:
  - The first and second waves of the COVID-19 pandemic and reflected AOD services adapting to other ways of delivering AOD treatment, such as, telehealth models.
  - Changes to coding practices: prior to 2020–21 treatment episodes provided to people diverted into AOD services by police and court diversion programs were recorded as information and education. From 2020–21, diversion programs are now reported as counselling in a few states. Caution should be used when comparing these data over time.
- Assessment only episodes have steadily increased from 28,310 (16%) in 2013–14 to 50,876 (22%) in 2022–23 (Figure TREATMENT CLIENTS 2, Table Trt.3). This increase may be due in part to recording a separate assessment only episode, prior to the commencement of the treatment episode in some states and territories.
- Support and case management episodes increased from 16,715 (9.2%) in 2013–14 to 35,712 (15%) in 2022–23, peaking at 38,050 in 2019–20 (Figure TREATMENT CLIENTS 2, Table Trt.3).
- Information and education episodes remained relatively steady between 2013–14 (15,709, or 8.7%) and 2018–19 (18,039 or 8.2%) before declining sharply (2022–23 5,681 or 2.4%) (Figure TREATMENT CLIENTS 2, Table Trt.3). This was due to:
  - Coding changes prior to 2020–21 for treatment episodes provided to people diverted into AOD services by police and court diversion programs were recorded as information and education. From 2020–21, police and court diversion programs are now reported as counselling. Caution should be used when comparing these data over time.
- 'Other' main treatment type increased from 3,854 (2.1%) in 2013–14 to 20,490 (8.7%) in 2022–23 (Figure TREATMENT CLIENTS 2, Table Trt.3). This increase is noticeable from 2019–20 and likely relates to:
  - Changes in coding of 'other' during COVID-19 where agencies were adapting to telephone/video conference consultations.

For further information on changes in the AODTS NMDS collection see 2022–23 AODTS NMDS Data Quality Statement - external site opens in new window.

Figure TREATMENT CLIENTS 2: Treatment episodes, by client type and main treatment type, 2013–14 to 2022–23

The line graph shows that counselling has remained the most common main treatment type among episodes provided to all clients across the period 2013–14 to 2022–23, accounting for 33.8% of episodes in 2022–23. In 2022–23, assessment only was the second most common main treatment type (21.6% of episodes), followed by support and case management (15.2%). A filter allows the user to select the measure, per cent and number of clients and to view data for all clients, clients seeking treatment for their own drug use or clients seeking treatment for someone else's drug use.



Figure TREATMENT CLIENTS 2: Treatment episodes, by client type and main treatment type, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table Trt.3.
http://www.aihw.gov.au

See notes >

Explore treatment provided:

- Assessment only
- Counselling
- Information and education
- Pharmacotherapy
- Rehabilitation
- Support and case management
- Withdrawal management
- Other main treatment

References

Department of Health and Aged Care 2019. National Framework for Alcohol, Tobacco and Other Drug Treatment 2019–29, - external site opens in new window Department of Health and Aged Care, Australian Government, accessed 6 March 2024.

Assessment only

Although all service providers would normally include an assessment component in all treatment types, assessment only episodes are those for which only an assessment has been provided to the client. Assessment interventions aim to reduce immediate or short-term harms, engage, and support people, and refer people into treatment. For more information on assessment only see glossary.

In 2022–23:

- Over 1 in 5 (22% or 50,876) of all treatment episodes were reported as an assessment only:
  - Over 1 in 5 (23%) of episodes for people receiving help for their own alcohol or drug use received assessment only as a main treatment.
  - Among those who received help for someone else's alcohol or drug use, 6.9% of episodes had an assessment only.
- Assessment only treatment episodes were most commonly provided to people whose principal drug of concern was either alcohol (42%) or amphetamines (24%) (tables Trt.3, Trt.32).

Client profile

In 2022–23, among clients whose main treatment was assessment only:

- Almost 2 in 3 (64%) people who received an assessment for their own alcohol or drug use were male.
- 3 in 5 (60%) people who received assistance for someone else's alcohol or drug use, were male.
- Almost 1 in 5 (18%) people who received an assessment for their own alcohol or drug use and less than 1 in 10 (8.7%) people who received support for someone else's alcohol or drug use were Aboriginal and Torres Strait Islander (First Nations) people, (tables SC.18, SC.20).

Counselling

Counselling is the most common treatment type for clients' who received treatment for alcohol or other drug use. Psycho-social counselling refers to evidence-informed talking therapies, aimed at helping the person develop skills (whether that be psychological skills, and/or practical skills) to reduce alcohol or other drug consumption and/or harms, in line with the person's own goals. For more information on counselling see glossary.

In 2022–23:

- Counselling was reported as a main treatment type in 34% (79,689) of all treatment episodes.
    - Over 1 in 3 (34%) episodes for people receiving treatment for their own alcohol or drug use involved counselling as the main treatment, a decline from 36% in 2021–22.
    - For treatment episodes where the client received support for someone else's drug use, more than 1 in 3 (34%) episodes involved counselling as the main treatment type, a decline from 36% in 2021–22.
- Among clients who received treatment for their own alcohol or drug use, counselling as a main treatment was most commonly provided where the principal drug of concern was alcohol (41%), amphetamines (24%) or cannabis (23%) (tables Trt.3, Trt.16).

Client profile

In 2022–23, for clients whose main treatment was counselling:

- More than 3 in 5 (61%) people who received counselling for their own alcohol or drug use were male,
- More than half (53%) of people who received treatment for someone else's alcohol or drug use were female (17% did not state their sex).
- Over half (52%) of people receiving counselling for their own alcohol or drug use were aged 20–39.
- Almost 3 in 5 (57%) people who received counselling for someone else's alcohol or drug use were aged 40 and over.
- Almost 1 in 5 (17%) Aboriginal and Torres Strait Islander (First Nations) people received treatment for their own alcohol or drug use, and 8.9% of First Nations people received counselling for someone else's alcohol or drug use (tables SC.18–20).

Treatment profile

Counselling treatment is provided for a client's own alcohol or drug use, as well as those who received support for someone else's alcohol or drug use.

Over the 10-year period to 2022–23 for clients who received counselling:

- Treatment episodes for counselling were longer than all other treatment types, ranging between a median length of 52 and 71 days. In 2022–23 the median length was 67 days (over 9 weeks) (Table OV.11).
- For their own alcohol or drug use, the proportion of treatment episodes that ended within 1 month fell from 32% to 28%.
- For someone else's alcohol or drug use, the proportion of treatment episodes ending within 1 month fell from 32% to 20%. In contrast, the proportion lasting 3 to 6 months increased from 19% in 2013–14 to 25% in 2022–23 (Table Trt.21).

Information and education

Information and education can be provided to clients as written information or a psycho-educational intervention program. See glossary for further information.

In 2022–23, information and education as a main treatment was reported for 2.4% (5,681) of all treatment episodes (where clients received treatment for their own or someone else's alcohol or drug use).

Most information and education episodes were provided to clients whose principal drug of concern was alcohol (45%) or cannabis (21%) (tables Trt.3, Trt.42).

Client profile

In 2022–23, for clients whose main treatment was information and education:

- About 2 in 3 people receiving information and education for their own alcohol or drug use were male (66%)
- Over half (54%) of people who received information and education for someone else's alcohol or drug use were female.
- Almost 2 in 3 (65%) of all people receiving information and education for their own alcohol or drug use were aged 10–39 (21% of clients aged 10–19, 21% aged 20–29 and 23% aged 30–39).
- In contrast, almost 3 in 5 (58%) people who received treatment for someone else's alcohol or drug use were aged 40 or over.
- Over 1 in 4 (26%) Aboriginal and Torres Strait Islander (First Nations) people received treatment for their own alcohol or drug use.
- Around 1 in 7 (15%) First Nations people received treatment for someone else's alcohol or drug use (tables SC.18–20).

Treatment profile

Among treatment episodes in 2022–23 with information and education as the main treatment, 2 in 5 (40%) of treatment episodes lasted 1 day for clients receiving treatment for their own alcohol or drug use. For those who received treatment for someone else's use, this proportion was 21% (Table Trt.44).

Over the 10-year period to 2022–23, among clients who received information and education:

- For their own alcohol or drug use: the proportion of treatment episodes that lasted 1 day decreased from 82% in 2013–14 to 40% in 2022–23. These recent decreases were likely due to:
  - Coding changes prior to 2020–21 for treatment episodes provided to people diverted into alcohol and other drug (AOD) services by police and court diversion programs were recorded as information and education. From 2020–21, police and court diversion programs are now reported as counselling. Caution should be used when comparing these data over time.
  - COVID-19 restrictions and reductions in service delivery from 2019–20 onwards.
- For someone else's alcohol or drug use: the proportion of treatment episodes that lasted one day decreased from 70% in 2013–14 to 21% in 2022–23.
- For all clients: the proportion of treatment episodes for lasting from 2 days to 3 months increased from 16% in 2013–14 to 53% in 2022–23 (Table Trt.44).

It is important to note that information and education treatment trends are influenced by differences in jurisdictional program practices over time.

Pharmacotherapy

There are several medications (pharmacotherapies) used to treat dependence on alcohol, tobacco and other drugs. These pharmacotherapies can be prescribed for a short, medium or long-term duration, depending on the person's goals.

In the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS), only episodes where pharmacotherapy was either an additional treatment, or where it was the main treatment with an additional treatment provided, are included. Episodes where pharmacotherapy was the main treatment only and no additional treatment was provided are excluded. Pharmacotherapy is only available to people receiving treatment for their own drug use. As most pharmacotherapy services are outside the scope of the AODTS NMDS, the data presented here are a substantial under-representation.

More information on opioid pharmacotherapy in Australia is available from the AIHW's National Opioid Pharmacotherapy Statistics (NOPSAD). The latest data from the National Opioid Pharmacotherapy Statistics indicate that on a snapshot day in 2023, around 53,300 people received pharmacotherapy for opioid dependence (AIHW 2024).

For services that were in scope of the AODTS NMDS in 2022–23:

- Pharmacotherapy treatment accounted for 1.9% (4,074) of total episodes for a client's own alcohol or drug use.
- Of these episodes, 27% (1,509) reported pharmacotherapy as an additional treatment (tables Trt.3, Trt.54).

Client profile

In 2022–23, for clients whose main treatment was pharmacotherapy:

- Seven in 10 (70%) people receiving treatment for their own alcohol or drug use were male.
- Almost two-thirds (64%) of all people were aged 30–49 and 20% were aged 50 and over.
- Around 1 in 6 (16%) people were Aboriginal and Torres Strait Islander (First Nations) people, (tables SC.18–20).

Treatment profile

For treatment episodes involving pharmacotherapy for a client's own alcohol or drug use:

- Over half (56%) of episodes lasted over 3 months, of which over 1 in 4 (26%) lasted over 12 months. Around 1 in 6 (16%) of episodes lasted 2–29 days.
- Where pharmacotherapy treatment was provided as a main treatment type, the most common principal drugs of concern were heroin (44%) and alcohol (16%) (tables Trt.55, Trt.59).

References

AIHW (2024) *National Opioid Pharmacotherapy Statistics Annual Data collection*, AIHW, Australian Government, accessed 30 May 2024.

Rehabilitation

Rehabilitation is an intensive treatment program that integrates a range of services and therapeutic activities, including counselling, behavioural treatment, social and community living skills, relapse prevention and recreational activities. This type of treatment is not available for people who received treatment for someone else's alcohol or drug use. See glossary for further information on Rehabilitation.

In 2022–23, for a client's own alcohol or drug use:

- More than 1 in 14 (7.2% or 15,689) treatment episodes included rehabilitation as the main treatment type.
- The most common principal drugs of concern were alcohol (46%) or amphetamines (36%) (tables Trt.3, Trt.47).

Client profile

In 2022–23, for clients whose main treatment was rehabilitation:

- Almost 2 in 3 (63%) people were male.
- Over half (58%) of people were aged 30–49.
- Around 3 in 10 (29%) of people were Aboriginal and Torres Strait Islander (First Nations) people, (tables SC.18–20).

Treatment profile

Among rehabilitation treatment episodes for a client's own alcohol or drug use:

- Over 1 in 3 (36%) episodes lasted 1–3 months, while a further 28% lasted between 2–29 days in 2022–23.
- Over the 10-year period to 2022–23, the duration of episodes of rehabilitation remained relatively stable, which may be related to rehabilitation treatment programs lasting a set period of time (Table Trt.52).
- In the 10 years to 2022–23, the median treatment duration for clients' own alcohol or drug use was highest in 2016–17 at 53 days and dropped to 43 days in 2022–23 (Table OV.11).

Support and case management

Support includes activities such as providing information and support to family members/friends/children, delivering peer-based support services, cultural support, and ongoing contact/regular communication between client/provider. Care co-ordination and case management involves ongoing treatment planning, goal setting and review and facilitation for client to achieve their goals. This includes supported referral and system navigation support to other services, if needed, such as health or social welfare services (Department of Health and Aged Care 2019). See glossary for further information on support and case management.

In 2022–23:

- Around 1 in 7 (15% or 35,712) treatment episodes reported a main treatment of support and case management:
  - Almost 1 in 8 (13%) episodes included support and case management for clients' own alcohol or drug use.
  - Almost half (46%) of episodes were for clients who received treatment for someone else's alcohol or drug use.
- Most support and case management treatment episodes for a client's own alcohol or drug use were for people whose principal drug of concern was alcohol (38%), amphetamines (23%) or cannabis (22%) (tables Trt.3, Trt.37).

Client profile

In 2022–23, for clients whose main treatment was support and case management:

- Almost 3 in 5 (57%) clients receiving treatment for their own alcohol or drug use were male.
- More than 2 in 3 (67%) people receiving treatment for either their own or someone else's alcohol or drug use were aged 10–39.
- Almost 1 in 5 (18%) people, were Aboriginal and Torres Strait Islander (First Nations) people received treatment for their own alcohol or drug use.
- Around 1 in 6 (16%) of First Nations people received support and case management for someone else's drug use (tables SC.18–20).

Treatment profile

Among support and case management treatment episodes for clients' own alcohol or drug use and someone else's alcohol or drug use:

- The proportion of episodes lasting 1 day was higher for clients receiving treatment for someone else's alcohol or drug use (73%) than for their own alcohol or drug use (12%).
- Most (79%) treatment episodes for support and case management lasted from one day to 3 months.

Over the 10-year period to 2022–23:

- For clients receiving treatment for their own alcohol or drug use, treatment episodes lasting 1 day increased from 10% in 2013–14 to 12% in 2022–23, peaking in 2015–16 (43%).
- Episodes lasting one to 3 months fell from 35% in 2013–14 to 31% in 2022–23.
- The proportion of treatment episodes for someone else's alcohol or drug use that lasted 1 day rose substantially from 2013–14 (14%) to 2018–19 (87%) before falling in 2022–23 (73%).
- Median treatment duration for own alcohol or drug use dropped over this period from 48 days to 38 days since 2013–14.
- For someone else's alcohol or drug use the median treatment duration dropped from 30 days to 1 day (tables Ov.11, Trt.39).

References

Department of Health and Aged Care 2019. National Framework for Alcohol, Tobacco and Other Drug Treatment 2019–29, - external site opens in new window Department of Health and Aged Care, Australian Government, accessed 6 March 2024.

Withdrawal management

Withdrawal management (detoxification) includes medicated and non-medicated treatment in a residential or non-residential setting, to help manage, reduce or stop the use of a drug of concern. This type of treatment is not available for people who received treatment for someone else's alcohol or drug use. See glossary for further information on withdrawal management.

In 2022–23:

- Over 1 in 10 (11% or 23,250) treatment episodes for a client's own alcohol or drug use involved withdrawal management as the main treatment.
- Of these, most episodes were for alcohol (57%) or amphetamines (18%) (tables Trt.3, Trt.24).

Client profile

In 2022–23, for clients whose main treatment was withdrawal management:

- Almost 3 in 5 (56%) of all people receiving treatment for their own alcohol or drug use were male.
- Over half (53%) of clients were aged 30–49.
- Around 1 in 8 (13%) people were Aboriginal and Torres Strait Islander (First Nations) people, (tables SC.18–20).

Treatment profile

Among withdrawal management treatment episodes as a main treatment type:

- Almost 3 in 4 treatment episodes (74%) lasted 2–29 days, followed by over 1 in 7 (12%) episodes lasting 1 day.
- Over the 10-year period to 2022–23, median treatment duration has remained stable at 8 days since 2013–14 (tables Ov.11, Trt.29).

Other main treatment

Other main treatment types are modes of treatment that do not fit the descriptions of the main treatment types. Examples of other main treatment types may be living skills classes, outdoor therapy, relapse prevention and safe using or drug use reduction education and support.

In 2022–23:

- Other treatment accounted for 8.7% (20,490) of all treatment episodes.
- Of these episodes, 28% (8,133) reported other treatment as an additional treatment (tables Trt.4, Trt.61).
- Most other treatment episodes for a client's own alcohol or drug use were for alcohol (39%), amphetamines (26%) or cannabis (15%) (tables Trt.4, Trt.61, Trt.63).

Over the 10-year period to 2022–23:

- For clients receiving treatment for their own alcohol or drug use, most episodes lasted less than one month, decreasing from 64% in 2013–14 to 44% in 2022–23:
  - Episodes lasting 1 to 3 months increased from 14% in 2013–14 to 34% in 2022–23.
  - Episodes lasting one day fell from 26% in 2013–14 to 12% in 2022–23.
- The proportion of other treatment episodes for someone else's alcohol or drug use that lasted 2–29 days increased from 15% in 2013–14 to 29% in 2022–23, and episodes lasting one to 3 months increased from 14% to 42% since 2013–14.
- Median treatment duration for other treatment ranged from 36 days to 47 days for all clients for most years between 2013–14 and 2022–23, with the exception of 2015–16 (19 days) (tables Ov.11, Trt.68).

Treatment referral and completion

Treatment referrals are part of interventions that aim to reduce immediate or short-term harms from alcohol and other drug (AOD) use, engage and support people affected, and connect people to treatment services where required. As part of care, case management co-ordination involves ongoing treatment planning, goal setting, review and facilitation for the client to achieve their goals, including a supported referral and system navigation support to other services. It includes ensuring links are made with health or social welfare services, and that care is coordinated across care settings and systems (Department of Health and Aged Care 2019).

Key findings

In 2022–23:

- Self/family was the most common source of referral into treatment (36%).
- Almost 8 in 10 (78%) episodes ended within 3 months.
- Around 3 in 5 (59%) treatment episodes had an expected/planned completion.
- The median duration of episodes for a clients' own alcohol or drug use and for someone else's alcohol or drug use was around 3 to 4 weeks (28 and 19 days, respectively).

Over the 10-year period to 2022–23:

- Self/family treatment referrals decreased from 43% in 2013–14 to 36% in 2022–23.
- The proportion of episodes with an expected completion decreased from 64% to 59%.

In 2022–23, for all clients (235,461 episodes):

- The most common source of referral into treatment was self/family (36% or 85,362 episodes) followed by health services (32% or 74,163 episodes):
  - This referral pattern into treatment was consistent for most treatment types.
  - Health services were the most common referral source for information and education (54%), other treatment (39%), and assessment only (34%) (Table Trt.11).
- Diversion referrals fell from 16% in 2013–14 to 8.4% in 2022–23 over the same period (Table Trt.11).
- There a referral came from an 'other' referral source, treatment episodes increased from 7.4% (12630) in 2013–14 to 16% (34,795) in 2019–2020, then decreased to 13% (27,410) in 2022–23.

The most common referrals into treatment for a client's own alcohol or drug use (217,303 episodes) and someone else's alcohol or drug use (18,158 episodes) were similar in 2022–23:

- Self/family (36%) was most common for a client's own alcohol or drug use, followed by health service (31%).
- Self/family (35%) was most common for clients who received treatment for someone else's alcohol or drug use, followed by health services (33%) (tables Trt.10, Trt.11).
- Diversion (19,593 episodes) referrals into treatment were most common for a client's own alcohol or drug use, such as ecstasy (33%), cocaine (23%), and cannabis (21%) (Table Drg.13).

Over the 10-year period to 2022–23, treatment episodes where the referral source was:

- Self/family referrals decreased from 43% (or 77,784) in 2013–14 to 36% (or 85,362) in 2022–23.
- Health services increased from 25% (or 46,052) to 32% (or 74,163) over this time (tables Trt.10, Trt.11).

The source of referral into treatment varied according to clients' principal drug of concern. For example, in the 10 years to 2022–23, among episodes for a client's own alcohol or drug use (217,303 episodes) (Figure TREATMENT 1, Table Drg.13):

- Where alcohol was the principal drug of concern, referrals from health service increased from 31% (or 21,698) in 2013–14 to 37% (34,607) in 2022–23.
- Where amphetamines were the principal drug of concern, referrals from a health service increased from 21% (or 6,115) to 26% (or 13,303), while self/family referrals decreased from 43% (or 12,364) to 36% (or 18,938).
- Where cannabis was the principal drug of concern, the proportion of diversion (police or court diversion program) referrals into treatment increased from 2013–14 (33% or 13,349) to 2014–15 (38% or 14,919) before falling to 21% (7,990) in 2022–23.

Figure TREATMENT 1: Treatment episodes for own drug use, by principal drug of concern and referral source, 2013–14 to 2022–23

The line graph shows the proportion of episodes by source of referral among treatment episodes with alcohol as the principal drug of concern. Self/family was the most common source of referral in most years between 2013–14 and 2022–23, except for 2020–21 where the most common source of referral was from health services. In 2022–23, self/family as a source of referral accounted for 40.8% of episodes. A filter allows the user to view data for different principal drugs of concern.



Figure TREATMENT 1: Treatment episodes for own drug use, by principal drug of concern and referral source, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set, Table Drg.13.
http://www.aihw.gov.au

See notes >

References

Department of Health 2019.National Framework for Alcohol, Tobacco and Other Drug Treatment 2019–29 - external site opens in new window. Canberra: Department of Health. Viewed 23 April 2021.

Duration of treatment

In 2022–23:

- Around 3 in 4 treatment episodes ended within 3 months, both for clients who received treatment for their own alcohol or drug use (77% or 124,610) and for someone else's alcohol or drug use (79% or 14,434) (Table Ov.9).
- The median duration of treatment episodes was 4 weeks (28 days) for clients' own alcohol or drug use and almost 3 weeks (19 days) for clients who received support for someone else's alcohol or drug use (Table Ov.10).
- For clients' own alcohol or drug use, counselling had the longest median duration (66 days), while assessment only had the shortest (3 days) (Figure DURATION 1) (Table Ov.11).

Over the 10 years to 2022–23:

- Treatment episodes ending within 3 months has remained the most common duration for client's own alcohol or drug use (77% or 124,610).
- For clients' own alcohol or drug use, the median duration of treatment episodes fluctuated, from a low of 16 days in 2015–16, to a high of 29 days in 2021–22 before falling slightly to 28 days in 2022–23:
  - These trends were driven primarily by changes in the duration of support and case management episodes.
  - The median duration of counselling has increased from 55 days to 66 days over this period (Figure DURATION 1).
- For clients who received support for someone else's alcohol or drug use, the median duration fluctuated more widely, rising from a low of 14 days in 2018–19 to a high of 37 days in 2020–21, falling to 19 days in 2022–23 (tables Trt.12, Ov.11). This fluctuation was driven primarily by decreases in support and case management treatment duration.

Figure DURATION 1: Median duration of treatment episodes, by client type and main treatment type, 2013–14 to 2022–23

The line graph shows that the median duration of treatment episodes provided to all clients was longest for episodes with counselling as the main treatment type across most years between 2013–14 and 2022–23. In 2022–23, counselling episodes had a median duration of 67 days, compared with 43 days for rehabilitation and 44 days for 'other' main treatment types. A filter allows the user to view data for all clients, clients seeking treatment for their own drug use or clients seeking treatment for someone else's drug use.



Figure DURATION 1: Median duration of treatment episodes, by client type and main treatment type and median duration, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table OV.11.
http://www.aihw.gov.au

See notes >

Completion of treatment

Reasons for clients who no longer received treatment from an alcohol and other drug (AOD) treatment service include:

- expected completions (for example, treatment program completed)
- unplanned completions (for example, the client ceased to participate in the treatment program without notice)
- administrative completion (for example, client transferred to another service provider) (see Key terminology and glossary).

In 2022–23, among treatment episodes for a client's own alcohol or drug use (217,303 episodes):

- 3 in 5 (60% or 130,826) treatment episodes ended as expected (planned) completions.
- Around 1 in 5 (20% or 44,008) of treatment episodes ended due to an unplanned completion (Table Trt.8).

This pattern differed slightly for clients who received treatment for someone else's alcohol or drug use (18,158 episodes). The proportion of treatment episodes that ended due to unplanned completion was lower (10% or 1,818) than for a client's own alcohol or drug use (Figure COMPLETION 1, Table Trt.8).

Figure COMPLETION 1: Treatment episodes, by client type and reason for completion, 2013–14 to 2022–23

The stacked horizontal bar graph shows that most treatment episodes in 2022–23 ended with an expected/planned completion, regardless of client type. Treatment episodes provided to clients for their own drug use were more likely to end with an expected completion than were episodes provided to clients for someone else's drug use 60.2% compared with 43.2%, respectively). 42.7% of episodes provided to clients for other's drug use ended for other reasons, compared to 12.3% of episodes for clients' own drug use. A filter allows the user to view data for different years.



Figure COMPLETION 1: Treatment episodes, by client type and reason for cessation, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table Ov.7 and Trt.8.
http://www.aihw.gov.au

See notes >

In 2022–23, completion of treatment for a client's own alcohol or drug use (217,303) varied by principal drug of concern. For example, treatment episodes for:

- The most common principal drugs of concern had expected completion proportions ranging from 64% (or 24,417) for cannabis to 53% (27,441) for amphetamines.
- Volatile solvents (71% or 241) and nicotine (70% or 1,627) as the principal drugs of concern had the highest proportion of episodes ending with an expected completion.
- Amphetamines had the highest proportion of episodes for unplanned completions (24% or 125,44), followed by, cannabis and oxycodone (both 20% or 7,641 and 161, respectively) (Table Drg.14, Figure COMPLETION 2).

Figure COMPLETION 2: Treatment episodes for selected drugs, by principal drug of concern and reason for completion, 2013–14 to 2022–23

The stacked horizontal bar chart shows that expected/planned completion was the most common reason for cessation in treatment episodes for all selected principal drugs of concern in 2022–23. The proportion of episodes that ended with an expected completion ranged from 52.9% for amphetamines as the principal drug of concern to 71.3% for volatile solvents. A filter allows the user to view data for different years.



Figure COMPLETION 2: Treatment episodes for selected drugs, by principal drug of concern and reason for cessation, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table Drg.12.
http://www.aihw.gov.au

See notes >

Over the 10 years to 2022–23, for a client's own alcohol or drug use (217,303 episodes), the proportion of treatment episodes that ended in an expected completion decreased overall, falling by 4 percentage points to 60% (or 130,826) (Table Ov.7):

- Where alcohol was the principal drug of concern, around 3 in 5 episodes ended with an expected completion (ranging from 62% to 66% between 2013–14 and 2022–23).
- Where amphetamines were the principal drug of concern, the proportion of treatment episodes with an expected completion decreased from a peak of 62% (or 28,724) in 2015–16 to 53% (27,441) in 2022–23.
- Where cannabis was the principal drug of concern, the proportion of treatment episodes with an expected completion decreased from a peak of 73% (or 30,521) in 2016–17 to 64% (or 24,417) in 2022–23.
- Where heroin was the principal drug of concern, the proportion of treatment episodes with an expected completion ranged between 54% and 61% between 2013–14 and 2022–23 (Table Drg.12).

Over the 10 years to 2022–23, for someone else's alcohol or drug use (18,158 episodes):

- the proportion of treatment episodes with an expected completion fell from 63% (or 5,675) in 2013–14 to 43% (or 7,845) in 2022–23
- conversely, 'other' as a reason for ceasing treatment increased from 20% (or 1,746) in 2013–14 to 42% (or 7,632) in 2022–23 (Table Ov.7).

Agencies

The Australian Government and state and territory governments fund non-government and government agencies to provide a range of alcohol and other drug (AOD) treatment services (see Key terminology and glossary). This is a service provision-based collection and not demand-based. Treatment services are delivered in both residential and non-residential settings, and often include treatments such as detoxification, rehabilitation, counselling and pharmacotherapy.

The Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) contains a subset of information on publicly funded AOD treatment agencies and their service delivery outlets. An agency can have more than one service delivery outlet, located in different areas (see Policy Framework for details of collection scope).

Key findings

In 2022–23:

- 1,280 publicly funded agencies provided data about their treatment services to the AODTS NMDS.
- Nearly 7 in 10 (69%) agencies were non-government.
- Nearly 3 in 5 (57%) agencies were located in *Major cities.*
- Nationally, counselling was the most common main treatment type provided by agencies across all remoteness areas.

Nationally, over the 10-year period to 2022–23, the total number of publicly funded agencies providing AOD treatment almost doubled from 796 in 2013–14 to 1,280 in 2022–23.

In 2022–23, 1,280 publicly funded AOD treatment agencies reported to the AODTS NMDS. The number of agencies in each jurisdiction ranged from 17 in the Australian Capital Territory to 478 in New South Wales. The number of agencies reporting to the AODTS NMDS in 2022–23 increased from 1,274 in 2021–22.

Over the last 10 years, the total number of AOD treatment agencies almost doubled (from 796 in 2013–14 to 1,280 in 2022–23). This has been driven by AOD service increases in New South Wales, Victoria, Queensland, and Western Australia. The expansion in the sector has seen a growth in the number of non-government AOD treatment services (from 443 in 2013–14 to 883 in 2022–23) (Figure AGENCIES 1, Table Agcy.1).

The expansion has included new funding arrangements for existing AOD programs to increase service capacity, expand collaboration across agencies and deliver new treatment services. See the Alcohol and other drug treatment services NMDS Data Quality Statement, 2022–23 - external site opens in new window for further information.

Figure AGENCIES 1: Treatment agencies, by state and territory, 2013–14 to 2022–23

The line graph shows the number of treatment agencies from 2013–14 to 2022–23. New South Wales had the most number of agencies followed by Victoria across the 10 years to 2022–23. In 2022–23, there was 478 agencies in New South Wales and 350 agencies in Victoria.



Figure AGENCIES 1: Treatment agencies, by state and territory, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table Agcy.1.
http://www.aihw.gov.au

See notes >

Explore agencies:

- Service sector
- Location of agencies

Service sector

A mix of government and non-government agencies deliver publicly funded alcohol and other drug (AOD) treatment services. Nationally in 2022–23, nearly 7 in 10 (69%) of AOD treatment agencies were non-government, and these agencies provided 73% of all treatment episodes. In the decade from 2013–14, the proportion of non-government services has increased from 56% to 69% nationally.

Across most states and territories in Australia in 2022–23, the majority of AOD treatment agencies were non-government services, with proportions ranging from 62% in South Australia to 99% in Victoria. The exception was New South Wales, where over half (60%) of AOD treatment agencies were government services (Figure AGENCIES SECTOR 1).

In 2022–23, nearly 3 in 5 (57%) agencies were located in *Major cities*. Seven in 10 (70%) agencies located in *Major cities* were non-government agencies (tables Agcy.1–3).

Figure AGENCIES SECTOR 1: Treatment agencies, by service sector and state or territory, 2013–14 to 2022–23

The horizontal bar chart shows that 68.9% of treatment agencies in Australia were non-government in 2022–23. New South Wales had the highest proportion of government agencies (60.0%), while Victoria had the highest proportion of non-government agencies (99.1%). A filter allows the user to view different years of data. Buttons allow the user to navigate to a line chart presenting trend data disaggregated by sector (government and non-government) and number of agencies.



Figure AGENCIES SECTOR 1: Treatment agencies, by service sector and state or territory, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table Agcy.1.
http://www.aihw.gov.au

Location of agencies

Alcohol and other drug (AOD) treatment agencies can be analysed by the state or remoteness area in which the agencies are located.

In 2022–23:

- Nearly 3 in 5 (57% or 733) treatment agencies were located in *Major cities* and a quarter (25% or 315) were in *Inner regional* areas. Agencies in these two areas provided 89% of all treatment episodes (Figure AGENCIES REMOTENESS 1, tables Agcy.3–Agcy.4).
- Relatively few treatment agencies were located in *Remote* (2.7% or 34) and *Very remote* areas (2.5% or 32). Agencies in these two areas provided 2.3% of all treatment episodes.
- This pattern was similar across most states and territories, except for the Northern Territory where, because it does not contain *Major cities* and *Inner regional* areas, half (50%) of all agencies were located in *Remote* (35.5%) and *Very remote* (14.5%) areas, with the other half in *Outer regional* (50%) areas (Figure AGENCIES 2, Table Agcy.3).

Over the 10-year period to 2022–23:

- Nationally, the total number of agencies delivering AOD services has increased, rising from 796 agencies in 2013–14 to 1,280 agencies in 2022–23.
- The majority of agencies were located in *Major cities*: this trend was similar for most states and territories but does not apply to the Northern Territory and Tasmania, which do not have *Major cities* as a remoteness area.

Figure AGENCIES REMOTENESS 1: Treatment agencies, by remoteness area and state or territory, 2022–23

The horizontal bar chart shows that most agencies in New South Wales (61.8%), Victoria (60.6%), Queensland (45.1%), Western Australia (56.6%), South Australia (46.8%) and the Australian Capital Territory (100%) were located in *Major cities*. Tasmania and Northern Territory do not have any areas classified as *Major cities*. Most agencies in Tasmania were located in *Inner regional* areas (58.3%) and most agencies in the Northern Territory were located in *Outer regional* areas (50.0%). A filter allows the user to view different years of data.



Figure AGENCIES REMOTENESS 1: Treatment agencies by remoteness area and state or territory, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table Agcy.3.
http://www.aihw.gov.au

See notes >

Treatment type delivery varied by agency remoteness. Nationally, in 2022–23:

- Counselling was the most common main treatment type provided by agencies across all remoteness areas.
- The proportion of treatment episodes provided by agencies for counselling ranged from as high as 52% in *Very remote* areas to 33% in *Inner regional* areas (Figure AGENCIES REMOTENESS 2, Table Agcy.6).

The delivery of main treatment types also varied by agency remoteness at a jurisdictional level.

In 2022–23:

- In New South Wales, agencies across the majority of remoteness areas except for *Very remote* areas, mainly provided counselling as a treatment, ranging from 87% of treatment episodes in *Remote* areas to 33% in *Inner regional* areas. Whereas in *Very remote* areas support and case management was the most common main treatment type (92%).
- In Victoria, agencies in *Major cities* mostly provided counselling and support and case management (23% and 22% of episodes, respectively). *Inner regional* and *Outer regional* agencies mainly provided assessment only (28%) and counselling (32%), respectively.
- In Queensland, assessment only was the most common treatment type in *Remote* (54%) and *Outer regional* (39%) areas.
- In Western Australia around 9 in 10 treatment episodes in *Very remote* areas were for counselling (96%).
- In South Australia, support and case management was more likely to be provided in more *remote* areas (ranging from 5.1% in *Inner Regional* to 47% in *Very remote*) compared to *Major cities* (2.1%), while *Major cities* had the highest proportion of withdrawal management treatment episodes (23%).
- In the Northern Territory, assessment only was the most common treatment across all remoteness areas ranging from 38% in *Remote* areas to 56% in *Very remote* areas.
- In Tasmania, counselling was the most common treatment in *Inner regional* (52%) and *Outer regional* (44%) areas while rehabilitation was the most common treatment in *Remote* areas (97%) (Figure AGENCIES REMOTENESS 2, Table Agcy.6).

Note that remoteness categories are derived by applying a correspondence based on the agency's Statistical Area level 2 code (SA2). Australian Capital Territory only has the one geographical classification of *Major cities*. See technical notes for information on how this affects the reporting of the number of agencies in a particular remoteness category.

Figure AGENCIES REMOTENESS 2: Treatment episodes, by remoteness area of agency, main treatment type and state or territory, 2022–23

The horizontal bar chart shows that nationally in 2022–23, counselling was the most common main treatment type in all remoteness areas, ranging from 32.5% of episodes in *Inner regional* areas to 52.1% of episodes in *Very remote* areas. Filters allow the user to view data for different years and by state/territory.



Figure AGENCIES REMOTENESS 2: Treatment episodes by remoteness area of agency, main treatment type and state or territory, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table Agcy.6.
http://www.aihw.gov.au

See notes >

State and territory summaries

This section presents key state and territory findings on specialist alcohol and other drug (AOD) treatment services, the people they treat, and the treatment they provided in 2022–23.

The technical notes page provides details on the data, with further information available in the Alcohol and other drug treatment services NMDS 2022–23 Quality Statement - external site opens in new window. In addition, a series of state and territory *supplementary tables* accompanying the annual report are also available.

Key findings

In 2022–23:

- 1,280 publicly funded agencies provided services for clients who received AOD treatment in Australia, ranging from 17 in the Australian Capital Territory to 478 in New South Wales.
- In all states and territories, the greatest numbers of clients were treated for alcohol as their principal drug of concern, ranging from 13,674 clients in Queensland to 1,224 in Tasmania.
- **Alcohol** was the most common principal drug of concern for treatment all states and territories; Northern Territory (69%), Tasmania (51%), Western Australia (48%), Australian Capital Territory (46%), New South Wales (44%), South Australia (41%), Queensland (41%) and Victoria (39%) (nationally 43% of treatment episodes).
- **Amphetamines** were the second most common principal drug of concern in most states except for Northern Territory. Treatment episodes for amphetamines ranged from 20% in Tasmania to 30% in South Australia (nationally the second most common drug of concern; 24%).
- **Counselling** was the most common main treatment type nationally (34%), and the most common in all states except the Northern Territory where the most common treatment type was assessment only.

Over the period 2013–14 to 2022–23:

- The **number of publicly funded agencies** rose from 796 to 1,280 in 2022–23, a change largely driven by increases in New South Wales (from 292 to 478) and Victoria (from 130 to 350).
- Consistently, the greatest numbers of clients have been treated for alcohol as their most common principal drug of concern in New South Wales, Tasmania, the Australian Capital Territory, and the Northern Territory. In the remaining states, amphetamines or cannabis briefly interrupted this trend.
- **Similar to national results, Alcohol, amphetamines, cannabis and heroin** were the most common principal drugs of concern treated in 4 of the 8 states and territories.
- **Counselling** was the most common main treatment type across most states and territories during this period.

State and territory client rates

Nationally, the rate of clients who received specialist AOD treatment was 568 per 100,000 people in 2022–23, the lowest rate since 2015–16 (Table SCR.21). The rate of clients treated by publicly funded AOD treatment agencies in each state and territory varied over time (Figure CLIENTS 1).

Figure CLIENTS 1: AODTS clients and treatment episodes, by state and territory, 2013–14 to 2022–23

The line chart shows that there were 568 clients per 100,000 population in Australia in 2022–23, decreasing from 576 clients per 100,000 population in 2021-22. Across the period 2013–14 to 2022–23, the rate of clients was highest in the Northern Territory (1,424 per 100,000 in 2022–23) and lowest in New South Wales (384 per 100,000 in 2022–23). A filter allows the user to view by rate of clients, number of clients or number of treatment episodes.



Title: Figure AODTS CLIENTS 1: AODTS clients and treatment episodes, by state and territory, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SCR.21
http://www.aihw.gov.au

See notes >

Over the period from 2013–14 to 2022–23, in 4 of 8 states and territories, the rate of clients remained consistently higher than the rate of clients nationally:

- In **New South Wales, Victoria and Queensland**, the rates of clients fluctuated but with no substantial or prolonged changes over this period.
- In **South Australia, Tasmania, and the Australian Capital Territory** there have been steady declines in the rates of clients.
- In the **Northern Territory**, the rate of clients increased from 1,397 clients per 100,000 in 2013–14 to 1,796 per 100,000 in 2019–20, falling to 1,424 per 100,000 in 2022–23.
- In **Western Australia**, the rate of clients increased between 2013–14 and 2018–19 from 697 per 100,000 to 845 per 100,000, then falling to 604 clients per 100,000 in 2022–23.

For more information see the Data quality statement - external site opens in new window.

Characteristics of clients

The following data visualisations shows:

- Number of clients by state/territory and client type, 2013–14 to 2022–23
- Number of clients by state/territory and sex, 2013–14 to 2022–23
- Number of clients by state/territory and age group, 2013–14 to 2022–23
- Number of clients by state/territory and Indigenous status, 2013–14 to 2022–23

Figure AODTS CLIENTS 2: Clients, by client type, sex, age group and Indigenous status, state and territory, 2013–14 to 2022–23

The stacked vertical bar chart shows the number of clients in New South Wales by client type across the period of 2013–14 to 2022–23. Across the 10 years, most clients in New South Wales received treatment for their own drug use. In 2022–23, 27,383 clients in New South Wales received treatment for their own drug use. The filter allows users to select a state or territory and to view the data by number of clients or per cent.

Navigation buttons allow the user to navigate between the following tabs: Client type, Sex, Age, and Indigenous status.

The following data visualisations shows:

- Number of clients by state/territory and principal drug of concern, 2013–14 to 2022–23
- Number of clients by state/territory and main treatment type, 2013–14 to 2022–23
- Number of clients by state/territory and source of referral, 2013–14 to 2022–23
- Number of clients by state/territory and reason for cessation, 2013–14 to 2022–23

Figure AODTS CLIENTS 3: Clients, by principal drug of concern, treatment characteristics and state and territory, 2013–14 to 2022–23

The stacked vertical bar chart shows the number of clients in New South Wales by principal drug of concern across the period of 2013–14 to 2022–23. Across the 10 years, alcohol was the most common principal drug of concern in New South Wales. In 2022–23, 11,165 clients in New South Wales had alcohol as a principal drug of concern. The filter allows users to select a state or territory and to view the data by number of clients or per cent.

Navigation buttons allow the user to navigate between the following tabs: Principal drug of concern, Main treatment, Referral source, and Reason for cessation.

Select disaggregation to view:

Principal drug of concern | Main treatment | Source of referral | Reason for cessation

Select state or territory: New South Wales

Select measure: Number of clients



Principal drug of concern (select to highlight):

Alcohol | Cannabis | Pharmaceuticals | Volatile solvents | All other drugs

Amphetamines | Heroin | Cocaine and MDMA | Nicotine | Not stated

Title: Figure AODTS CLIENTS 3: Clients, by principal drug of concern and treatment characteristics and state and territory, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SCR NSW.5-8, SCR VIC.5-8, SCR QLD.5-8, SCR WA.5-8, SCR SA.5-8, SCR TAS.5-8, SCR ACT.5-8, SCR NT.5-8
http://www.aihw.gov.au

See notes >

Explore state and territory summaries

- New South Wales
- Victoria
- Queensland
- Western Australia
- South Australia
- Tasmania
- Australian Capital Territory
- Northern Territory
- Technical notes - state and territory summaries

New South Wales

In 2022–23, 478 publicly funded alcohol and other drug (AOD) treatment agencies in New South Wales provided 44,963 treatment episodes to 27,874 clients (tables ST NSW.1, Agcy.1, SCR.21).

New South Wales reported:

- While client numbers have decreased between 2021-22 and 2022-23 (28,364 to 27,874), both years were an increase from 2013-14 (24,184).
- More clients are accessing AOD services in 2022–23 than 2013–14, after adjusting for population growth (384 clients per 100,000 people compared with 372 per 100,000, respectively).
- The number of treatment episodes increased by 6% between 2013–14 and 2022–23 (42,406 and 44,963 episodes, respectively), peaking in 2018–19 (52,563 episodes) (tables ST NSW.2, SCR.21).

During 2023, there was a transition between data warehouses in New South Wales, this may impact the data for the 2022–23 period.

New South Wales, 2022–23

The visualisation shows that 44,963 treatment episodes were provided to 27,874 clients in New South Wales in 2022–23. This equates to a rate of 619 episodes and 384 clients per 100,000 population, which is lower than the national rate (1,017 episodes and 568 clients per 100,000 population).



Note: Proportions were calculated based on total closed treatment episodes and estimated clients.
Title: New South Wales, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SCR.21.
http://www.aihw.gov.au

In 2022–23, most clients in New South Wales attended 1 agency (79% of clients) (Table SCR.23). Clients received an average of 1.6 treatment episodes, similar to the national average (1.8 episodes) (Table SCR.21).

Client demographics

In 2022–23:

- Nearly all (98%) clients in New South Wales received treatment for their own alcohol or drug use, of which almost 2 in 3 people were male (63%) (Figure NSW 1).
- Females were more likely to receive treatment for someone else's drug use than males (56% of female clients compared with 42% of male clients).
- Nearly half (49%) of all clients were aged 20–39 years.
- 1 in 5 (20%) of all clients were Aboriginal and Torres Strait Islander (First Nations) people, consistent with the national proportion (18%).
- The majority (86%) of all clients were born in Australia and nearly all (97%) reported English as their preferred language (tables SC.5, SC NSW.1–3, SC NSW.21–22).

Figure NSW 1: AODTS clients by client type and selected demographics, New South Wales, 2022–23

The visualisation includes a series of horizontal bar graphs showing that, in 2022–23 in New South Wales, around two-thirds (62%) of all clients were male, 49% were aged 20–39 and 20% were First Nations people. Nearly all clients (97%) listed English as their preferred language and most (86%) were born in Australia.



Title: Figure NSW 1: AODTS clients by client type and selected demographics, New South Wales, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC NSW.1–3 and SC NSW.21–22.
http://www.aihw.gov.au

New and returning clients

In 2022–23:

- Over half (56% or 15,285) of all clients in New South Wales were returning clients, who have previously received AOD treatment from a service at some point since 2013–14.
- Around 4 in 9 (44% or 12,105) of all clients in New South Wales were a new client, who had not previously received treatment since 2013–14 (see Key terminology and glossary) (Table SCR.28).

Drugs of concern

In 2022–23, among clients in New South Wales who received treatment for their own alcohol or drug use (44,117 episodes):

- Alcohol was the most common principal drug of concern (44% or 19,268 episodes).
- Amphetamines as a principal drug of concern accounted for over 1 in 5 episodes (23% or 10,295), followed by cannabis (15% or 6,458) (Figure NSW.2, tables SC.1, ST NSW.6).

Figure NSW 2: Proportion of treatment episodes for own drug use, by drug of concern, New South Wales, 2013–14 to 2022–23 (per cent)

The grouped horizontal bar chart shows that, in 2022–23, alcohol was the most common principal drug of concern in treatment episodes provided to clients in New South Wales for their own drug use (43.7%). This was followed by amphetamines (23.3%), cannabis (14.6%), and heroin (7.1%). Nicotine and cannabis were the most common additional drugs of concern (11.6% and 11.7% of episodes, respectively), followed by amphetamines (7.5%) and alcohol (6.5%).



Title: Figure NSW 2: Proportion of treatment episodes for own drug use, by drug of concern, New South Wales, 2013–14 to 2022–23 (per cent)
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST NSW 7.
http://www.aihw.gov.au

In 2022–23, for clients who received treatment for their own use of amphetamines (10,295 episodes):

- Methamphetamine was reported as a principal drug of concern in 93% (9,605) of treatment episodes (Figure NSW 3, Table Drg.4).
- Over half (52%) of the treatment episodes where methamphetamine was the principal drug of concern, smoking was the most common method of use, followed by injecting (38%) (Figure NSW 3).

Figure NSW 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), New South Wales (per cent)

The line graph shows that, between 2013–14 and 2022–23, methamphetamine has remained the most common drug of concern among amphetamine-related treatment episodes for clients' own drug use. The proportion of methamphetamine-related episodes increased from 54.8% of amphetamine-related episodes in 2013–14 to 93.3% in 2022–23. The user can use buttons to view data for method of use.



Notes:
1. Other amphetamines includes Dexamphetamine, Amphetamine analogues and Amphetamines nec.
2. Amphetamines nfd are amphetamines not further defined.
3. Coding of methamphetamines has improved over time due to advancements in workforce training, agency coding practices and new system updates.
Title: Figure NSW 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), New South Wales (per cent)
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. ST NSW.6.
http://www.aihw.gov.au

Clients can nominate up to 5 additional drugs of concern; these drugs are not necessarily the subject of any treatment within the episode (see technical notes).

In 2022–23, where additional drugs of concern were reported, cannabis and nicotine were the most common additional drugs of concern (both 12% of episodes), followed by amphetamines (7.5%) and alcohol (6.5%) (Table ST NSW.7).

Over the period 2013–14 to 2022–23 New South Wales was consistent with national trends:

- Alcohol remained the most common drug of concern, although there was variation in treatment episode numbers during this time, fluctuating from 17,851 to 19,268 episodes over this period.
  - The proportion of alcohol treatment episodes relative to all other drugs of concern, declined from 44% in 2013–14 to 37% in 2016–17, rising to 44% again in 2022–23 (Figure NSW 2, Table ST NSW.6).
- Amphetamines were the second most common principal drug of concern in 2022–23 and have increased since 2013–14 (from 17% or 6,748 episodes to 23% or 10,295 episodes).
  - Within the amphetamines group, methamphetamine was reported as the principal drug of concern in over half (55%) of episodes in 2013–14, rising to 63% in 2017–18 before a considerable increase to 93% in 2022–23 (Figure NSW 3).
  - The rise in episodes may be related to increases in funded treatment services and/or improvement in agency coding practices for methamphetamine.
- Cannabis was the third most common principal drug of concern, decreasing from 20% (8,359 episodes) to 15% (6,458 episodes) in 2022–23 (Figure NSW 2, Table ST NSW.6).

Treatment

In 2022–23, for treatment episodes in New South Wales (44,963 episodes):

- Counselling was the most common main treatment provided (37% of episodes), followed by support and case management (15%) and withdrawal management (14%).
- Where an additional treatment was provided as a supplementary to the main treatment, 'other' treatment (14%) was the most common, followed by counselling (8.8%) (Table ST NSW.13). See technical notes for further information on calculating proportions for additional treatment type.

Over the period 2013–14 to 2022–23:

- Counselling remained the most common treatment type for all episodes relative to other treatment types, rising from 35% (14,977 episodes) in 2013–14 to 42% (16,090) in 2016–17, dropping to 37% (16,690) in 2022–23.
- Withdrawal management episodes have fallen in the 10 years to 2022–23 from 18% (7,618 episodes) to 14% (6,345 episodes) (tables ST NSW.13, NSW.15).

Figure NSW 4: Proportion of treatment episodes, by treatment type, New South Wales, 2013–14 to 2022–23
The grouped horizontal bar chart shows that, in 2022–23, the most common main treatment type provided to clients in New South Wales for their own drug use was counselling (37.1% of episodes). This was followed by support and case management (15.3%) and withdrawal management (14.1%). 'Other' was the most common additional treatment type (14.2%), followed by counselling (8.8%).



Agencies

In 2022–23, in New South Wales:

- 3 in 5 (60% or 287) AOD agencies were government treatment agencies.

- The majority (64%) of the 478 publicly funded treatment agencies were located in *Major cities*, followed by *Inner regional* areas (31%).
- Agencies located in *Major cities* provided over 2 in 3 (69%) of all treatment episodes.
- Less than 1% of treatment agencies were located in *Remote* or *Very remote* areas – these provided less than 1% of all treatment episodes (156 episodes)
- Across all remoteness areas, the majority of agencies were government agencies, ranging from 50% in *Very remote* areas and 100% in *Remote areas* (Figure NSW 5, tables Agcy.1, Agcy.3–4).

In the period 2013–14 to 2022–23, the number of publicly funded treatment agencies in New South Wales rose from 292 to 478 (Table Agcy.1).

Figure NSW 5: Number of agencies, by remoteness area and sector, New South Wales, 2022–23

The horizontal bar chart shows that most treatment agencies in New South Wales in 2022–23 were located in *Major cities* (304 agencies), followed by *Inner regional areas* (146 agencies) and *Outer regional areas* (25 agencies). 4 treatment agencies were located in *Remote* and *Very remote* areas. Of the total 478 treatment agencies, 60.0% (287 agencies) were government agencies.



Title: Figure NSW 5: Number of agencies, by remoteness area and sector, New South Wales, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set.
http://www.aihw.gov.au

Victoria

In 2022–23, 350 publicly funded alcohol and other drug (AOD) treatment agencies in Victoria provided 92,888 treatment episodes to 37,417 people (tables Agcy.1, SCR.21).

Victoria reported:

- There was a 2.9% increase in client numbers in 2022–23 (37,417) compared with the previous year where client numbers were impacted due to COVID-19 and state-wide system changes.
- Client numbers increased gradually from 2013–14 (29,548), with the largest increase in clients from 2017–18 (33,006) to 2019–20 (37,391).
- More clients are accessing AOD services in 2022–23 than 2013–14, after adjusting for population growth (633 clients per 100,000 people compared with 580 per 100,000, respectively).
- A 6% increase in treatment episodes from 2021–22 (87,630 episodes) to 2022–23 (92,888 episodes) (Table SCR.21).
- The number of treatment episodes increased by 56% since 2013–14 (59,392 episodes) to 2022–23 (92,888 episodes), falling to its lowest number of episodes in 2014–15 (45,855 episodes) (Table ST VIC.2).

Victoria, 2022–23

The visualisation shows that 92,888 treatment episodes were provided to 37,417 clients in Victoria in 2022–23. This equates to a rate of 1,571 episodes and 633 clients per 100,000 population, which is higher than the national rate (1,017 episodes and 568 clients per 100,000 population).



Note: Proportions were calculated based on total closed treatment episodes and estimated clients.
Title: Victoria, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SCR.21.
http://www.aihw.gov.au

In 2022–23, over 7 in 10 (72%) clients in Victoria attended 1 agency and received an average of 2.5 treatment episodes, which is higher than the national average of 1.8 treatment episodes (tables SCR.21, SCR.23). This is due to the methods used in Victoria's data collection system, where each type of treatment (regardless of main or additional treatment) results in a separate treatment episode (see Data Quality Statement - external site opens in new window for further information).

Client demographics

In 2022–23:

- Nearly 9 in 10 (87%) clients in Victoria received treatment for their own alcohol or drug use, of which over half (53%) of people were male (Figure VIC 1, tables SC VIC.1, SCR.27).
- 2.2% of all clients reported sex as 'another term', the highest proportion reported across all states and territories in the collection period. 'Another term' replaced the category 'other' in 2022–23. 'Other' was collected for the first time in 2018–19 (Table SC VIC.1).
- Over half (53%) of all people were aged 20–39 years.
- Almost 1 in 10 (9.8%) of all clients were Aboriginal and Torres Strait Islander (First Nations) people, which is lower than the national proportion (18%).
- The majority (82%) of all clients were born in Australia and mostly (95%) reported English as their preferred language (tables SC VIC.1–3, SC.4, SC VIC.21–22).

Figure VIC 1: AODTS clients by client type and selected demographics, Victoria, 2022–23

The visualisation includes a series of horizontal bar graphs showing that, in 2022–23 in Victoria, 52% of all clients were male, 53% were aged 20–39 and 9.8% were First Nations people. Nearly all clients (95%) listed English as their preferred language and most (82%) were born in Australia.



Title: Figure VIC 1: AODTS clients by client type and selected demographics, Victoria, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC VIC.1–3 and SC VIC.21–22.
http://www.aihw.gov.au

New and returning clients

In 2022–23:

- Over half (55% or 20,580) of all clients in Victoria were returning clients, who have previously received AOD treatment from a service at some point since 2013–14.
- Around 4 in 9 (45% or 16,733) of all clients in Victoria were a new client, who had not previously received treatment since 2013–14 (see Key terminology and glossary) (Table SCR 28).

Drugs of concern

In 2022–23 for clients in Victoria who received treatment for their own alcohol or drug use (78,323 episodes):

- Alcohol was the most common principal drug of concern, accounting for 39% (30,859) of treatment episodes.
- Amphetamines (26% or 20,514 episodes) were the second most common principal drug of concern, followed by cannabis (17% or 13,287) (Figure VIC 2, Table ST VIC.6).

Figure VIC 2: Proportion of treatment episodes for own drug use, by drug of concern, Victoria, 2013–14 to 2022–23

The grouped horizontal bar chart shows that, in 2022–23, alcohol was the most common principal drug of concern in treatment episodes provided to clients in Victoria for their own drug use (39.4%). This was followed by amphetamines (26.2%), cannabis (17.0%), and heroin (4.4%). Cannabis was the most common additional drug of concern (6.9% of episodes), followed by nicotine (4.0%) and alcohol (4.5%).



Title: Figure VIC 2: Proportion of treatment episodes for own drug use, by drug of concern, Victoria, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables ST VIC.7.
http://www.aihw.gov.au

In 2022–23, for clients who received treatment for their own use of amphetamines (20,514 episodes):

- Methamphetamine was reported as a principal drug of concern in nearly 7 in 10 (68% or 14,019) of treatment episodes (Figure VIC 3).
- Smoking was the most common method of use in 57% of episodes where methamphetamine was the principal drug of concern, followed by injecting (18%) (Figure VIC 3).

Victoria is working with service providers to encourage more specific reporting of amphetamine use (for example, to reduce the use of 'amphetamines not further defined' code where possible).

Figure VIC 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), Victoria (per cent)

The line graph shows that, from 2013–14 to 2018–19, 'amphetamines not further defined' was the most common drug of concern among amphetamine-related treatment episodes for clients' own drug use. In 2019–20, methamphetamine became the most common drug of concern. The proportion of episodes for amphetamines not further defined decreased from 2017–18 (91.4% of amphetamine-related episodes) to 2022–23 (30.5%), while episodes increased for methamphetamines (from 5.9% to 68.3%). Buttons allow the user to navigate to data on method of use.



Notes
1. Other amphetamines includes Dexamphetamine, Amphetamine analogues and Amphetamines nec.
2. Amphetamines nfd are amphetamines not further defined.
3. Coding of methamphetamines has improved over time due to advancements in workforce training, agency coding practices and new system updates.
Title: Figure VIC 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), Victoria (per cent)
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST VIC.6.
http://www.aihw.gov.au

In 2019–20, Victoria reported comparatively high incidences of 'Not stated drugs' (15%) as the drug of concern. This proportion decreased in 2020–21 (2.1%), due to work with service providers by the Victorian Agency for Health Information to encourage more specific reporting of drug of concern. In 2022–23, this remains low, 4.6% of treatment episodes. For more information see the Data

quality statement - external site opens in new window.

Clients can nominate up to 5 additional drugs of concern; these drugs are not necessarily the subject of any treatment within the episode (see technical notes).

In 2022–23, where additional drugs of concern were reported, cannabis was the most common (6.9% of episodes), followed by alcohol and nicotine (4.5% and 4.0%, respectively) (Table ST VIC.7).

Over the period 2013–14 to 2022–23:

- Alcohol was the most common principal drug of concern for treatment episodes except in 2019–20 when amphetamines were the most common principal drug of concern (28% and 29% respectively):
  - The proportion of episodes ranged from 41% in 2013–14 to 28% in 2019–20, before increasing to 39% in 2022–23.
  - The number of episodes fell 26% from 21,259 in 2013–14 to 15,820 in 2014–15, before almost doubling to 30,859 episodes in 2022–23 (Figure VIC 2, Table ST VIC.7).
- Amphetamines were the second most common principal drug of concern for treatment episodes except in 2013–14 and 2014–15, when cannabis was the second most common principal drug of concern (21% and 22% respectively):
  - The proportion of episodes with a principal drug of concern for amphetamines increased from 16% in 2013–14 to peak at 30% in 2018–19, decreasing in 2022–23 (26%).
  - Within the amphetamines group, methamphetamine was reported as the principal drug of concern for the first time in 2014–15 (2.2% of episodes) followed by a large increase in 2018–19 (43%) and 2022–23 (68%) (Figure VIC 3).
  - The rise in episodes for methamphetamine is mainly due to improvements in agency coding practices for methamphetamine, although some of the increase in episodes could be related to increases in funded treatment services.
- The proportion of treatment episodes for cannabis decreased from 21% in 2013–14 to 17% in 2022–23 (Figure VIC 2, Table ST VIC.7).

Treatment

In 2022–23, for treatment episodes in Victoria (92,888 episodes):

- Counselling was the most common treatment type (23% of episodes) followed by support and case management and assessment only (both 22% of episodes) (Figure VIC 4; Table ST VIC.13).
- The majority of services who submit AODTS NMDS data use the Victorian Alcohol and Drug Collection (VADC), which does not differentiate between main and other treatment types. A small proportion of services who submit AODTS NMDS data use their own data collection systems, which do differentiate between main and other treatment types.

Over the period from 2013–14 to 2022–23:

- Counselling remained one of the most common main treatments for all episodes in 2022–23 (23%), though this proportion has halved since 2013–14 (56%).
- Support and case management as a main treatment increased from 12% in 2013–14, peaking in 2015–16 (30%) and falling to 22% in 2022–23.
- Assessment only as a main treatment increased from 6.5% in 2013–14 to 22% in 2022–23.
- Withdrawal management decreased from 19% to 11% and 'other' treatment increased from 0.5% to 17% over the same period (Figure VIC 4, Table ST VIC.13).

Increases in 'other' treatment in Victoria relate to additional funding for programs where the main treatment type was categorised as 'other'. This includes other types of services coded through the VADC collection (which started in 2018), these may not align with the main treatment types.

Figure VIC 4: Proportion of treatment episodes, by treatment type, Victoria, 2013–14 to 2022–23

The grouped horizontal bar chart shows that, in 2022–23, the most common main treatment type provided to clients in Victoria for their own drug use was counselling (23.3% of episodes). This was followed by support and case management (22.1%), and assessment only (22.1%). Information and education was the most common additional treatment type (0.6%), followed by support and case management (0.4%).



Agencies

In 2022–23, in Victoria:

- Only 3 of the 350 AOD agencies that received public funding were government treatment agencies.
- Almost 3 in 5 (59%) treatment agencies were located in *Major cities*, followed by *Inner regional* areas (29%) (Figure VIC 5; Table Agcy.3)
- Victoria does not have any areas classified as *Remote* or *Very remote.*

In the period from 2013–14 to 2022–23, the number of publicly funded treatment agencies in Victoria increased from 130 in 2013–14 to 404 in 2018–19, dropping to 350 in 2022–23 (Table Agcy.1).

The increase in agency numbers over time in Victoria is attributed to counting each location of a service delivery outlet, which may be located in different areas for a single agency.

Figure VIC 5: Number of agencies, by remoteness area and sector, Victoria, 2022–23

The horizontal bar chart shows that most treatment agencies in Victoria were located in *Major cities* (207 agencies), followed by *Inner regional areas* (103 agencies) and *Outer regional areas* (40 agencies) in 2022–23. Of the total 350 treatment agencies, 99.1% (347 agencies) were non-government agencies.



Title: Figure VIC 5: Number of agencies, by remoteness area and sector, Victoria, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set.
http://www.aihw.gov.au

Queensland

In 2022–23, 179 publicly funded alcohol and other drug (AOD) treatment agencies in Queensland provided 53,280 treatments to 36,331 clients (tables Agcy.1, SCR.21).

Queensland reported:

- Client numbers increased from 28,960 in 2013–14 to 36,331 in 2022–23. There was a 5.1% increase between 2021–22 and 2022–23 from 34,565 to 36,331.
- More clients are accessing AOD services in 2022–23 than 2013–14, after adjusting for population growth (768 clients per 100,000 people compared with 714 per 100,000, respectively) (Table SCR.21).
- A 7.3% increase in treatment episodes from 49,674 in 2021–22 to 53,280 in 2022–23, and a 48% increase in treatment episodes since 2013–14 (36,093) (Table ST QLD.2).

Queensland, 2022–23

The visualisation shows that 53,280 treatment episodes were provided to 36,331 clients in Queensland in 2022–23. This equates to a rate of 1,126 episodes and 768 clients per 100,000 population, which is higher than the national rate (1,017 episodes and 568 clients per 100,000 population).



Note: Proportions were calculated based on total closed treatment episodes and estimated clients.
Title: Queensland, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SCR.21.
http://www.aihw.gov.au

In 2022–23, most (85%) clients in Queensland attended 1 agency, and received an average of 1.5 treatment episodes, which is lower than the national average of 1.8 treatment episodes (tables SCR.21, SCR.23).

Client demographics

In 2022–23:

- Nearly all (97%) clients in Queensland received treatment for their own alcohol or drug use, of which over 3 in 5 (63%) people were male (Figure QLD 1).
- Clients who received treatment for someone else's alcohol or drug use were more likely to be female (around 7 in 10 or 72%).
- Almost half (48%) of people were aged 20–39 years, and 12% were aged 10–19 years which is higher than the national proportion for clients aged 10–19 years (9.3%).
- About 1 in 5 (19%) of all clients were Aboriginal and Torres Strait Islander (First Nations) people, which is consistent with the national proportion (18%).
- The majority (89%) of all clients were born in Australia and nearly all (99%) reported English as their preferred language (tables SC QLD.1–3, SC.3–4, SC QLD.21–22).

Figure QLD 1: AODTS clients by client type and selected demographics, Queensland, 2022–23

The visualisation includes a series of horizontal bar graphs showing that, in 2022–23 in Queensland, 62% of all clients were male, 48% were aged 20–39 and 19% were First Nations people. Nearly all clients (99%) listed English as their preferred language and most (89%) were born in Australia.



Title: Figure QLD 1: AODTS clients by client type and selected demographics, Queensland, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC QLD.1–3 and SC QLD.21–22.
http://www.aihw.gov.au

New and returning clients

In 2022–23, of all clients in Queensland there was an equal proportion of both returning and new clients:

- Half (50% or 18,145) of all clients were returning clients, who have previously received AOD treatment from a service at some point since 2013–14.
- Half (50% or 17,983) of all clients were a new client, who had not previously received treatment since 2013–14 (see Key terminology and glossary) (Table SCR 28).

Drugs of concern

In 2022–23, for clients in Queensland who received treatment episodes for their own alcohol or drug use (52,127 episodes):

- Alcohol was the most common principal drug of concern (41% or 21,407 episodes) (Figure QLD 2, Table ST QLD.6).
- Amphetamines and cannabis were the second most common principal drugs of concern in Queensland, with 22% for amphetamines (11,563 episodes) and 22% for cannabis (11,286 episodes).
- In Queensland, the level of cannabis reported as the principal drug of concern is a result of the police and illicit drug court diversion programs operating in the state (Table ST QLD.12).

Figure QLD 2: Proportion of treatment episodes for own drug use, by drug of concern, Queensland, 2013–14 to 2022–23

The grouped horizontal bar chart shows that, in 2022–23, alcohol was the most common principal drug of concern in treatment episodes provided to clients in Queensland for their own drug use (41.1%). This was followed by cannabis (21.7%) and amphetamines (22.2%). Cannabis was the most common additional drug of concern (8.7% of episodes), followed by alcohol (5.0%) and amphetamines (4.6%).



Title: Figure QLD 2: Proportion of treatment episodes for own drug use, by drug of concern, Queensland, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST QLD.7.
http://www.aihw.gov.au

In 2022–23, for clients who received treatment for their own use of amphetamines (11,563):

- Methamphetamine was reported as a principal drug of concern in over 9 in 10 (91%) treatment episodes (Figure QLD 3).
- In almost half (49%) of treatment episodes where methamphetamine was the principal drug of concern, injecting was the most common method of use, followed by smoking (38%) (Figure QLD 3).

Figure QLD 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), Queensland (per cent)

The line graph shows that, from 2013–14 to 2014–15, 'amphetamines not further defined' was the most common drug of concern among amphetamine-related treatment episodes for clients' own drug use. In 2015–16, methamphetamine became the most common drug of concern. The proportion of episodes for amphetamines not further defined decreased from 2014–15 (46.2% of amphetamine-related episodes) to 2022–23 (3.8%), while episodes increased for methamphetamines (from 43.7% to 91.0%). Buttons allow the user to navigate to data on method of use of amphetamines.



Notes
1. Other amphetamines includes Dexamphetamine, Amphetamine analogues and Amphetamines nec.
2. Amphetamines nfd are amphetamines not further defined.
3. Coding of methamphetamines has improved over time due to advancements in workforce training, agency coding practices and new system updates.
Title: Figure QLD 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), Queensland (per cent)
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST QLD.6.
http://www.aihw.gov.au

Clients can nominate up to 5 additional drugs of concern; these drugs are not necessarily the subject of any treatment within the episode (see technical notes).

Where additional drugs of concern were reported, cannabis was the most common additional drug (8.7% of episodes), followed by nicotine (5.3%) and alcohol (5.0%) (Table ST QLD.7).

Over the period 2013–14 to 2022–23:

- Alcohol was the most common principal drug of concern in 2013–14, and in 2018–19 replaced cannabis as the most common principal drug of concern.
  - The proportion of episodes for alcohol as a principal drug of concern increased from 38% in 2013–14 to 41% in 2022–23, relative to all other principal drugs of concern. However, the number of treatment episodes almost doubled over this period from 13,188 episodes to 21,407 (Table ST QLD.7).
- Cannabis was the second most common principal drug of concern, with treatment episodes increasing from 34% in 2013–14, peaking at 39% in 2015–16 and falling to 22% in 2022–23. From 2013–14 to 2022–23, treatment episodes decreased from 11,796 to 11,286.
- The proportion of episodes for amphetamines as a principal drug of concern doubled since 2013–14 (12% to 22%), with the number of treatment episodes increasing from 4,362 to 11,563 over this period.
  - Within the amphetamines group, methamphetamine was reported as the principal drug of concern in 26% of episodes in 2013–14, rising to 65% in 2015–16, then 91% in 2022–23 (Figure QLD 3).
  - The rise in episodes where methamphetamine was the principal drug of concern may be related to increases in funded treatment services and improvements in agency coding practices for methamphetamine.
- The proportion of treatment episodes in Queensland where cannabis was the principal drug of concern was higher than the national proportion in 2022–23 (22% compared with 17%) (Table Drg.1). This trend has been consistent for the 10-year period.

Treatment

Changes to AOD reporting in Queensland

In 2020–21, Queensland Health transitioned to an integrated public AOD and mental health system for reporting. The introduction of this system improved the capability to report assessment only as a main treatment type. This resulted in increases in treatment episodes with assessment only as a main treatment type and is considered a more accurate representation of the treatment being provided by the sector.

Prior to 2020–21, treatment episodes provided to people diverted into AOD services by police and court diversion programs were recorded as information and education. This resulted in a high proportion of information and education treatment episodes in Queensland. From 2020–21, the police and court diversion programs are now reported as counselling which is a more accurate representation of the treatment being provided. See Data Quality Statement - external site opens in new window for further information.

In 2022–23, for treatment episodes in Queensland (53,280 episodes):

- Counselling was the most common main treatment (40% of episodes), followed by assessment only (34%) (Figure QLD 4).
- The proportion of episodes for information and education as a main treatment dropped 17 percentage points from 2019–20 (21%) to 2022–23 (3.7%). This was due to a review of coding practices which resulted a large proportion of episodes previously coded as information and education being coded as counselling (Table ST QLD.13).
- Where an additional treatment was provided as supplementary to the main treatment, support and case management (1.5%) was also the most common type of additional treatment, followed by information and education (1.2%). See technical notes for further information on calculating proportions for additional treatment type.

Over the period 2013–14 to 2022–23:

- The proportion of all treatment episodes where counselling was the main treatment type increased from 30% in 2013–14 to 40% in 2022–23. Counselling replaced information and education as the most common treatment in 2016–17.
- The proportion of withdrawal management as a main treatment type decreased from 8.4 down to 4.9 in 2022–23.
- The proportion of information and education as a main treatment decreased from 31% in 2013–14 to 3.7% in 2022–23.

Figure QLD 4: Proportion of treatment episodes, by treatment type, Queensland, 2013–14 to 2022–23
The grouped horizontal bar chart shows that, in 2022–23, the most common main treatment type provided to clients in Queensland for their own drug use was counselling (39.7% of episodes). This was followed by assessment only (34.1%) and support and case management (8.2%). Support and case management was the most common additional treatment type (1.5%), followed by Information and education (1.2%).



Agencies

In 2022–23, in Queensland:

- More than 7 in 10 (72%) AOD agencies that received public funding were non-government treatment agencies (Table Agcy.1).
- Almost half (47%) of the 179 treatment agencies were located in *Major cities*, followed by *Outer regional* (23%) and *Inner regional* (21%) areas.
- 2 in 5 (8.9%) of all government treatment agencies were located in *Remote* and *Very remote* areas (Figure QLD 5; Table Agcy.3).

In the 10 years to 2022–23, the number of publicly funded treatment agencies in Queensland steadily increased from 141 in 2013–14 to 194 in 2019–20, falling to 179 in 2022–23. The recent change in agency numbers is attributed to a review of the agency coding structure in the public sector. As a result, there have been significant agency identifier changes which have been constructed to align with the Queensland Health Corporate Reference Database System, providing a more accurate representation of number of agencies reporting at the service outlet level (Table Agcy.1).

Figure QLD 5: Number of agencies, by remoteness area and sector, Queensland, 2018–19 to 2022–23

The horizontal bar chart shows that most treatment agencies in Queensland were located in *Major cities* (84 agencies), followed by *Outer regional areas* (41 agencies) and *Inner regional areas* (37 agencies) in 2022–23. 16 agencies were located in *Remote* and *Very remote* areas. Of the total 179 treatment agencies, 71.5% (128 agencies) were non-government agencies.



Title: Figure QLD 5: Number of agencies, by remoteness area and sector, Queensland, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set.
http://www.aihw.gov.au

Western Australia

In 2022–23, 124 publicly funded alcohol and other drug (AOD) treatment agencies in Western Australia provided 19,671 treatment episodes to 14,947 clients (tables Agcy.1, SCR.21).

Western Australia reported:

- Client numbers increased from 2013–14 (15,146) to 2018–19 (19,348), decreasing steadily to 14,947 in 2022–23.
- Fewer clients are accessing AOD services in 2022–23 than 2013–14, after adjusting for population growth (604 compared with 697 per 100,000 people, respectively) (Table SCR.21).
- A 3.2% decrease in treatment episodes from 20,314 in 2021–22 to 19,671 in 2022–23, and a 5.7% decrease in episodes since 2013–14 (20,867) (Table ST WA.2).

Western Australia, 2022–23

The visualisation shows that 19,671 treatment episodes were provided to 14,947 clients in Western Australia in 2022–23. This equates to a rate of 795 episodes and 604 clients per 100,000 population, compared with the national rate of 1,017 episodes and 568 clients per 100,000 population.



Note: Proportions were calculated based on total closed treatment episodes and estimated clients.
Title: Western Australia, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SCR.21.
http://www.aihw.gov.au

In 2022–23, most (86%) clients in Western Australia attended 1 agency, and received an average of 1.3 treatment episodes, which is lower than the national average of 1.8 treatment episodes (tables SCR.21, SCR.23).

Client demographics

In 2022–23:

- Most (95%) clients in Western Australia received treatment for their own alcohol or drug use, of which 2 in 3 (64%) people were male (Figure WA 1).
- Three-quarter of people who received treatment for someone else's alcohol or drug use were female (75%).
- Over half (52%) of the people who received treatment for their own alcohol or drug use were aged 20–39 years; in contrast, people who received treatment for someone else's alcohol or drug use were more likely to be aged 50 and over (52%).
- 1 in 5 (21%) of all clients were Aboriginal and Torres Strait Islander (First Nations) people, which is higher than the national proportion (18%).
- The majority (82%) of all clients were born in Australia and nearly all (98%) reported English as their preferred language (tables SC WA.1–3, SC.4, SC WA.21–22).

Figure WA 1: AODTS clients by client type and selected demographics, Western Australia, 2022–23

The visualisation includes a series of horizontal bar graphs showing that, in 2022–23 in Western Australia, just under two-thirds (62%) of all clients were male, 50% were aged 20–39 and 21% were First Nations people. Nearly all clients (98%) listed English as their preferred language and most (82%) were born in Australia.



Title: Figure WA 1: AODTS clients by client type and selected demographics, Western Australia, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC WA.1–3 and SC WA.21–22.
http://www.aihw.gov.au

New and returning clients

In 2022–23:

- Over half (53% or 7,931) of all clients in Western Australia were returning clients, who have previously received AOD treatment from a service at some point since 2013–14.
- Nearly half (47% or 6,977) of all clients in Western Australia were a new client, who had not previously received treatment since 2013–14 (see Key terminology and glossary) (Table SCR 28).

Drugs of concern

In 2022–23, for clients in Western Australia who received treatment episodes for their own alcohol or drug use (18,785 episodes), alcohol was the most common principal drug of concern (48% or 9,017 episodes), followed by amphetamines (22% or 4,108) (Figure WA 2; tables ST WA.2 and ST WA.6).

Figure WA 2: Proportion of treatment episodes for own drug use, by drug of concern, Western Australia, 2013–14 to 2022–23

The grouped horizontal bar chart shows that, in 2022–23, alcohol was the most common principal drug of concern in treatment episodes provided to clients in Western Australia for their own drug use (48.0%). This was followed by amphetamines (21.9%) and cannabis (19.5%). Cannabis was the most common additional drug of concern (16.6% of episodes), followed by alcohol (10.5%) and amphetamines (9.3%).



Title: Figure WA 2: Proportion of treatment episodes for own drug use, by drug of concern, Western Australia, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST WA.7.
http://www.aihw.gov.au

In 2022–23, for clients who received treatment for their own use of amphetamines (4,108 episodes):

- Methamphetamine was reported as a principal drug of concern in almost 9 in 10 (89%) treatment episodes.
- In over half of treatment episodes where methamphetamine was the principal drug of concern, injecting was the most common method of use (53%), followed by smoking (43%) (Figure WA 3).

Figure WA 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), Western Australia (per cent)

The line graph shows that, in 2013–14, amphetamine were the most common drugs of concern among amphetamine-related treatment episodes for clients' own drug use. In 2014–15, methamphetamine became the most common drug of concern. The proportion of episodes for methamphetamine increased from 33.0% in 2013–14 to 88.9% in 2022–23. Buttons allow the user to navigate to data on amphetamines by method of use.



Notes
1. Other amphetamines includes Dexamphetamine, Amphetamine analogues and Amphetamines nec.
2. Amphetamines nfd are amphetamines not further defined.
3. Amphetampines nfd were not reported from 2016–17 to 2019–20.
4. Coding of methamphetamines has improved over time due to advancements in workforce training, agency coding practices and new system updates.
Title: Figure WA 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), Western Australia (per cent)
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST WA.6.
http://www.aihw.gov.au

Clients can nominate up to 5 additional drugs of concern; however, these drugs are not necessarily the subject of any treatment within the episode (see technical notes).

In 2022–23, where additional drugs of concern were reported, cannabis was the most common additional drug (17% of episodes), followed by alcohol and nicotine (10% and 9.7% respectively) and amphetamines (9.3%) (Table ST WA.7).

Over the period 2013–14 to 2022–23:

- The proportion of treatment episodes for alcohol as a principal drug of concern relative to all other principal drugs of concern fell from 36% (6,973) in 2013–14 to 29% in 2016–17 (6,723), before rising to 48% (9,017 episodes) in 2022–23.
- The proportion of treatment for amphetamines as a principal drug of concern increased from 23% in 2013–14, peaking at 36% in 2016–17 then falling to 22% in 2022–23 (Table ST WA.6).
  - Within the amphetamines group, methamphetamine was reported as the principal drug of concern in 33% of episodes in 2013–14, rising to 89% in 2022–23 (Figure WA 3).
- The proportion of treatment for cannabis decreased from 25% in 2013–14 to 19% in 2022–23.

Treatment

In 2022–23, for treatment episodes in Western Australia (19,671 episodes), counselling was the most common main treatment (65% of episodes), followed by support and case management 11% (Figure WA 4, Table ST WA.13).

Over the period 2013–14 to 2022–23:

- Counselling remained the most common main treatment for all episodes.
- The proportion of episodes where counselling was a main treatment type remained substantially higher in Western Australia than nationally over the period, ranging from 60% to 71% in Western Australia compared with 34% to 43% nationally (tables ST WA.13, Trt.3).
- The next most common main treatment types were support and case management (5.1% to 11% of episodes) and withdrawal management (5.6% to 8.7%).

Figure WA 4: Proportion of treatment episodes, by treatment type, Western Australia, 2013–14 to 2022–23
The grouped horizontal bar chart shows that, in 2022–23, the most common main treatment type provided to clients in Western Australia for their own drug use was counselling (64.5% of episodes). This was followed by support and case management (10.8%) and withdrawal management (7.7%).



Agencies

In 2022–23, in Western Australia:

- 9 in 10 (90%) AOD agencies that received public funding were non-government treatment agencies (Table Agcy.1).
- Almost 3 in 5 (56%) of the 124 treatment agencies were located in *Major cities* (Figure WA 5, Table Agcy.3).
- *Very remote* areas were the only areas where there were more government than non-government agencies (8 and 6, respectively).

In the 10 years to 2022–23, the number of publicly funded treatment agencies in Western Australia rose from 80 to 124 (Table Agcy.1).

Figure WA 5: Number of agencies, by remoteness area and sector, Western Australia, 2022–23

The horizontal bar chart shows that most treatment agencies in Western Australia were located in *Major cities* (70 agencies), followed by *Outer regional areas* (17 agencies) and *Remote (15 agencies) and Very remote areas* (14 agencies each) in 2022–23. 8 agencies were located in *Inner regional* areas. Of the total 124 treatment agencies, 89.5% (111 agencies) were non-government agencies.



Title: Figure WA 5: Number of agencies, by remoteness area and sector, Western Australia, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set.
http://www.aihw.gov.au

South Australia

In 2022–23, 83 publicly funded alcohol and other drug (AOD) treatment agencies in South Australia provided 9,769 treatment episodes to 6,718 clients (tables Agcy.1, SCR.21).

South Australia reported:

- Client numbers decreased steadily from 9,215 in 2013–14 to 6,718 in 2022–23.
- Fewer clients are accessing AOD services in 2022–23 than 2013–14, after adjusting for population growth (412 clients per 100,000 people compared with 624 per 100,000, respectively) (Table SCR.21).
- A decrease in treatment episodes since 2013–14, falling from 13,155 to 9,769 episodes in 2022–23 (Table ST SA.2).

South Australia, 2022–23

The visualisation shows that 9,769 treatment episodes were provided to 6,718 clients in South Australia in 2022–23. This equates to a rate of 599 episodes and 412 clients per 100,000 population, lower than the national rate (1,017 episodes and 568 clients per 100,000 population).



Note: Proportions were calculated based on total closed treatment episodes and estimated clients.
Title: South Australia, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SCR.21.
http://www.aihw.gov.au

In 2022–23, most (86%) clients in South Australia attended 1 agency, and received an average of 1.5 treatment episodes, which is lower than the national average of 1.8 treatment episodes (tables SCR.21, SCR.23).

Client demographics

In 2022–23:

- Nearly all (over 99%) clients in South Australia received treatment for their own alcohol or drug use, of which over 3 in 5 (63%) people were male (Figure SA 1).
- Over half of people who received treatment for someone else's alcohol or drug use were female (54%).
- Over half (53%) of all people were aged 30–49 years.
- Over 1 in 6 (17%) people were Aboriginal and Torres Strait Islander (First Nations) people, which is lower than the national proportion (18%).
- The majority (92%) of clients were born in Australia and nearly all (98%) reported English as their preferred language (tables SC SA.1–3, SC.4, SC SA.21–22).

Figure SA 1: AODTS clients by client type and selected demographics, South Australia, 2022–23

The visualisation includes a series of horizontal bar graphs showing that, in 2022–23 in South Australia, two-thirds (63%) of all clients were male, 53% were aged 30–49 and 17% were First Nations people. Nearly all clients (98%) listed English as their preferred language and most (92%) were born in Australia.



Title: Figure SA 1: AODTS clients by client type and selected demographics, South Australia, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC SA.1–3 amd SC SA.21–22.
http://www.aihw.gov.au

New and returning clients

In 2022–23:

- Over half (53% or 3,525) of all clients in South Australia were returning clients, who have previously received AOD treatment from a service at some point since 2013–14.
- Nearly half (47% or 3,166) of all clients in South Australia were a new client, who had not previously received treatment since 2013–14 (see Key terminology and glossary) (Table SCR 28).

Drugs of concern

In 2022–23, for clients in South Australia who received treatment episodes for their own alcohol or drug use (9,687 episodes):

- Alcohol was the most common principal drug of concern (41% or 3,936 episodes) (Figure SA 2).
- Amphetamines accounted for one-third of treatment episodes (30% or 2,913), followed by cannabis (15% or 1,478).

Figure SA 2: Proportion of treatment episodes for own drug use, by drug of concern, South Australia, 2013–14 to 2022–23

The grouped horizontal bar chart shows that, in 2022–23, alcohol was the most common principal drug of concern in treatment episodes provided to clients in South Australia for their own drug use (40.6%). This was followed by amphetamines (30.1%) and cannabis (15.3%). Cannabis was the most common additional drug of concern (18.4% of episodes), followed by amphetamines (10.0%) and alcohol (8.9%).



Title: Figure SA 2: Proportion of treatment episodes for own drug use, by drug of concern, South Australia, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST SA.7.
http://www.aihw.gov.au

In 2022–23, for clients who received treatment for their own use of amphetamines (2,913 episodes):

- Methamphetamine was reported as a principal drug of concern in approximately 82% of treatment episodes.
- Where methamphetamine was the principal drug of concern, smoking was the most common method of use in 58% of treatment episodes, followed by injecting (33%) (Figure SA 3).

Figure SA 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), South Australia (per cent)

The line graph shows that, from 2013–14 to 2014–15, 'amphetamines not further defined' was the most common drug of concern among amphetamine-related treatment episodes for clients' own drug use. In 2015–16, methamphetamine became the most common drug of concern. The proportion of episodes for methamphetamine increased from 12.1% in 2013–14 to 82.3% in 2022–23, while episodes for amphetamines not further defined decreased from 79.2% to 8.5% over the same period. Buttons allow the user to navigate to data on amphetamines by method of use.



Notes
1. Other amphetamines includes Dexamphetamine, Amphetamine analogues and Amphetamines nec.
2. Amphetamines nfd are amphetamines not further defined.
3. Coding of methamphetamines has improved over time due to advancements in workforce training, agency coding practices and new system updates.
Title: Figure SA 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), South Australia (per cent)
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST SA.6.
http://www.aihw.gov.au

Clients can nominate up to 5 additional drugs of concern; these drugs are not necessarily the subject of any treatment within the episode (see technical notes).

In 2022–23, where additional drugs of concern were reported, nicotine was the most common (22% of episodes), followed by cannabis (18%) (Table ST SA.7).

Over the period 2013–14 to 2022–23:

- Alcohol was the most common principal drug of concern over this period, from 36% of episodes in 2013–14, falling to 27% in 2016–17, increasing to 41% in 2022–23 (Table ST SA.7).
- Amphetamines have remained the second most common principal drug of concern, increasing from 27% in 2013–14 to 37% in 2016–17, before falling to 30% in 2022–23.
- Amphetamine treatment episodes decreased over this period from 3,562 in 2013–14, peaking at 4,288 in 2018–19, falling to 2,913 in 2022–23:
  - For episodes where amphetamines were the principal drug of concern, the proportion of treatment episodes with methamphetamine has increased more than 15-fold since 2013–14 (from 12% to 82% in 2022–23 (Figure SA 3).
  - The rise in episodes may be related to increases in funded treatment services and/or improvement in agency coding practices for methamphetamine.

The proportion of treatment episodes for amphetamines as a principal drug of concern has been consistently higher in South Australia than the national proportion (30% and 24% respectively in 2022–23). This is related to a state government legislated program regarding assessments provided under a Police Drug Diversion initiative. The program results in comparatively high proportions of engagement with methamphetamine users.

In addition, due to the Cannabis Expiation Notice legislation in South Australia, adult simple cannabis offences are not diverted to treatment and so are not included in the data (see the Data Quality Statement - external site opens in new window).

Treatment

In 2022–23, for treatment episodes in South Australia (9,769 episodes):

- Counselling was the most common main treatment (36% of episodes), followed by assessment only (26%) and withdrawal management (18%) (Figure SA 4, Table ST SA.13).
- Where an additional treatment was provided as a supplementary to the main treatment, support and case management (15%) was the most common additional treatment, followed by counselling (7.3%). See technical notes for further information on calculating proportions for additional treatment type.

Over the period 2013–14 to 2022–23:

- Counselling as main treatment has almost doubled from 22% in 2013–14 to 40% in 2021–22, before falling to 36% in 2022–23.
- The proportion of episodes with rehabilitation as main treatment fell from 9.0% to 1.6%.
- The proportion of episodes where assessment only was the main treatment has almost halved since 2013–14, falling from 44% to 26% in 2022–23.
- However, assessment only in South Australia remained considerably higher than the national proportion (ranging from 16% to 22%) (tables ST SA.13, Trt.4).

The high proportion of treatment episodes where assessment only is the most common treatment type relates in part to the SA Police Drug Diversion Initiative (PDDI).

Figure SA 4: Proportion of treatment episodes, by treatment type, South Australia, 2013–14 to 2022–23
The grouped horizontal bar chart shows that, in 2022–23, the most common main treatment type provided to clients in South Australia for their own drug use was counselling (35.5% of episodes). This was followed by assessment only (25.5%) and withdrawal management (18.3%). Support and case management was the most common additional treatment type (15.1% of episodes), followed by counselling (7.3%).



Agencies

In 2022–23, in South Australia:

- 3 in 5 (62%) of 87 AOD agencies that received public funding were non-government treatment agencies.
- Almost 3 in 5 (59%) of all treatment agencies were located in *Major cities*, followed by *Outer regional* areas (23%) and *Inner regional* areas (13%) (Figure SA 5, Table Agcy.3)
- In *Very Remote* areas all agencies were government organisations.

Over the 10 years to 2022–23, the number of publicly funded treatment agencies in South Australia decreased from 94 to 87 (Table Agcy.1).

Figure SA 5: Number of agencies, by remoteness area and sector, South Australia, 2018–19 to 2022–23

The horizontal bar chart shows that most treatment agencies in South Australia were located in *Major cities* (51 agencies), followed by *Outer regional (20 agencies)* and *Inner regional* areas (11 agencies each) in 2022–23. 3 agencies were located in *Remote* areas and 2 agencies were located in *Very remote* areas. Of the total 87 treatment agencies, 62.1% (54 agencies) were non-government agencies.



Title: Figure SA 5: Number of agencies, by remoteness area and sector, South Australia, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set.
http://www.aihw.gov.au

Tasmania

In 2022–23, 21 publicly funded alcohol and other drug (AOD) treatment agencies in Tasmania provided 3,536 treatment episodes to 2,642 clients (tables Agcy.1, SCR.21).

Tasmania reported:

- Client numbers increased from 2,432 in 2013–14 to 2,642 in 2022–23, a similar number to 2021–22 (2,684).
- Fewer clients are accessing AOD services in 2022–23 than 2013–14, after adjusting for population growth (517 clients per 100,000 people compared with 540 per 100,000, respectively) (Table SCR.21).
- A 8.4% decrease in treatment episodes from 3,859 in 2020–21 to 3,536 in 2022–23, and a 24% increase in treatment episodes since 2013–14 (2,841) (Table ST TAS.2).

Tasmania, 2022–23

The visualisation shows that 3,536 treatment episodes were provided to 2,642 clients in Tasmania in 2022–23. This equates to a rate of 692 episodes and 517 clients per 100,000 population, lower than the national rate (1,017 episodes and 568 clients per 100,000 population).



Note: Proportions were calculated based on total closed treatment episodes and estimated clients.
Title: Tasmania, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SCR.21.
http://www.aihw.gov.au

In 2022–23, most (86%) clients in Tasmania attended 1 agency, and received an average of 1.3 treatment episodes, which is lower than national average of 1.8 treatment episodes (tables SCR.21, SCR.23).

Client demographics

In 2022–23:

- Most (95%) clients in Tasmania received treatment for their own alcohol or drug use, of which 3 in 5 (61%) people were male (Figure TAS 1).
- People who received treatment for someone else's alcohol or drug use were most likely to be female (74%).
- Almost half (48%) of all clients were aged 20–39 years.
- Around 1 in 8 (13%) of all clients were Aboriginal and Torres Strait Islander (First Nations) people, which is lower than the national proportion (18%).
- The majority (93%) of all clients were born in Australia and nearly all (97%) reported English as their preferred language (tables SC Tas.1–3, SC.4, SC TAS.21–22).

Figure TAS 1: AODTS clients by client type and selected demographics, Tasmania, 2022–23

The visualisation includes a series of horizontal bar graphs showing that, in 2022–23 in Tasmania, just under three in five (60%) of all clients were male, 48% were aged 20–39 and 13% were First Nations people. Nearly all clients (97%) listed English as their preferred language and most (93%) were born in Australia.



Title: Figure TAS 1: AODTS clients by client type and selected demographics, Tasmania, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC TAS.1 –3 and SC TAS.21–22.
http://www.aihw.gov.au

New and returning clients

In 2022–23:

- About half (51% or 1,321) of all clients in Tasmania were returning clients, who have previously received AOD treatment from a service at some point since 2013–14.
- About half (49% or 1,272) of all clients in Tasmania were a new client, who had not previously received treatment since 2013–14 (see Key terminology and glossary) (Table SCR 28).

Drugs of concern

In 2022–23, for clients in Tasmania who received treatment episodes for their own alcohol or drug use (3,368 episodes):

- Alcohol was the most common principal drug of concern (51% or 1,709 episodes) (Figure TAS 2, Table ST TAS.7)
- Amphetamines as a principal drug of concern accounted for 1 in 4 treatment episodes (22% or 725 episodes).

Figure TAS 2: Proportion of treatment episodes for own drug use, by drug of concern, Tasmania, 2013–14 to 2022–23

The grouped horizontal bar chart shows that, in 2022–23, alcohol was the most common principal drug of concern in treatment episodes provided to clients in Tasmania for their own drug use (50.7%). This was followed by amphetamines (21.5%) and cannabis (16.9%). Cannabis was the most common additional drug of concern (15.3% of episodes), followed by amphetamines (9.9%) and alcohol (7.4%).



Title: Figure TAS 2: Proportion of treatment episodes for own drug use, by drug of concern, Tasmania, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST TAS.7.
http://www.aihw.gov.au

In 2022–23, for clients who received treatment for their own use of amphetamines (725 episodes):

- Methamphetamine was reported as a principal drug of concern in over 8 in 10 (86%) treatment episodes.
- In almost half (48%) of treatment episodes where methamphetamine was a principal drug of concern, injecting was the most common method of use, followed by smoking (36%) (Figure TAS 3).

Figure TAS 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), Tasmania (per cent)

The line graph shows that, in 2013–14, amphetamine was the most common drug of concern among amphetamine-related treatment episodes for clients' own drug use. In 2014–15, methamphetamine became the most common drug of concern. The proportion of episodes for methamphetamine increased from 25.9% in 2013–14 to 86.2% in 2022–23, while episodes for amphetamine decreased from 69.7% to 5.9% over the same period. Buttons allow the user to navigate to data for amphetamines by method of use.



Notes:
1. Other amphetamines includes Dexamphetamine, Amphetamine analogues and Amphetamines nec.
2. Amphetamines nfd are amphetamines not further defined.
3. Amphetamines nfd were not reported from 2015–16 onwards.
4. Coding of methamphetamines has improved over time due to advancements in workforce training, agency coding practices and new system updates.
Title: Figure TAS 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), Tasmania (per cent)
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST TAS.6.
http://www.aihw.gov.au

Clients can nominate up to 5 additional drugs of concern; these drugs are not necessarily the subject of any treatment within the episode (see technical notes).

In 2022–23, where additional drugs of concern were reported, cannabis was the most common additional drug of concern (15% of episodes), followed by amphetamines (9.9%), then nicotine (9.2%) (Table ST TAS.7).

Over the period 2013–14 to 2022–23:

- Alcohol was the most common principal drug of concern, increasing from 41% of episodes in 2013–14 (1,078 episodes) to 51% (1,709) in 2022–23 (Table ST TAS.7).
- Treatment episodes for amphetamines increased from 11% (290 episodes) to 22% (725) over the period.
- Treatment episodes for cannabis decreased from 30% (784 episodes) to 17% (570). While the number of treatment episodes increased, the proportion in relation to all principal drugs of concern decreased.
- Within the amphetamines group, methamphetamine was reported as the principal drug of concern in 26% of episodes in 2013–14, rising to 93% in 2019–20, falling to 86% in 2022–23 (Figure TAS 3). The rise in episodes may be related to increases in funded treatment services and/or improvement in agency coding practices for methamphetamine.

Treatment

In 2022–23, for treatment episodes in Tasmania (3,536 episodes):

- Counselling was the most common main treatment (50% of episodes), followed by rehabilitation (22%) (Figure TAS 4, Table ST TAS.13).
- Where an additional treatment was provided as a supplementary to the main treatment, support and case management (5.5%) was the most common type of additional treatment, followed by counselling (4.1%) and information and education (1.6%). See technical notes for further information on calculating proportions for additional treatment type.

Over the period 2013–14 to 2022–23:

- Counselling remained the most common main treatment, with the proportion of episodes peaking at 62% in 2013–14, falling to 37% in 2016–17, before fluctuating between 48% to 50% from 2018–19 onwards.
- Rehabilitation increased from 2013–14 (5.5%) peaking in 2016–17 (24%) before decreasing in 2022–23 (22%); the proportion of episodes for rehabilitation is higher than the national proportion over this period (ranging from 5.5–6.6%) (tables ST TAS.13, Trt.1).

Figure TAS 4: Proportion of treatment episodes, by treatment type, Tasmania, 2013–14 to 2022–23

The grouped horizontal bar chart shows that, in 2022–23, the most common main treatment type provided to clients in Tasmania for their own drug use was counselling (50.4% of episodes). This was followed by rehabilitation (22.5%) and assessment only (16.2%). Support and case management was the most common additional treatment type (5.5% of episodes), followed by counselling (4.1%).



Agencies

Tasmania only has the geographical classifications of *Inner regional*, *Outer regional* and *Remote* areas.

In 2022–23, in Tasmania:

- Almost 9 in 10 (86%) of the 21 AOD agencies that received public funding were non-government treatment agencies.
- 52% of agencies were located in *Inner regional* areas, followed by *Outer regional* (48%) (Figure TAS 5, Table Agcy.3).
- Agencies located in *Inner regional* and *Outer regional* areas were more likely to be non-government organisations.

In the 10 years to 2022–23, the number of publicly funded treatment agencies in Tasmania has been consistent from 2013–14 (22 agencies) to 2022–23 (21 agencies) (Table Agcy.1).

Note that remoteness categories are derived by applying a correspondence based on the agency's Statistical Area level 2 code (SA2). Not all SA2 codes fit neatly within a single remoteness category, and a ratio is applied to reapportion each SA2 to the applicable remoteness categories. As a result, it is possible that the number of agencies in a particular remoteness category is not a whole number. After rounding, this can result in there being '<0.5%' agencies in a remoteness area, due to the agency's SA2 partially crossing into the remoteness area. See technical notes for further details.

Figure TAS 5: Number of agencies, by remoteness area and sector, Tasmania, 2022–23

The horizontal bar chart shows that most treatment agencies in Tasmania were located in *Inner regional areas* (11 agencies), followed by *Outer regional areas* (10 agencies) in 2022–23. Of the total 21 treatment agencies, most (18 agencies) were non-government agencies.



Title: Figure TAS 5: Number of agencies, by remoteness area and sector, Tasmania, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set.
http://www.aihw.gov.au

Australian Capital Territory

In 2022–23, 17 publicly funded alcohol and other drug (AOD) treatment agencies in the Australian Capital Territory provided 5,879 treatment episodes to 3,599 clients (tables Agcy.1, SCR.21).

The Australian Capital Territory reported:

- Client numbers increased from 2,949 in 2013–14 to 4,109 in 2017–18, then fell to 3,599 in 2022–23.
- More clients are accessing AOD services in 2022–23 than 2013–14, after adjusting for population growth (887 clients per 100,000 people compared with 877 per 100,000, respectively) (Table SCR.21).
- A 26% increase in treatment episodes between 2013–14 to 2022–23, from 4,652 episodes to 5,879 episodes (Table ST ACT.2).

Australian Capital Territory, 2022–23

The visualisation shows that 5,879 treatment episodes were provided to 3,599 clients in the Australian Capital Territory in 2022–23. This equates to a rate of 1,449 episodes and 887 clients per 100,000 population, which is higher than the national rate (1,017 episodes and 568 clients per 100,000 population).



Note: Proportions were calculated based on total closed treatment episodes and estimated clients.
Title: Australian Capital Territory, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SCR.21.
http://www.aihw.gov.au

In 2022–23, most (79%) clients in the Australian Capital Territory attended 1 agency, and received an average of 1.6 treatment episodes, which is lower than the national average of 1.8 treatment episodes (tables SCR.21, SCR.23).

Client demographics

In 2022–23:

- Nearly all (95%) clients in the Australian Capital Territory received treatment for their own alcohol or drug use, of which almost 2 in 3 (64%) people were male (Figure ACT 1).
- People who received treatment for someone else's alcohol or drug use were mostly female (67%).
- Nearly half (49%) of all clients were aged 30–49 years.
- Around 1 in 8 (13%) of all clients were Aboriginal and Torres Strait Islander (First Nations) people, which is lower than the national proportion (18%).
- The majority (85%) of all clients were born in Australia and nearly all (98%) reported English as their preferred language (tables SC ACT.1–3, SC.4, SC ACT.21–22).

Figure ACT 1: AODTS clients by client type and selected demographics, Australian Capital Territory, 2022–23

The visualisation includes a series of horizontal bar graphs showing that, in 2022–23 in the Australian Capital Territory, just under two-thirds (63%) of all clients were male, 49% were aged 30–49 and 13% were First Nations people. Nearly all clients (98%) listed English as their preferred language and most (85%) were born in Australia.



Title: Figure ACT 1: AODTS clients by client type and selected demographics, Australian Capital Territory, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC ACT.1–3 and SC ACT.21–22.
http://www.aihw.gov.au

New and returning clients

In 2022–23:

- 3 in 5 (60% or 2,073) of all clients in Australian Capital Territory were returning clients, who have previously received AOD treatment from a service at some point since 2013–14.
- 2 in 5 (40% or 1,398) of all clients in Australian Capital Territory were a new client, who had not previously received treatment since 2013–14 (see Key terminology and glossary) (Table SCR 28).

Drugs of concern

In 2022–23, for clients in the Australian Capital Territory who received treatment episodes for their own alcohol or drug use (5,692 episodes):

- Alcohol was the most common principal drug of concern (46% or 2,643 episodes) (Figure ACT 2, Table ST ACT.7).
- Amphetamines accounted for 1 in 5 (22% or 1,269) treatment episodes.

Figure ACT 2: Proportion of treatment episodes for own drug use, by drug of concern, Australian Capital Territory, 2013–14 to 2022–23

The grouped horizontal bar chart shows that, in 2022–23, alcohol was the most common principal drug of concern in treatment episodes provided to clients in the Australian Capital Territory for their own drug use (46.4%). This was followed by amphetamines (22.3%), heroin (12.4%) and cannabis (9.9%). Cannabis was the most common additional drug of concern (14.2% of episodes), followed by nicotine (13.3%) and amphetamines (9.1%).



Title: Figure ACT 2: Proportion of treatment episodes for own drug use, by drug of concern, Australian Capital Territory, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST ACT.7.
http://www.aihw.gov.au

In 2022–23, for clients who received treatment for their own use of amphetamines (1,269 episodes):

- Methamphetamine was reported as a principal drug of concern for over 9 in 10 (92%) treatment episodes.
- In almost half (46%) of the treatment episodes where methamphetamine was the principal drug of concern, injecting was the most common method of use, followed by smoking (37%) (Figure ACT 3).

Figure ACT 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), Australian Capital Territory (per cent)

The line graph shows that in 2013–14, methamphetamine was the most common principal drug of concern within the amphetamines group. The proportion of methamphetamine-related episodes increased from 43.1% of amphetamine-related episodes in 2013–14 to 92.0% in 2022–23.



Notes
1. Other amphetamines includes Dexamphetamine, Amphetamine analogues and Amphetamines nec.
2. Amphetamines nfd are amphetamines not further defined.
3. Coding of methamphetamines has improved over time due to advancements in workforce training, agency coding practices and new system updates.
Title: Figure ACT 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), Australian Capital Territory (per cent)
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST ACT.6.
http://www.aihw.gov.au

Clients can nominate up to 5 additional drugs of concern; these drugs are not necessarily the subject of any treatment within the episode (see technical notes).

In 2022–23, where additional drugs of concern were reported, cannabis was the most common additional drug (14%), followed by nicotine (13%) (Table ST ACT.7).

Over the period 2013–14 to 2022–23:

- Alcohol was the most common principal drug of concern relative to all other drugs accounting for almost half (47%) of episodes in 2013–14, falling to 43% of episodes in 2021–22, before increasing to 46% in 2022–23 Table ST ACT.7).

- The proportion of episodes with amphetamines as the principal drug of concern increased from 15% (677 episodes) in 2013–14 to a peak in 2016–17 of 25% (1,572 episodes), before falling to 22% (1,269 episodes) in 2022–23.
  - Within the amphetamines group, methamphetamine was reported as the principal drug of concern in 43% of episodes in 2013–14, rising to 92% in 2022–23 (Figure ACT 3).
  - The rise in episodes may be related to increases in funded treatment services and/or improvement in agency coding practices for methamphetamine.
- The proportion of episodes with heroin as a principal drug of concern fell from 11% in 2013–14 to 8–9% between 2014–15 and 2017–18, before rising to 14% in 2020–21, then falling to 12% in 2022–23 (higher than the national proportion of 4.5%) (Table Drg.5).
- The proportion of episodes for cannabis as the principal drug of concern has steadily declined from 2013–14 (18% to 9.9% in 2022–23).

Treatment

In 2022–23, for treatment episodes in the Australian Capital Territory (5,879 episodes):

- Information and education was the most common main treatment (25% of episodes) (Figure ACT 4, Table ST ACT.13).
- Counselling was the second most common treatment (23%), followed by support and case management (15%).
- Where an additional treatment was provided as a supplementary to the main treatment support and case management (3.2%) was the most common additional treatment, followed by counselling (1.9%). See technical notes for further information on calculating proportions for additional treatment type.

Over the period 2013–14 to 2022–23:

- Information and education became the most common main treatment type in 2022–23; in the 10 years prior, the proportion of episodes with information and education as main treatment ranged from 21% in 2013–14 to 32% in 2017–18, before decreasing to 19% in 2021–22, then increasing to 25% in 2022–23 (Table ST ACT.13).
- The proportion of episodes with counselling as main treatment ranged from 19% in 2013–14 to 28% in 2018–19, before decreasing to 23% in 2022–23.
- Compared to national proportions, fewer treatment episodes provided in the ACT had counselling as main treatment over the 10 years to 2022–23 (ranging from 19% to 28% in the ACT, compared with 34% to 43% nationally).
- Conversely, more treatment episodes in the ACT had information and education as main treatment (ranging from 16% to 32% in the ACT compared with 2.4% to 10% nationally) (tables ST ACT.13, Trt.3).

Figure ACT 4: Proportion of treatment episodes, by treatment type, Australian Capital Territory, 2013–14 to 2022–23

The grouped horizontal bar chart shows that, in 2022–23, the most common main treatment type provided to clients in the Australian Capital Territory for their own drug use was information and education (25.2% of episodes). This was followed by counselling (22.5%), and support and case management (14.7%). Other treatments and support and case management were the most common additional treatment types (5.0% and 3.2% of episodes respectively).



Agencies

The Australian Capital Territory only has the one geographical classification of *Major city,* and the majority of treatment agencies are non-government organisations (88%) (Figure ACT 5, Table Agcy.3).

Over the period 2013–14 to 2022–23, the number of publicly funded treatment agencies rose from 15 to 17 agencies (Table Agcy.1).

Figure ACT 5: Number of agencies, by remoteness area and sector, Australian Capital Territory, 2022–23

The horizontal bar chart shows that all treatment agencies in the Australian Capital Territory were located in *Major cities* in 2022–23. Of the total 17 treatment agencies, most (15 agencies) were non-government agencies.



Title: Figure ACT 5: Number of agencies, by remoteness area and sector, Australian Capital Territory, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set.
http://www.aihw.gov.au

Northern Territory

In 2022–23, 24 publicly funded alcohol and other drug (AOD) treatment agencies in the Northern Territory provided 5,475 treatment episodes to 3,066 clients (tables Agcy.1–2, SCR.21).

The Northern Territory reported:

- Client numbers increased from 2,870 in 2013–14 to 3,776 in 2019–20 then dropped to 3,066 in 2022–23.
- More clients are accessing AOD services in 2022–23 than 2013–14, after adjusting for population growth (1,424 clients per 100,000 people compared with 1,397 per 100,000, respectively) (Table SCR.21).
- An 8% decrease in treatment episodes from 5,953 in 2021–22 to 5,475 in 2022–23, but a 25% increase in treatment episodes since 2013–14 (4,377) (Table ST NT.2).

Northern Territory, 2022–23

The visualisation shows that 5,475 treatment episodes were provided to 3,066 clients in the Northern Territory in 2022–23. This equates to a rate of 2,542 episodes and 1,424 clients per 100,000 population, which is higher than the national rate (1,017 episodes and 568 clients per 100,000 population).



Note: Proportions were calculated based on total closed treatment episodes and estimated clients.
Title: Northern Territory, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table SCR.21.
http://www.aihw.gov.au

In 2022–23, most (81%) clients in the Northern Territory attended 1 agency, and received an average of 1.8 treatment episodes, which is the same as the national average of 1.8 treatment episodes (tables SCR.21, SCR.23).

Client demographics

In 2022–23:

- Most (93%) clients in the Northern Territory received treatment for their own alcohol or drug use, of which over 7 in 10 (73%) people were male (Figure NT 1)
- People who received treatment for someone else's alcohol or drug use were more likely to be female (66%).
- Over half (54%) of all people were aged 20–39 years, and 12% of people were aged 10–19 years which is higher the national proportion (9.3%).
- 7 in 10 (70%) of all clients were Aboriginal and Torres Strait Islander (First Nations) people, more than 4 times higher than the national proportion (18%).
- Nearly all (95%) people were born in Australia and over 3 in 5 (60%) reported English as their preferred language, with nearly 1 in 3 (31%) reporting Indigenous languages as their preferred language (tables SC NT.1–3, SC.3–4, SC NT.21–22).

Figure NT 1: AODTS clients by client type and selected demographics, Northern Territory, 2022–23

The visualisation includes a series of horizontal bar graphs showing that, in 2022–23 in the Northern Territory, over two-thirds (71%) of all clients were male, 54% were aged 20–39 and 70% were Fist Nations people. Around 3 in 5 (60%) listed English as their preferred language and most (95%) were born in Australia.



Title: Figure NT 1: AODTS clients by client type and selected demographics, Northern Territory, 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Tables SC NT.1–3 and SC NT.21–22.
http://www.aihw.gov.au

New and returning clients

In 2022–23:

- Over half (58% or 1,742) of all clients in Northern Territory were returning clients, who have previously received AOD treatment from a service at some point since 2013–14.
- Over 2 in 5 (42% or 1,280) of all clients in Northern Territory were a new client, who had not previously received treatment since 2013–14 (see Key terminology and glossary) (Table SCR.28).

Drugs of concern

In 2022–23, for clients in the Northern Territory who received treatment episodes for their own alcohol or drug use (5,204 episodes):

- Alcohol was the most common principal drug of concern for clients (69% or 3,578 episodes) (Figure NT 2, tables ST NT.7).
- Cannabis (13% or 664 episodes) and amphetamines (9.9% or 515 episodes) were the second and third most common principal drugs of concern.
- Volatile solvents (3.1% or 161 episodes) were the next most common principal drug of concern, with proportions higher than the national level (less than 1%) (Table Drg.1).

Figure NT 2: Proportion of treatment episodes for own drug use, by drug of concern, Northern Territory, 2013–14 to 2022–23

The grouped horizontal bar chart shows that, in 2022–23, alcohol was the most common principal drug of concern in treatment episodes provided to clients in the Northern Territory for their own drug use (68.8%). This was followed by cannabis (12.8%) and amphetamines (9.9%). Cannabis was the most common additional drug of concern (26.2% of episodes), followed by nicotine (17.4%) and alcohol (10.0%).



Title: Figure NT 2: Proportion of treatment episodes for own drug use, by drug of concern, Northern Territory, 2013–14 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST NT.7.
http://www.aihw.gov.au

In 2022–23, for clients who received treatment for their own use of amphetamines (515 episodes):

- Methamphetamine was reported as a principal drug of concern in almost 4 in 5 (76%) treatment episodes.
- Over half (57%) of treatment episodes where methamphetamine was a principal drug of concern, injecting was the most common method of use, followed by smoking (34%) (Figure NT 3).

Figure NT 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), Northern Territory (per cent)

The line graph shows that, in 2013–14, amphetamine and amphetamines not further defined were the most common drugs of concern among amphetamine-related treatment episodes for clients' own drug use. In 2014–15, methamphetamine became the most common principal drug of concern within the amphetamines group. The proportion of methamphetamine-related episodes increased from 31.9% of amphetamine-related episodes in 2013–14 to 76.1% in 2022–23, while the proportion of episodes for amphetamines not further defined decreased from 32.6% to a low of 0.3% in 2017–18, then increasing to 23.1% in 2022–23. Buttons allow the user to navigate to data on amphetamines by method of use.



Notes
1. Other amphetamines includes Dexamphetamine, Amphetamine analogues and Amphetamines nec.
2. Amphetamines nfd are amphetamines not further defined.
3. Other amphetamines not reported from 2015–16 to 2018–19.
4. Coding of methamphetamines has improved over time due to advancements in workforce training, agency coding practices and new system updates.
Title: Figure NT 3: Proportion of treatment episodes for own drug use, by amphetamine group (2013–14 to 2022–23) or method of use (2022–23), Northern Territory (per cent)
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. Table ST NT.6.
http://www.aihw.gov.au

Clients can nominate up to 5 additional drugs of concern; these drugs are not necessarily the subject of any treatment within the episode (see technical notes).

In 2022–23, where additional drugs of concern were reported, cannabis was the most common additional drug of concern (26% of episodes), followed by nicotine (17%) (Table ST NT.7).

Over the period 2013–14 to 2022–23:

- Alcohol remained the most common principal drug of concern, increasing from 61% in 2013–14 (2,371 episodes) to peak at 72% in 2020–21 (5,531 episodes), falling to 69% (3,578 episodes) in 2022–23.
  - The proportion of episodes for alcohol, relative to all other principal drugs of concern, remained consistently higher than the national proportion (for example, 69% compared with 43% nationally in 2022–23) (tables ST NT.7, Drg.1).
- Treatment episodes for amphetamines as a principal drug of concern increased over this period (7.1% to 14%):
  - Within the amphetamines group, treatment for methamphetamine as a principal drug of concern was reported as the principal drug of concern in 32% of episodes in 2013–14, rising to 85% in 2017–18, dropping to 76% in 2022–23 (Figure NT 3).
  - The rise in methamphetamine episodes may be related to changes in the illicit drug market and/or changes in service provider practices.
- The proportion of treatment episodes for volatile solvents as a principal drug of concern decreased from 11% in 2013–14 to 3.1% in 2022–23 (Table Drg.1).

Treatment

In 2022–23, for treatment episodes in the Northern Territory (5,475 episodes):

- Assessment only was the most common main treatment (47% of episodes), followed by counselling (17%) (Figure NT 4, Table ST NT.13).
- Where an additional treatment was provided as a supplementary to the main treatment, counselling (15%) was the most common additional treatment, followed by support and case management (7.0%) (Table ST NT.13). See technical notes for further information on calculating proportions for additional treatment type.

All agencies in the Northern Territory are required to complete a separate assessment only episode prior to the commencement of treatment. This is due to a policy of monitoring the volume of assessment work performed by agencies and understanding the relationship between assessment and subsequent treatment, particularly in relation to certain alcohol-related legislative-based programs. This policy was introduced in 2018 (reported in the 2017–18 collection year).

Over the period 2013–14 to 2022–23:

- Assessment only remained the most common main treatment, although the proportion of episodes fluctuated (increasing from 40% in 2013–14 to 47% in 2022–23).
- The proportion of episodes where counselling was the main treatment fluctuated from 25% in 2013–14, before halving to 13% in 2019–20 and rising to 17% in 2022–23.
- The proportion of treatment episodes where rehabilitation was the main treatment fluctuated since 2013–14, rising from 16% (703) to 25% (1,343) in 2016–17 before falling to 12% (967) in 2020–21, then increasing to 21% (1,147) in 2022–23 (Table ST NT.13).

Figure NT 4: Proportion of treatment episodes, by treatment type, Northern Territory, 2013–14 to 2022–23
The grouped horizontal bar chart shows that, in 2022–23, the most common main treatment type provided to clients in the Northern Territory for their own drug use was assessment only (46.6% of episodes). This was followed by counselling (17.0%) and rehabilitation (21.0). Counselling was the most common additional treatment type (15.0% of episodes), followed by support and case management (7.0%).



Agencies

The Northern Territory does not have any areas classified as *Major city* or *Inner regional*. It only has locations classified as *Outer regional*, *Remote* or *Very remote*.

In 2022–23:

- The majority of the 24 treatment agencies were in the non-government sector (79%).
- *Outer regional* areas contained the most treatment agencies (50%), followed by *Remote* areas (38%) (Figure NT 5, Table Agcy.3).

In the 10 years to 2022–23, the number of publicly funded treatment agencies rose from 22 to 24 (Table Agcy.1).

Figure NT 5: Number of agencies, by remoteness area and sector, Northern Territory, 2022–23

The horizontal bar chart shows that all treatment agencies in the Northern Territory were located in *Outer regional areas* (12 agencies), followed by *Remote areas* (9 agencies) and *Very remote areas* (3 agencies) in 2022–23. Of the total 24 treatment agencies, most (19 agencies) were non-government agencies.



Technical notes - state and territory summaries

General notes

1. Data are subject to minor revisions over time.
2. Components of figures may not sum to totals due to rounding.

Client demographics

1. Data are based on client records with a valid Statistical Linkage Key (SLK-581).
2. Client data exists from the 2013–14 collection onwards.
3. The client data used in these visualisations is not imputed. Therefore, these numbers may differ from what have been previously published.
4. Rates are crude rates based on the Australian estimated resident population as at 31 December of the reference year. Rates for previous years may differ to those previously reported due to updated estimated resident populations.
5. Proportions are calculated based on overlapping unit record data sorted by state/territory. As clients can receive treatment in multiple states/territories within the same collection period, the total number of clients is less than the summed number of clients for each state/territory. Therefore, the proportions by each state/territory may differ from those reported elsewhere as they are calculated from the summed number of clients in each state/territory.
6. The COVID-19 pandemic and the resulting Australian Government closure of the international border from 20 March 2020, caused significant disruptions to the usual Australian population trends. This report uses Australian Estimated Resident Population (ERP) estimates that reflect these disruptions.

   In the year July 2020 to June 2021, the overall population growth was much smaller than the years prior and in particular, there was a relatively large decline in the population of Victoria. ABS reporting indicates these were primarily due to net-negative international migration (National, state and territory population, June 2021 - external site opens in new window).

   Please be aware that this change in the usual population trends may complicate interpretation of statistics calculated from these ERPs. For example, rates and proportions may be greater than in previous years due to decreases in the denominator (population size) of some sub-populations.

Drugs of concern

1. Unlike the principal drug of concern, additional drug/s of concern is not necessarily the subject of any treatment within the episode.
2. The proportion of episodes for an additional drug of concern is calculated by the number of treatment episodes for that particular additional drug (up to 5 drug types can be reported) divided by the total number of treatment episodes for clients who received treatment for their own alcohol or drug use in the collection year.
3. The AODTS NMDS contains data on drugs of concern that are coded using the ABS's Australian Standard Classification of Drugs of Concern (ASCDC) (ABS 2011 - external site opens in new window). Pharmaceuticals were grouped using the following 10 drug categories and ASCDC codes:

Table 1: Pharmaceutical drugs of concern, ASCDC codes and classifications

Drug category	ASCDC code
Codeine	1101
Morphine	1102
Buprenorphine	1201
Oxycodone	1203
Methadone	1305

Benzodiazepines	2400–2499
Steroids	4000–4999
Other opioids	1100, 1199, 1200, 1299, 1300–1304, 1306–1399
Other analgesics	0005, 1000, 1400–1499
Other sedatives and hypnotics	2000, 2200–2299, 2300–2399, 2500–2599, 2900–2999

Jurisdictional notes regarding principal drug of concern

Victoria reported comparatively high incidences of 'Not stated drugs' (15%) as the drug of concern. This is in part due to service providers adjusting to changes in reporting practices associated with the implementation of a new data collection system in 2019–20. In 2020–21, these drugs of concern were coded as 'Other drugs of concern' (14%) to realign with previous coding practices for Victoria. Victoria is working with service providers to encourage more specific reporting of drug of concern.

In Queensland, the level of cannabis reported as the principal drug of concern is a result of the Police Drug Diversion Program, Illicit Drugs Court Diversion Program and Drug and Alcohol Assessment Referral Program (DAAR) operating in the state.

South Australia reports a high proportion of treatment episodes where amphetamines are the principal drug of concern due to the SA Police Drug Diversion Initiative (PDDI). In addition, adult cannabis offences are not included in the PDDI due to the SA Cannabis Expiation Notice legislation.

In the Australian Capital Territory, removal of criminal penalties for possession of small quantities of cannabis in the ACT at the end of January 2020 reduced the number of cannabis-related diversions recorded as treatment episodes to low levels (mainly under-18s). Data collection improvements at government-operated services resulted in fewer 'not stated' responses in the 2022–23 collection.

Treatment

1. The proportion of episodes for an additional treatment type is calculated by the number of treatment episodes for that particular additional treatment type divided by the total number of treatment episodes for main treatment type in the collection year.
2. Rehabilitation, withdrawal management (detoxification), and pharmacotherapy are not available for clients who received treatment for someone else's alcohol or other drug use.
3. The main treatment type of 'other' includes pharmacotherapy. In 2019–20, changes were made to categories under Main Treatment; the word 'only' was removed from code 5 (support and case management) and code 6 (information and education). The removal of the word 'only' from support and case management and information and education, changed reporting rules for agencies; allowing agencies to be able to report and more accurately capture these items as an additional treatment in conjunction with a main treatment type. Main treatment code for 'Other' changed from 8 to 88.
4. Changes were also made to Other Treatment type (or additional treatment) categories, which added the codes 5 (Support and case management) and code 6 (Information and education) as categories to allow agencies to better reflect and record the current use of these treatment types in services. Other treatment type coding for the category 'Other' changed from 5 to 88.
5. In 2019–20, 2020–21 and 2021–22, unprecedented restrictions related to the COVID-19 pandemic impacted delivery of some AOD services including withdrawal management, residential rehabilitation, counselling and face-to-face outreach services, which moved to providing telehealth services to ensure social distancing guidelines were met. Withdrawal and rehabilitation bed-based occupancy decreased compared to pre-COVID occupancy in most states. See State and Territory Data Quality or further information.

Agencies

1. An agency's remoteness area is derived by applying an ABS Australian Statistical Geography Standard (ASGS) Edition 3 Remoteness Structure 2021 and 2021 to Statistical Area Level 2 code (SA2) correspondence. Some SA2s are split between multiple remoteness areas. Where this is the case, the data are weighted according to the proportion of the population of the SA2 in each remoteness area. As a result, it is possible that the number of agencies in a particular remoteness area is not a whole number. After rounding, this can result in there being '<0.5' or '<0.5%' of agencies in a remoteness area due to the agency's SA2 partially crossing into the remoteness area.
2. The number of agencies by remoteness or sector may not sum to the total number of agencies due to rounding.
3. The number of agencies is not an accurate reflection of all in-scope AOD specialist treatment services in Australia, as some agencies fail to report data during a collection for various reasons. See the Alcohol and other drug treatment services NMDS 2022–23 data quality statement - external site opens in new window for further details.
4. In 2018–19, the AOD treatment agency counting methodology was revised to better reflect the number of unique AOD treatment service outlets. There is a level of agency duplication, due to agencies splitting out episode data related to the funding source for that program/service. A small number of agencies split their data submission according to state funded service episodes, which are reported to relevant state or territory departments; and Commonwealth funded service episodes are reported to a peak body or directly to the AIHW. This has resulted in the double counting of some services over time. This revision has been applied to all time-series; the main changes in data related to AOD service counts are from 2014–15 to 2017–18.
5. Data for SA2 only available for 2014–15 collection onwards.

For further technical information regarding the AODTS NMDS see Annual report technical notes.

Data quality statement

AODTS NMDS 2022–23 data quality statement - external site opens in new window

Data

2022–23 States and territories (episodes) data tables

2022–23 Clients (states and territories) data tables

References

ABABS 2011. Australian Standard Classification of Drugs of Concern, 2011 - external site opens in new window. ABS cat. no. 1248.0. Canberra: ABS.

Data – Primary Health Network

In December 2015, the Australian Government announced the release of the *Australian Government Response to the National Ice Taskforce Final Report* (the Response). The Response underpinned the National Ice Action Strategy (NIAS), which was endorsed by the Council of Australian Governments (COAG) on 11 December 2016.

The Australian Government invested approximately $561 million over four years from 1 July 2016 in drug and alcohol treatment services, as part of a $713 million investment in reducing the impact of drug and alcohol misuse on individuals, families and communities under the *Drug and Alcohol Program*.

Approximately $412.1 million of this investment was provided to Primary Health Networks (PHNs) to commission locally based treatment in line with community need. This included the $241.5 million committed under the NIAS. This funding was delivered through the Australian Government's *Drug and Alcohol Program* and aims to improve the access to, and effectiveness of drug and alcohol treatment services in the community.

In April 2020, the Australian Government announced an additional $6 million would be invested in online and phone support services for people experiencing substance issues during the COVID-19 pandemic.

The main source of data about specialist drug and alcohol treatment services in Australia is the Alcohol and Other Drug Treatment Services National Minimum Data Set (the AODTS NMDS), compiled on an annual basis from administrative data by the Australian Institute of Health and Welfare (AIHW).

PHN-commissioned specialist alcohol and other drug treatment providers collect data, in accordance with the AODTS NMDS, on in-scope specialist treatment services and provide it to the AIHW. Alcohol and other drug treatment agencies funded by PHN organisations under the *Drug and Alcohol Program* submitted data to the AODTS NMDS for the first time in 2016–17.

The following set of data visualisations present information at PHN geographic areas. The data presented are from all publicly funded AOD treatment services (which includes PHN-commissioned services) that have reported to the AODTS NMDS (see technical notes for more details).

PHNs are organisations that connect health services across a specific geographic area (PHN areas). There are 31 PHN areas that cover the whole of Australia with the boundaries defined by the Australian Government Department of Health - external site opens in new window. Some states/territories consist of a single PHN area, while others are made up of multiple PHN areas.

Alcohol and other drug treatment services dashboards

Click on the icon maps to explore the dashboards

- For the best experience use Chrome, Edge or Firefox browsers. For more information on browser compatibility, see Supported browsers - external site opens in new window
- Best viewed on a desktop, laptop or tablet.

Alcohol and other drug treatment agencies map, 2018–19 to 2022–23

Primary Health Network

Alcohol and other drug treatment map, 2018–19 to 2022–23

Primary Health Network

Principal drug of concern map, 2018–19 to 2022–23

Primary Health Network

Alcohol and other drug treatment

The following data visualisation shows:

- Treatment episodes, by PHN area of client and main treatment type, 2018–19 to 2022–23.
- Treatment episodes, by PHN area of client and source of referral, 2022–23.
- Treatment episodes, by PHN area of client and treatment delivery setting, 2022–23.

Figure AODTS PHN 1: Alcohol and other drug treatment, 2018–19 to 2022–23

The interactive data dashboard shows that there were 235,460 treatment episodes provided to clients in Australia in 2022–23. A horizontal bar chart and line graph show the proportion of treatment episodes by main treatment type in 2022–23 (bar chart) and between 2018–19 and 2022–23 (line graph). Counselling remained the most common main treatment type between 2018–19 and 2022–23, accounting for 33.8% of episodes in 2022–23.

A horizontal bar chart and a donut chart show the proportion of treatment episodes by treatment delivery setting in 2022–23. Most episodes were delivered in non-residential treatment settings (66.2%) and the most common sources of referral were self/family (36.3% of episodes) and health services (31.5%). A filter allows the user to view data for Australia or by Primary Health Network area.



Title: Figure AODTS PHN 1: Alcohol and other drug treatment, 2018–19 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set.Tables PHN AODTS Episode 1, PHN AODTS Episode 3 and PHN AODTS Episode 4.
www.aihw.gov.au

See notes >

Client demographics

The following data visualisation shows:

- Clients by PHN area of client, client type and sex, 2022–23.

- Clients by PHN area of client, client type and age group, 2022–23.
- Clients by PHN area of client, client type and Indigenous status, 2022–23.

Figure AODTS PHN 2: Client demographics, 2022–23

The interactive data dashboard shows that there were 137,839 estimated clients in Australia in 2022–23. A horizontal bar chart shows that most clients in 2022–23 sought treatment for their own drug use (94.2%, compared with 5.8% of clients seeking treatment for someone else's drug use).

A vertical bar chart shows the proportion of clients by age group in 2022–23. Most clients were aged 30–39 (27.4%) or 20–29 (23.3%).

Two donut charts show the proportion of clients by sex and Indigenous status in 2022–23, respectively. Most clients were male (59.7%, compared with 34.7% for females) and 17.9% were First Nations people.



Principal drug of concern

The following data visualisation shows:

- Treatment episodes for clients who received treatment for their own drug use by PHN area of client and principal drug of concern, 2018–19 to 2022–23.
- Treatment episodes for clients who received treatment for their own drug use by PHN area of client and main treatment type, 2022–23.
- Treatment episodes for clients who received treatment for their own drug use by PHN area of client and source of referral, 2022–23.

Figure AODTS PHN 3: Principal drug of concern, 2018–19 to 2022–23
The interactive data dashboard shows that there were 217,302 treatment episodes provided to clients for their own drug use in Australia in 2022–23.

A horizontal bar chart and a line graph show the 4 most common principal drugs of concern among these episodes in 2022–23 (bar chart) and between 2018–19 and 2022–23 (line graph). Alcohol was the most common principal drug of concern across the period, accounting for 42.5% of episodes in 2022–23. This was followed by amphetamines (23.9% of episodes in 2022–23) and cannabis (17.5%).

A horizontal bar chart shows the proportion of treatment episodes provided to clients for their own drug use in 2022–23 by main treatment type. Counselling was the most common main treatment type (33.9% of episodes), followed by assessment only (22.8%).

A donut chart shows that proportion of treatment episodes by source of referral in 2022–23. The most common source of referral was self/family (36.4% of episodes), followed by health services (31.4%).

A filter allows the user to view data for Australia or by Primary Health Network.



Title: Figure AODTS PHN 3: Principal drug of concern, 2018–19 to 2022–23
Source: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set. PHN AODTS Episode 1, PHN AODTS Episode 2 and PHN AODTS Episode 3.
www.aihw.gov.au

See notes >

Data tables

PHN AODTS NMDS data tables

Data – pharmacotherapy in Australia

Opioid pharmacotherapy is one of the main treatment options for dependence on opioid drugs, such as heroin and morphine. Treatment involves replacing the opioid drug of dependence with a legally obtained, longer-lasting opioid. In Australia, clients attend dosing point sites (for example, pharmacies) regularly to take the dose of their prescribed medication under the supervision of a pharmacist or other health professional.

Clients who receive pharmacotherapy treatment can be captured in various data sources. The two national sources presented in this report are:

- Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS).
- National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD) Collection.

Due to the specifications of these collections, it is not possible to directly compare or identify people who received pharmacotherapy treatment via dosing point site as well as treatment from a publicly funded alcohol and other drug (AOD) service (see technical notes for more details). However, exploring this information in parallel can provide a more detailed picture about pharmacotherapy treatment in Australia.
The interactive data dashboard provides an overview of pharmacotherapy treatment in AODTS NMDS in 2022–23 and in the NOPSAD collection on a snapshot day in June 2023 (NOPSAD data does not include Queensland).

In 2022–23, 1.9% of AODTS NMDS treatment episodes provided to clients for their own drug use involved pharmacotherapy as the main treatment type. Among these episodes, the most common principal drug of concern was heroin (44.4% of AODTS NMDS pharmacotherapy episodes).

On a snapshot day in June 2023, 53,272 clients received opioid pharmacotherapy in the NOPSAD collection. The most common pharmacotherapy treatment type was methadone (47.2% of clients) and the most common opioid drug of dependence was heroin (33.8% of NOPSAD clients).

Navigation buttons allow the user to navigate between the following tabs: Overview, Client age and sex, and Treatment.



Sources: AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set (Tables Trt.2 and Trt.55), AIHW National Opioid Pharmacotherapy Statistics Annual Data Collection (Tables S4 and S10).
http://www.aihw.gov.au

Data tables

Data tables (AODTS NMDS)

Data tables (NOPSAD collection)

Australian Government
Australian Institute of Health and Welfare

Data – diversion programs in Australia

What are drug diversion programs?

In Australia, drug diversion treatment programs (diversion programs) divert people who have been apprehended or sentenced for a minor drugs offence from the criminal justice system. Diversions often result in clients being referred to drug treatment agencies, including publicly funded alcohol and other drug (AOD) treatment agencies captured in Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) data. Treatment services for clients referred via diversion programs range from short-term assessment (such as information or education sessions) to longer-term treatments (such as counselling or withdrawal management).

There are 2 key types of diversion programs in Australia that are captured in AODTS NMDS data:

- **Police diversion** occurs when an offence is first detected by a law enforcement officer. This typically applies for minor drug offences (for example, drug possession or use), often relating to cannabis. The offender may receive a caution or fine and will sometimes be required to attend mandatory drug assessment or education sessions.
- **Court diversion** occurs after a charge has been laid. It is usually applied for offences where criminal behaviour was related to drug use (for example, burglary or public order offence). Bail-based programs generally involve drug assessment and treatment, while pre– and post–sentence programs (such as drug courts) are aimed at repeat offenders and may involve more intensive treatment.

For more information on diversion programs, refer to the Key terminology and glossary.

Diversion has several objectives, including:

- avoiding the negative labelling and stigma associated with criminal conduct and contact with the criminal justice system
- preventing further offending by minimising a person's contact with, and progression through, the criminal justice system
- reducing the number of people reaching the courts and prisons, thereby lightening the heavy caseload of courts and reducing delays as well as costs of court processes and incarceration
- reducing unnecessary social controls
- providing appropriate interventions to those offenders who are in need of treatment or other services.

About the diversion client data visualisation

This interactive data visualisation is based on AODTS NMDS data on clients who are referred to treatment via police or court diversion programs. It includes all clients who received at least 1 treatment episode for their own drug use with diversion as the referral source in a given collection period (that is, financial year). In this visualisation:

- **Diversion clients** include all clients who were referred to treatment via a diversion program (police or court) in at least 1 treatment episode in the collection period. For example, where clients received more than 1 treatment episode in the same collection period, if at least 1 had a diversion referral source, then they are counted in 'Diversion clients' for the purpose of this analysis.
- **Non-diversion clients** include all clients who did not receive any episodes with a diversion referral source in the collection period.

Police and court diversion client counts are reported both separately and combined in this visualisation. The sum of clients for police and court diversion exceeds the total number of diversion clients reported due to overlap where, for example, clients received at least 2 treatment episodes with referrals from police and court diversion in the same collection period.

How do we count treatment episodes provided to diversion clients?

Standard AODTS NMDS reporting counts diversion treatment episodes as the total number of episodes in which the source of referral was listed as 'diversion'. For this feature diversion visualisation, treatment episodes are counted as follows:

- **Treatment episodes provided to non-diversion clients** include all treatment episodes provided to non-diversion clients in the collection period.

- **Treatment episodes provided to diversion clients** include all treatment episodes provided to diversion clients (police or court). Where diversion clients received multiple treatment episodes in the collection period, all episodes related to these clients are counted as 'diversion treatment episodes' regardless of the referral source. For example, if a client received 2 treatment episodes in 2022–23 and 1 of these listed 'diversion' as the referral source, both episodes are counted as treatment episodes for a diversion client even if the second episode did not list diversion as the referral source.

Treatment episodes in this visualisation are only included for clients with a valid SLK. The total number of treatment episodes reported is lower here than in the standard AODTS NMDS report, where all treatment episodes are counted regardless of client SLK.

The interactive data dashboard provides an overview of treatment episodes provided to diversion clients in Australia in 2022–23.

A series of tiles show that, in 2022–23, 187,821 treatment episodes were provided to non-diversion clients, 26,904 episodes were provided to all diversion clients, 15,632 episodes were provided to court diversion clients and 11,783 episodes were provided to police diversion clients.

A stacked horizontal bar graph shows that alcohol was the most common principal drug of concern (PDOC) in treatment episodes provided to non-diversion clients (46.4% of episodes), while cannabis was the most common PDOC among episodes provided to all diversion clients (33.8% of episodes). The proportion of episodes with cannabis as the PDOC was higher for police diversion clients (55.6% of episodes) than court diversion clients (18.1%).

Filters allow the user to view data by year (2018–19 to 2022–23) and by state or territory. Navigation buttons allow the user to navigate between the following tabs: Overview, Clients and Treatment episodes.



Australian Government
Australian Institute of
Health and Welfare

Technical notes

Policy framework

Drug use in Australia

Alcohol and tobacco are 2 of the most widely used drugs in Australia. The most recent 2022–2023 National Drug Strategy Household Survey reported that of people aged 14 and over in Australia:

- 8.3% smoked tobacco daily.
- 77% consumed an alcoholic drink in the previous 12 months.

About 1 in 3 (31% or 6.6 million) people aged 14 and over consumed alcohol in ways that put their health at risk according to the Australian Alcohol Guidelines - external site opens in new window (drinking more than 10 standard drinks per week on average or more than four standard drinks in a single day at least once a month; NHMRC 2020). This was similar to 2019, when 32% of the population (around 6.7 million people) reported drinking at risky levels (AIHW 2024a).

In 2022–2023, illicit drug use was relatively common among people aged 14 and over in Australia:

- 47% self-reported they had illicitly used a drug at some point in their life (including pharmaceuticals used for non-medical purposes) and 17.9% had done so in the last 12 months.
- Cannabis continued to be the most commonly used illicit drug with more than 1 in 3 (41%) having used it in their lifetime and 11.5% using it in the previous 12 months.
- Ecstasy and cocaine were the second and third most common illicit drugs used in a lifetime (13.6% and 13.5%, respectively) and in the last 12 months (2.1% and 4.5%, respectively) (AIHW 2024a).

Health impacts

The health impacts associated with alcohol and other drug (AOD) use include hospitalisation, mental health conditions, physical injury, overdose and mortality. Tobacco, alcohol and illicit drug use together account for 16.1% of the burden of disease in Australia (AIHW 2021).

Social impacts

The social impacts of AOD use in Australia include involvement in criminal activity, engagement in risky behaviours, victimisation and road trauma. In 2022–2023, 1 in 5 people (21%) aged 14 and over were victims of alcohol-related incidents and 1 in 10 people (10.1%) were victims of illicit drug-related incidents. Alcohol and illicit drug related incidents include verbal abuse, physical abuse, or being put in fear by someone under the influence of a substance in the previous 12 months (AIHW 2024). This trend was similar in 2019, where 1 in 5 (21%) people in Australia aged 14 and over were victims of an alcohol-related incident and 10.5% were victims of an illicit drug-related incident (AIHW 2020).

Economic impacts

The use and misuse of licit and illicit drugs imposes a heavy financial cost on the Australian community. In recent years, the separate costs of tobacco ($136.9 billion in 2015–16), opioid ($15.76 billion in 2015–16), methamphetamine (over $5 billion in 2013–14) and alcohol use ($66.8 billion in 2017–18) in Australia have been estimated, utilising different methodologies (Whetton et al. 2021; Whetton et al. 2020; Whetton et al. 2019; Whetton et al. 2016).

The National Drug Strategy

Australia has had a coordinated approach to dealing with alcohol and other drugs since 1985. The National Drug Strategy (NDS) 2017–2026 - external site opens in new window is the 7th and latest iteration of the cooperative strategy between the Australian Government, state and territory governments, and the non-government sector. The NDS provides a framework that identifies national priorities relating to alcohol, tobacco and other drugs, guides action by governments – in partnership with service providers and the community – and outlines a national commitment to harm minimisation through balanced adoption of effective demand, supply, and harm reduction strategies.

The objective of the National Drug Strategy

The NDS has an overarching approach of harm minimisation and encompasses 3 pillars, each with specific objectives (NDSC 2017):

- demand reduction
  - to prevent the uptake and/or delay the onset of use of alcohol, tobacco, and other drugs
  - to reduce the misuse of alcohol, tobacco, and other drugs in the community
  - to support people to recover from dependence through evidence-informed treatment
- supply reduction
  - to prevent, stop, disrupt, or otherwise reduce the production and supply of illegal drugs
  - to control, manage, and/or regulate the availability of illegal drugs
- harm reduction
  - to reduce the adverse health, social and economic consequences of the use of drugs for consumers, their families, and the wider community.

The collection of treatment services data, for example in the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS), forms part of the evidence base reinforcing harm reduction actions in the strategy, which include (NDSC 2017):

- increasing access to pharmacotherapy treatment to reduce drug dependence and reduce the health, social, and economic harms to individuals and the community that arise from misuse of opioids
- monitoring emerging drug issues to provide advice to the health, law enforcement, education, and social services sectors to inform individuals and the community regarding risky behaviours
- developing and promoting culturally appropriate alcohol, tobacco, and other drug information and support resources for individuals, families, communities, and professionals in contact with people at increased risk of harm from alcohol, tobacco, and other drugs
- providing opportunities for intervention among high-prevalence or high-risk groups and locations, including the implementation of settings-based approaches to modify risk behaviours
- enhancing systems to facilitate greater diversion into health interventions from the criminal justice system, particularly for Aboriginal and Torres Strait Islander (First Nations) people, young people, and other at risk populations who may be experiencing disproportionate harm.

Alcohol and other drug treatment services

AOD treatment services provide support to people regarding their use of alcohol or drugs through a range of treatments. Treatment objectives can include reduction or cessation of substance use, as well as improving social and personal functioning. Treatment and assistance may also be provided to support the family and friends of people who use alcohol or other drugs. Treatment services include detoxification and rehabilitation, counselling, and pharmacotherapy, and are delivered in residential and non-residential settings.

In Australia, publicly funded treatment services for AOD use are available in all states and territories. Most of these services are funded by state and territory governments, while some are funded by the Australian Government. Information on publicly funded AOD treatment services in Australia, clients, and drug treatment are collected through the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS). The AODTS NMDS is one of several NMDS that collect data under the 2012 National Healthcare Agreement - external site opens in new window to inform policy and help improve service delivery (COAG 2012).

Other available data sources that support a more complete picture of AOD treatment in Australia include:

- the National Opioid Pharmacotherapy Statistics Annual Data collection
- the National Hospital Morbidity Database
- the Specialist Homelessness Services collection
- the National Prisoner Health Data collection.

The Alcohol and Other Drug Treatment Services National Minimum Data Set

The Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) is a service based collection. It contains information on treatment provided to clients by publicly funded alcohol and other drug (AOD) treatment services, including government and non-government organisations. Information on clients and treatment services are included in the AODTS NMDS when a treatment episode provided to a client is closed (see Key terminology and glossary). This is a service-based collection and not a demand-based collection. This is a service-based collection and not a demand-based collection.

Information on the following types of treatment are reported:

- assessment only
- counselling

- information and education
- pharmacotherapy
- rehabilitation
- support and case management
- withdrawal management
- other (see Key terminology and glossary).

The AODTS NMDS collects data about services provided to people who received treatment for their own alcohol or drug use and those who received support for someone else's alcohol or drug use.

Client information is collected at the episode level in the AODTS NMDS. Further details on the estimation of client numbers and the imputation methodology can be found in data and methods.

Data collected by treatment agencies are forwarded to the relevant state and territory health departments, who then extract required data according to the specifications in the AODTS NMDS. Data are submitted to the AIHW annually for national collation and reporting.

Coverage and data quality

Although the AODTS NMDS collection covers the majority of publicly funded AOD treatment services, including government and non-government organisations, it is difficult to fully quantify the scope of AOD services in Australia.

The current scope of the collection, includes:

- All publicly funded (state, territory or Australian Government level) government and non-government agencies that provide one or more specialist alcohol and other drug treatment services, whether residential or non-residential.
- Acute care hospitals or psychiatric hospitals if they have specialist alcohol and other drug units that provide treatment to non-admitted patients (for example, outpatient services).
- Aboriginal or mental health services if they provide specialist alcohol and other drug treatment.

People receive treatment for alcohol and other drug-related issues in a variety of settings not in scope for the AODTS NMDS. Excluded settings:

- services provided by other not-for-profit organisations and private treatment agencies that do not receive public funding
- alcohol and other drug treatment units in acute care or psychiatric hospitals that provide treatment only to admitted patients
- prisons, correctional facilities and detention centres
- primary health-care services, including general practitioner settings, community-based care, First Nation-specific primary health-care services and dedicated substance use services
- health promotion services (for example, needle and syringe programs)
- accommodation services (for example, halfway houses and sobering-up shelters) (Figure AODTS 1).

In addition, agencies whose sole function is prescribing or providing dosing services for opioid pharmacotherapy are excluded from the AODTS NMDS. These data are captured in the AIHW's National Opioid Pharmacotherapy Statistics Annual Data collection.

Figure AODTS1: Alcohol and other drug treatment and support services in Australia



Note: Those in scope for the AODTS NMDS are shaded darker blue.

Aboriginal and Torres Strait Islander (First Nations) people

The Australian Government funds primary healthcare services and substance use services specifically for First Nations people. These services may be in scope for the AODTS NMDS but not all of the services currently report to the NMDS. These services previously reported via the Australian Government-funded First Nations substance use services, via the Online Services Report (OSR) data collection up to 2017–18 (AIHW 2024b). However, the substance use services program was transferred to the Indigenous Affairs Group within the Department of Prime Minister and Cabinet in September 2013 and then to the National Indigenous Australians Agency in July 2019 (Australian National Audit Office 2017, National Indigenous Australians Agency 2024). Since the cessation of substance use services data being collected by the OSR, the number of substance use services for First Nations people in-scope and reporting to the AODTS NMDS has gradually increased.

The National Agreement on Closing the Gap - external site opens in new window noted that funding for First Nations Alcohol and Other Drugs (AOD) services and support will increase by up to $66 million to 2024–25, in addition to current funding. First Nations' AOD Treatment Services funded under the Indigenous Advancement Strategy (IAS) currently assists more than 65 providers to deliver AOD activities (Department of Prime Minister and Cabinet 2024). The Commonwealth also provides AOD treatment services and prevention, research and communication activities through the Drug and Alcohol Program (DAP) and funding to Primary Health Networks (PHNs), with nearly 30% of PHN funding allocated for First Nations specific treatment services (National Indigenous Australians Agency 2022).

In 2022–23, 95.6% (1,280) of in-scope agencies submitted data to the AODTS NMDS. Overall, from 2021–22 to 2022–23, there was a decrease of less than 1 percentage point (0.3%) in the proportion of in-scope agencies that reported to the collection. For the 2014–15 and 2015–16 reporting periods, sector reforms and system issues in some jurisdictions affected the number of in-scope agencies that reported. This led to an under-count of the number of closed treatment episodes reported for these years, so results, especially across reporting years, should be interpreted with caution.

Further details on scope, coverage and data quality are available from the AODTS NMDS 2022–23 Data Quality Statement - external site opens in new window.

References

ANAO (Australian National Audit Office) (2017). Indigenous Advancement Strategy: Department of the Prime Minister and Cabinet - external site opens in new window, ANAO, Australian Government, accessed 6 March 2023.

AIHW (Australian Institute of Health and Welfare) 2020. National Drug Strategy Household Survey 2019: detailed findings. Drug Statistics series no. 32. Cat. no. PHE 270. Canberra: AIHW.

AIHW 2021. Australian Burden of Disease Study: Impact and causes of illness and death in Australia 2018. Cat. no. BOD 29. Canberra: AIHW. Viewed 9 March 2022.

AIHW 2024a. National Drug Strategy Household Survey 2022–2023 Cat. no: PHE 340 AIHW, Australian Government, accessed 29 February 2024.

AIHW 2024b. Online Services Report (OSR) for Aboriginal and Torres Strait Islander specific primary health care organisations, 2022–23; Quality Statement - external site opens in new window, AIHW METEOR Metadata Online Registry website, accessed 6 March 2024.

COAG (Council of Australian Governments) 2012. The National Health Reform Agreement - external site opens in new window. Canberra: COAG. Viewed 18 March 2022.

Department of Prime Minister and Cabinet (2024), Funding boost for First Nations Alcohol and Other Drug treatment services - external site opens in new window, Department of Prime Minister and Cabinet website, accessed 8 April 2024.

NDSC (National Drug Strategy Committee) 2017. National Drug Strategy 2017–2026 - external site opens in new window. Canberra: Commonwealth of Australia.

NHMRC (National Health and Medical Research Council) 2020. Australian guidelines to reduce health risks from drinking alcohol - external site opens in new window. Canberra: Commonwealth of Australia.

NIAA (National Indigenous Australians Agency) (2022). Commonwealth Closing the Gap Annual Report 2022 - external site opens in new window, NIAA, Australian Government, accessed 6 March 2023.

NIAA (2024). *Our Business* - external site opens in new window, NIAA, Australian Government, accessed 6 March 2024.

Whetton S, Shanahan M, Cartwright K, Duraisingam V, Ferrante A, Gray D, Kaye S, Kostadinov V, McKetin R, Pidd K, Roche A, Tait R, Allsop S 2016. The social costs of methamphetamine in Australia 2013/14 - external site opens in new window. National Drug Research Institute, Curtin University, Perth, Western Australia.

Whetton S, Tait R, Scollo M, Banks E, Chapman J, Dey T, Abdul Halim S, Makate M, McEntee A, Muhktar A, Norman R, Pidd K 2019. Identifying the Social Costs of Tobacco Use to Australia in 2015/16 - external site opens in new window. National Drug Research Institute, Curtin University, Perth, Western Australia. Viewed 22 October 2019.

Whetton S, Tait R, Chrzanowka A, Donnelly N, McEntee, Muhktar A, et al. 2020. Quantifying the social costs of pharmaceutical opioid misuse & illicit opioid use to Australia in 2015/16 - external site opens in new window. National Drug Research Institute, Curtin University, Perth, Western Australia.

Whetton S, Tait R J, Gilmore W, Dey T, Agramunt S, Abdul Halim S, McEntee A, Mukhtar A, Roche A, Allsop S and Chikritzhs T (2021) Examining the social and economic costs of alcohol use in Australia: 2017/18 - external site opens in new window, National Drug Research Institute, Curtin University, Perth, accessed 31 March 2022.

Data and methods

For technical notes on the state and territory summaries refer to Technical notes - state and territory summaries.

Age

Age is calculated as at the start of the episode.

Counting clients

Every client in the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) is assigned a statistical linkage key (SLK-581).

Clients are counted based on the number of SLK-581s in the AODTS NMDS.

National counts are based on the first time a client's SLK-581 appears in the AODTS NMDS. All clients are counted once.

State and territory counts are based on counting the occurrence of SLK-581s for each client in the AODTS NMDS in each jurisdiction. This may result in clients being counted more than once. This is most common among clients who travel interstate for treatment. For example, clients who reside in Queanbeyan, NSW and travel to Canberra, ACT for treatment. This means that the sum of clients at the state and territory level can be greater than the national total.

This report uses both national and state and territory counts to describe trends at both national and jurisdictional levels, as well as movements between jurisdictions. For more information, refer to the supplementary table footnotes and the SLK-581 guide for use.

Data collection process

For most states and territories, the data provided for the national collection are a subset of a more detailed jurisdictional data set used for planning and policy. Figure A1 shows the processes involved in constructing the national data.

Figure A1: Alcohol and other drug treatment data collection flowchart



Drugs of concern

The Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) contains data on drugs of concern that are coded using the ABS's Australian Standard Classification of Drugs of Concern (ASCDC) - external site opens in new window (ABS 2011). In this report, these drugs are grouped (Table A1).

Table A1: Groupings of drugs of concern

Group	ASCDC codes	Category	Includes
Analgesics	1000–1999	Codeine	
		Morphine	
		Buprenorphine	
		Heroin	
		Methadone	
		Other opioids	Oxycodone, fentanyl, pethidine
		Other analgesics	Paracetamol
Sedatives and hypnotics	2000–2999	Alcohol	Ethanol, methanol and other alcohols
		Benzodiazepines	Clonazepam, diazepam and temazepam
		Other sedatives and hypnotics	Ketamine, nitrous oxide, barbiturates and kava
Stimulants and hallucinogens	3000–3999	Amphetamines	Amphetamine, dexamphetamine and methamphetamine

		Ecstasy (MDMA)	
		Cocaine	
		Nicotine	
		Other stimulants and hallucinogens	Volatile nitrates, ephedra alkaloids, phenethylamines, tryptamines and caffeine
Cannabinoids	7000–7199	Cannabis	
Other	4000–6999 9000–9999	Other	Anabolic agents and selected hormones, antidepressants and antipsychotics, volatile solvents, diuretics and opioid antagonists
Not stated	0000–0002	Not stated	

In this report, pharmaceutical drugs were grouped using 10 drug types, making up the pharmaceuticals group for the purposes of the analysis. These drugs correspond to the ASCDC codes and classifications (Table A2).

Table A2: Pharmaceutical drugs of concern, ASCDC codes and classifications

Drug category	**ASCDC code**	**ASCDC classification (broad group and narrow group/s)**	**Drug description (ASCDC base level unit/s)**
Codeine	1101	Analgesics Organic opiate analgesics	Codeine
Morphine	1102	Analgesics Organic opiate analgesics	Morphine
Buprenorphine	1201	Analgesics Semisynthetic opioid analgesics	Buprenorphine
Oxycodone	1203	Analgesics Semisynthetic opioid analgesics	Oxycodone
Methadone	1305	Analgesics Synthetic opioid analgesics	Methadone
Benzodiazepines	2400–2499	Sedatives and hypnotics Benzodiazepines	Benzodiazepines n.f.d., alprazolam, clonazepam, diazepam, flunitrazepam, lorazepam, nitrazepam, oxazepam, temazepam, benzodiazepines n.e.c.

Steroids	4000–4999	Anabolic agents and selected hormones Anabolic androgenic steroids Beta2 agonists Peptide hormones, mimetics and analogues Other anabolic agents and selected hormones Not further defined	Anabolic agents and selected hormones n.f.d., anabolic androgenic steroids n.f.d., boldene, dehydroepiandrosterone, fluoxymesterone, mesterolone, methandriol, methenolone, nandrolone, oxandrolone, stanozolol, testosterone, anabolic androgenic steroids n.e.c., beta2 agonists n.f.d., eformoterol, fenoterol, salbutamol, beta2 agonists n.e.c., peptide hormones, mimetics and analogues n.f.d., chorionic gonadotrophin, corticotrophin, erythropoietin, growth hormone, insulin, peptide hormones, mimetics and analogues n.e.c., other anabolic agents and selected hormones n.f.d., sulfonylurea hypoglycaemic agents, tamoxifen, thyroxine, other anabolic agents and selected hormones n.e.c.
Other opioids	1100, 1199, 1200, 1299, 1300–1304, 1306–1399	Analgesics Organic opiate analgesics Semisynthetic opioid analgesics Synthetic opioid analgesics Not further defined	Organic opiate analgesics n.f.d., organic opiate analgesics n.e.c., semisynthetic opioid analgesics n.f.d., semisynthetic opioid analgesics n.e.c., synthetic opioid analgesics n.f.d., fentanyl, fentanyl analogues, levomethadyl acetate hydrochloride, meperidine analogues, pethidine, tramadol, synthetic opioid analgesics n.e.c.
Other analgesics	0005, 1000, 1400–1499	Analgesics Non-opioid analgesics Not further defined	Analgesics n.f.d., non-opioid analgesics n.f.d., acetylsalicylic acid, paracetamol, ibuprofen, non-opioid analgesics n.e.c.
Other sedatives and hypnotics	2000, 2200–2299, 2300–2399, 2500–2599, 2900–2999	Sedatives and hypnotics Anaesthetics Barbiturates Gamma-hydroxybutyrate (GHB) type drugs and analogues Other sedatives and hypnotics	Sedatives and hypnotics n.f.d., anaesthetics n.f.d., ketamine, nitrous oxide, phencyclidine, propofol, anaesthetics n.e.c., barbiturates n.f.d., amylobarbitone, methylphenobarbitone, phenobarbitone, barbiturates n.e.c., GHB-type drugs and analogues n.f.d., GHB, gamma-butyrolactone, 1,4-butanediol, GHB-type drugs and analogues n.e.c., other sedatives and hypnotics n.f.d., chlormethiazole, kava lactones, zopclone, doxylamine, promethazine, zolpidem, other sedatives and hypnotics n.e.c.

n.f.d – not further defined; n.e.c – not elsewhere classified.

Jurisdictional notes regarding principal drug of concern:

- Victoria reported comparatively high incidences of 'Not stated drugs' (15%) as the drug of concern. This is in part due to service providers adjusting to changes in reporting practices associated with the implementation of a new data collection system in 2019–20. In 2020–21, these drugs of concern were coded as 'Other drugs of concern' (14%) to realign with previous coding practices for Victoria. Victoria is working with service providers to encourage more specific reporting of drug of concern.
- In Queensland, the proportion of cannabis episodes reported as the principal drug of concern is a result of the Police Drug Diversion Program, Illicit Drugs Court Diversion Program and Drug and Alcohol Assessment Referral Program (DAAR) operating in the state.

- South Australia reports a high proportion of treatment episodes where amphetamines are the principal drug of concern due to the SA Police Drug Diversion Initiative (PDDI). In addition, adult cannabis offences are not included in the PDDI due to the SA Cannabis Expiation Notice legislation.
- In the Australian Capital Territory, removal of criminal penalties for possession of small quantities of cannabis in the ACT at the end of January 2020 reduced the number of cannabis-related diversions recorded as treatment episodes to low levels (mainly under-18s). Data collection improvements at government-operated services resulted in fewer 'not stated' responses in the 2022–23 collection.

Drugs of concern supplementary tables

Data for drugs of concern published in the supplementary tables may differ from results published within other tables, due to different counting methodology. Tables have been footnoted where there is different counting methodology. For example, where the principal drug of concern is coded as fentanyl (1301) and other drug of concern is coded as tramadol (1307), these drugs are within the same drug grouping (synthetic opioid analgesics) and counted only once.

Duration

Duration is calculated in whole days, and only for closed episodes.

Population rates

In this publication, crude rates were calculated using the ABS's estimated resident population at the midpoint of the data range: that is, rates for 2022–23 data were calculated using the estimated resident population at 31 December 2022.

The COVID-19 pandemic and the resulting Australian Government closure of the international border from 20 March 2020 caused significant disruptions to the usual Australian population trends. This report uses Australian Estimated Resident Population (ERP) estimates that reflect these disruptions.

In the year July 2020 to June 2021, the overall population growth was much smaller than the years prior and, in particular, there was a relatively large decline in the population of Victoria. ABS reporting indicates these were primarily due to net-negative international migration; for further information, refer to National, state and territory population, June 2021 - external site opens in new window.

Note that this change in the usual population trends may affect interpretation of statistics calculated from these ERPs. For example, rates and proportions may be greater than in previous years due to decreases in the denominator (population size) of some sub-populations.

Reason for cessation

The AODTS NMDS contains data on the reason an episode ended (reason for cessation). In this report, these reasons are grouped (Table A3), but data for the individual end reasons are available in the online supplementary tables.

A different method was used for grouping end reasons in reports released before 2014, so trend comparisons across reports should be made with caution. It is possible to compare data at the individual end reasons using the supplementary tables.

Table A3: Grouping of cessation reasons, by indicative outcome type

Outcome type	Reason for cessation
Expected/planned completion	Treatment completed
	Ceased to participate at expiation
	Ceased to participate by mutual agreement
Ended due to unplanned completion	Ceased to participate against advice
	Ceased to participate without notice
	Ceased to participate due to non-compliance
Referred to another service/change in treatment mode	Change in main treatment type
	Change in delivery setting

	Change in principal drug of concern
	Transferred to another service provider
Other	Drug court or sanctioned by court diversion service
	Imprisoned (other than drug court sanctioned)
	Died
	Other
	Not stated

Remoteness area

This report uses the ABS's Australian Statistical Geography Standard (ASGS) Edition 3 (ABS 2021) to analyse the proportion of AOD treatment agencies by remoteness area. This structure allows areas that share common characteristics of remoteness to be classified into broad geographic regions of Australia. These areas are:

- *Major cities*
- *Inner regional*
- *Outer regional*
- *Very remote*
- *Remote*

The remoteness structure divides each state and territory into several regions based on their relative access to services.

Examples of urban centres in each remoteness area are:

- *Major cities:* Canberra, Newcastle
- *Inner regional:* Hobart, Bendigo
- *Outer regional:* Cairns, Darwin
- *Remote: K*atherine, Mount Isa
- *Very remote:* Tennant Creek, Meekatharra.

For this report, the remoteness area of the agency was determined using the Statistical Area Level 2 (SA2) of the agency. Not all SA2 codes fit neatly within a single remoteness category, and a ratio is applied to reapportion each SA2 to the applicable remoteness categories. As a result, it is possible that the number of agencies in a particular remoteness category is not a whole number. After rounding, this can result in there being '<0.5%' agencies in a remoteness area, due to the agency's SA2 partially crossing into the remoteness area.

The Australian Statistical Geography Standard ASGS has replaced the Australian Standard Geographical Classification 2006 (ABS 2006), which was used in previous reports to calculate remoteness areas. Therefore, remoteness data for 2011–12 and previous years are not comparable with those for 2012–13 and subsequent years.

Service sectors

From 2008–09, agencies funded by the Department of Health and Aged Care under the Non-Government Organisation Treatment Grants Program (NGOTGP) were classified as non-government agencies. Before this, many of these agencies were classified as government agencies. As a result, trends in service sectors of agencies should be interpreted with caution.

Source of referral – diversion

Throughout Australia, there are programs that divert people who have been apprehended or sentenced for a minor drugs offence from the criminal justice system. Many of these diversions result in clients receiving drug treatment services, who have been referred to treatment agencies as part of a drug diversion program. Since the 1980s, Australian governments have supported programs aimed at diverting from the criminal justice system people who have been apprehended or sentenced with a minor drugs offence.

In Australia, drug diversion program come in 2 main forms:

- **Police diversion** occurs when an offence is first detected by a law enforcement officer. It usually applies for minor use or possession offences, often relating to cannabis, and can involve the offender being cautioned, receiving a fine and/or having to attend education or assessment sessions.

- **Court diversion** occurs after a charge is laid. It usually applies for offences where criminal behaviour was related to drug use (for example, burglary or public order offence). Bail-based programs generally involve assessment and treatment, while pre- and post-sentence programs (including drug courts) tend to involve intensive treatment and are aimed at repeat offenders.

Treatment

The number of closed treatment episodes for counselling as a main treatment type has remained the most common treatment type for all clients over all collection years. All information included in the AODTS NMDS regarding clients and treatment services are based on a closed treatment episode (there is an end date which falls within the reporting period). Fluctuations over time in closed treatment episodes for particular treatment types may be influenced by coding practices, increased funding or changes in treatment policies or capacity to provide specialised alcohol and other drug treatment services, which may contribute to variation in treatment types over time.

Trends

Trend data may differ from data published in previous versions of Alcohol and other drug treatment services in Australia, due to data revisions.

Imputation methodology for AOD clients

From the inception of the AODTS NMDS, data have been collected only about treatment episodes provided by AOD treatment services. Data about the clients those episodes relate to have not been available at a national level. A Statistical Linkage Key-581 (SLK) was introduced into the AODTS NMDS for the 2012–13 collection to enable the number of clients receiving treatment to be counted, while continuing to ensure the privacy of these individuals receiving treatment.

An imputation strategy for the collection was developed to correct for the impact of invalid or missing SLKs on the total number of clients. This strategy takes into account several factors relating to the number of episodes per client and makes assumptions relating to spread across agencies. It also takes into consideration the likelihood that an episode with a missing SLK relates to a client that has already been counted through other episodes with a valid SLK.

To ensure an accurate representation of the AODTS client population, imputation was applied to the 2012–13, 2013–14 and 2015–16 AODTS NMDS to account for the proportion of valid SLKs being less than 95% for these years. The national rate of valid SLKs for these years was largely affected by low proportions of valid SLKs in New South Wales.

Attributing the number of clients to a set of records missing SLK

The AODTS NMDS collects information at the service record level. Service records are associated with individual clients through an SLK. There are a number of records that have missing or invalid SLK data that cannot be attributed to a client. This leads to an under-reporting of the total number of clients using the services, because some (but not all) of the records will belong to clients who are not observed via a valid SLK.

This document describes the method of using the available data—after making several assumptions about the behaviour of the whole population—to estimate the total number of clients.

Imputation groups

Imputation groups are formed to improve the performance of the estimates. The service records were grouped according to properties that are thought to influence the behaviour of clients and the quality of SLK data, and then the imputation was performed at this imputation group level.

Possible properties used to develop groups include location, provider size (measured by number of service records) and service type. The data are also grouped according to any subpopulations that are going to be reported upon, such as jurisdiction.

The final imputation groups were formed by balancing the often-competing priorities of having homogenous groups and the need to have groups large enough to ensure that the imputation is robust.

Assumptions and approximations

Assumption 1: randomness and independence

This imputation method assumes that whichever service provider a client attends for each incidence of service is random and independent of any other incidents of service the client may have. It is further assumed that the validity or otherwise of the SLK recorded on each service record is random, and independent of both the client and the service provider with which the record is associated.

Assumption 2: distribution of the number of service records per client

This method also assumes that the distribution of the number of records per client for all clients is similar to that observed using the subset of records with valid SLKs.

Approximation 1: no client has more than 10 service records

This imputation method uses the approximation that no client has more than 10 service records.

In order to implement this approximation, any clients observed to have more than 10 service records were treated as if they had only 10, and the proportion of clients with 10 service records calculated accordingly.

Notation

The definition of the notation used in this document is as follows:

N_t
: the (unknown) total number of clients

N_t'
: the imputed total number of clients

N_{SLK1}
: the number of clients observed using the records with a valid SLK

P_{SLK1}
: the proportion of clients with at least 1 service record with a valid SLK

P_{Ni}
: the (unknown) proportion of clients with
i
service records

P_{Ni}'
: the imputed proportion of clients with
i
service records

$P_{Ni,SLK1}$
: the proportion of clients with
i
service records as observed using records with valid SLKs

n_t
: the total number of service records

$n_t|N_t,P_{Ni}$
: the number of service records given the total number of clients and the proportions of clients with
i
service records,
i
= 1,2, ... 10

n_{SLK1}
: the number of service records with a valid SLK

n_{SLK0}

: the number of service records with an invalid SLK

p_{SLK0}
: the proportion of service records with an invalid SLK.

Methodology

Given Assumption 1 and Approximation 1, the proportion of clients who have at least 1 service record with a valid SLK is:

$$P_{SLK1} = \sum_{i=1}^{10} P_{Ni}\left(1 - p_{SLK0}^{i}\right)$$

Now:

$$N_{SLK1} = P_{SLK1} \times N_t$$

so it follows that the total number of clients is:

$$N_t = \frac{N_{SLK1}}{P_{SLK1}}$$

To resolve this equation for

N_t
the values of the

P_{Ni}
is required. These are unknown, given it is not possible to observe the whole population due to the records with invalid SLK values. This method imputes the unknown

P_{Ni}
using numerical methods, then uses these values to impute

N_t
.

The process starts with the distribution of number of records per client that were observed using the records with valid SLKs (

$P_{Ni,SLK1}$
). These values are then adjusted so that the following conditions are met.

Constraint 1

The sum of the imputed proportions is equal to 1. That is:

$$\sum_{i=1}^{10} P'_{Ni} = 1$$

Constraint 2

The imputed proportion of clients with 1 service record is less than or equal to the observed equivalent proportion among clients with records with valid SLKs. That is:

$$P'_{N1} \leq P_{N1,SLK1}$$

This constraint is used because some of the clients observed to have only 1 record will, in fact, have additional records with invalid SLKs. It is unlikely that the true proportion of clients with 1 service record is higher than that observed using records with valid SLKs.

Constraint 3

The total number of service records that the imputed total number of clients and the imputed distribution of records per client imply is equal to the observed number of service records.

That is:

$$n_t | N'_t, P'_{Ni} = N'_t \sum_{i=1}^{10} (i \times P'_{Ni}) = n_t.$$

This constraint is used to ensure that the imputed values are consistent with the observed number of records.

Penalty function

Under Assumption 2 we want to limit how much the imputed proportions differ from the proportions observed via the records with valid SLK data. To achieve this we use a penalty function that increases as the distance between the imputed and observed proportions increases. This function is defined to be:

$$f(P_{N1,SLK1}, P_{N2,SLK1}, \dots, P_{N10,SLK1}, P'_{N1}, P'_{N2}, \dots, P'_{N10}) = \sum_{i=1}^{10} \frac{(P'_{Ni} - P_{Ni,SLK1})^2}{P_{Ni,SLK1}}$$

Using numerical methods, the

$P'_{N1}, P'_{N2}, \dots P'_{N10}$

are chosen such that the penalty function is minimised, subject to the 3 constraints.

The final step is to use the imputed proportions to calculate the imputed total number of clients:

$$N'_t = \frac{N_{SLK1}}{\sum_{i=1}^{10} P'_{Ni}(1 - p^i_{SLK0})}$$

The resulting number is then rounded to the nearest integer.

Discussion

This imputation technique uses available information to impute the total number of clients. The methodology takes into account the proportion of records with invalid SLK data and the distribution of the number of service records per client, as observed via the records with valid SLK data. It is apparent that the assumptions made do not hold for every client or service record. It is reasonable to expect that a client's attendance at a service provider will be affected by location and any prior contact they had with a provider. It should also be noted that some service providers failed to collect SLK for any service record during the reference period.

Despite the known cases where Assumption 1 does not hold, it is reasonable to hope that, across the population as a whole, the assumption is a reasonable representation of the populations of clients and service records.

It is believed that the impact of Approximation 1 will be small because, given Assumption 1, the chance that a client with more than 10 service records is not observed via a record with a valid SLK is extremely small. The chance diminishes as the proportion of records with an invalid SLK decreases and across jurisdictions the highest proportion observed is about 0.3. It should also be noted that the largest proportion of clients with 10 or more service records observed in the data at the jurisdiction level was only 0.007.

There are many different penalty functions that could be used in this imputation. The function used was chosen because, compared with the other penalty functions investigated, it produced imputed proportions that were generally as close or closer to the observed proportions. It also most consistently resulted in a distribution that was similar in shape to the observed distribution of the number of records per client.

Historical data element changes

Details on historical data element changes are found in Appendix A of the AODTS NMDS Data Collection Manual 2022–23 [PDF 735kB].

References

ABS (Australian Bureau of Statistics) 2006. Statistical geography: volume 1—Australian Standard Geographical Classification (ASGC) - external site opens in new window. ABS cat. no. 1216.0. Canberra: ABS.

ABS 2011. Australian Standard Classification of Drugs of Concern, 2011 - external site opens in new window. ABS cat. no. 1248.0. Canberra: ABS.

ABS 2016. Estimates of Aboriginal and Torres Strait Islander Australians, July 2016 - external site opens in new window. ABS cat. no.1270.0.55.005. Canberra: ABS.

ABS 2021. Australian Statistical Geography Standard Edition 3 - external site opens in new window. Canberra: ABS.

State and territory data quality

COVID-19

From 2019–20 to 2021–22, restrictions related to the COVID-19 pandemic continued and impacted delivery of services including AOD treatment for withdrawal management and residential rehabilitation. The latter included closure of services for a period of time in some states. Withdrawal and rehabilitation bed-based occupancy decreased compared to pre-COVID-19 occupancy in most states. Counselling and face-to-face outreach services also moved to providing telehealth services to ensure social distancing and public health guidelines were met. The number of AOD referrals decreased and the number of admission cancellations increased for residential withdrawal and rehabilitation services. The majority of providers moved to a telehealth model and discontinued face-to-face contact with clients unless the client received withdrawal or rehabilitation services.

Summary information provided by states and territories, regarding the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) data collection:

New South Wales

From 2019–20 to 2021–22, the ongoing impact of COVID has seen:

- services use telehealth, primarily telephone or video conferencing for group sessions
- staff turnover and sickness impacting ability to deliver services, including increased workload as well as additional tasks (for example, ongoing cleaning)
- some treatment services (such as withdrawal management and residential rehabilitation services) were impacted due to social distancing rules and continued to have limited occupancy rates and bed capacity in both non-government and government services. These constraints meant services had to reduce the availability of treatment places
- constraints to service delivery also had an impact on data collection including less timely data uploads due to staff working from home. Local health districts also reported unexpected data system loading issues
- risk management practices and PPE increased workloads for staff and mask wearing was a barrier to engaging with clients and seeing non-verbal cues
- some services closed, which increased the workload of services that remained open
- all home visits/ external (outreach) service visits were suspended for a period of time
- difficulty accessing technology for some clients
- new client assessments decreased as treatment places were limited
- access for agencies regarding ICT infrastructure and internet capacity highlighted a divide for regional and rural services; weak connectivity contributed to potential decline of some service delivery
- some local health districts reported workforce and service delivery issues, which may have impacted the number of closed episodes
- regional and rural services were less affected; however, access to metropolitan services by rural clients was affected.

Victoria

The impact of COVID from 2019–20 to 2021–22 saw the majority of providers move to telehealth service provision, discontinuing face-to-face contact with clients unless they were receiving residential withdrawal and rehabilitation services.

Impacts on residential withdrawal and rehabilitation services included:

- bed based units operating at reduced bed capacity during lockdowns, ensuring social distancing requirements were met. Occupancy across all residential services fell compared to pre-COVID as a result of social distancing requirements
- COVID-19 restrictions also reduced the number of referrals and increased the number of admission cancellations to residential withdrawal and rehabilitation services
- wait times between referrals and admissions also increased due to reduced capacity. Leave and visitors were prohibited during residential stays to decrease risk
- services reduced the number of referrals and increased the number of admission cancellations.

While the number of non-residential withdrawal episodes increased slightly between 2019–20 and 2020–21, during extensive COVID-19 lockdowns non-residential withdrawal service contacts included an electronic process rather than face-to-face, which may have been coded as ‘other’ setting rather than a non-residential treatment facility setting.

Queensland

From 2019–20 to 2021–22, the impact of COVID-19 has seen:

- a decrease in closed treatment episodes across all treatment types for the period of Mar–Jun 2020, particularly for counselling and information and education
- there was also a decrease in the reporting of diversion referrals from the justice system due to public restrictions being in place and restricted operation of the Magistrates Courts. From March to August 2020, most police and court diversion appointments were scheduled to occur by telephone, with only a few providers offering face-to-face appointments. In 2020–21, diversion referral episodes from the justice system increased compared to 2019–20, potentially due to the easing of public restrictions
- in January 2022, there was a lockdown in Queensland and services continued to provide treatment episodes via different modes of delivery. There was a drop in appointments for the Police Drug Diversion Program, Illicit Drugs Court Diversion Program and Drug and Alcohol Assessment Referral Program. Diversion treatment episodes (and hence AODTS interventions) also decreased between financial years; however, this may be for a number of reasons (including COVID lockdown).
- Referrals to the Police Drug Diversion Program, Illicit Drugs Court Diversion Program and Drug and Alcohol Assessment Referral Program (DAAR) have continued to decline, continuing a trend that commenced in 2015-16.

Western Australia

As a result of COVID–19, services offered more telehealth appointments and organisations continued to report COVID impacted service delivery from 2019–20 to 2021–22. Examples include:

- inability to recruit staff due to border restrictions
- staff sickness and isolation periods affecting workforce availability
- staff not being vaccinated in line with government requirements
- residential services were required to close beds at times due to government public health restrictions, which may result in less episodes at some agencies
- decreased bed capacity across residential services, including rehabilitation and withdrawal services.

South Australia

From 2019–20 to 2021–22, the impacts for treatment service delivery due to COVID-19 included:

- a proportion of counselling services shifted from face-to-face appointments to telehealth and telephone clinical support to clients in treatment
- there was decreased bed capacity across residential services and withdrawal services, reducing the amount of people accessing these services
- medically assisted treatment for Opioid Dependence prescription review periods were increased from 3 to 6 months during COVID restrictions
- Drug and Alcohol Services SA (DASSA) were asked to implement a Work from Home (WFH) mandate
- eligibility criteria for entry into DASSA's inpatient withdrawal management facility was reviewed during COVID-19, resulting in cannabis and amphetamine withdrawal management clients being referred to outpatient services and SA's non-government sector.

Tasmania

COVID-19 restrictions in Tasmania from 2019–20 to 2021–22 saw:

- an overall reduction in the number of closed AOD treatment episodes in Tasmania from April 2020, as a result of COVID-19 restrictions
- rehabilitation and counselling episodes decline over the April to June 2020 period and face-to-face outreach services moved to providing telehealth services. From mid-July 2020, in-person service delivery resumed from a telehealth model; however, social-distancing measures remained. This resulted in a minor reduction in capacity for some bed-based services
- inpatient withdrawal units were operating at reduced capacity for the entire 2021–22 period due to COVID-19 restrictions
- a small decrease in the average new referrals (episode) totals for non-residential settings was noted in July 2020, potentially due to client hesitancy to access health settings. However, this temporary trend reversed by August 2020
- reduced face to face appointments on site with preference for services to be conducted through telehealth and phone.

Australian Capital Territory

As a result of COVID-19 restrictions from 2019–20 to 2021–22:

- services slowed intake into residential withdrawal programs, which slowed admission to rehabilitation programs and decreased bed capacity in residential rehabilitation and withdrawal services
- services shifted to telehealth services and online programs (for example, face-to-face programs, including group programs, were suspended, or reconvened online)
- staff illness and absence affected programs during both the lockdown period and other parts of the year, requiring staff to isolate at home if unwell and to take time off work
- agency staff relocated to working from home
- reductions in service operating hours
- ceased or reduced intake of new clients to residential and non-residential treatment services.

Northern Territory

From 2019–20 to 2021–22:

- COVID-safe procedures in residential rehabilitation resulted in a decrease in the number of people that could be accommodated in each facility (for example, one person per room) to ensure social distancing guidelines were adhered to. While different service types were impacted in different ways, no service completely closed during this time. There was short-term reduction in capacity, but this eased quickly to business-as-usual once services learnt how to operate under the new COVID environments
- outreach services increased to compensate for reduced residential services.

Policy, legislation and environmental changes

New South Wales

In 2019–20, a number of natural disasters impacted the 2019–20 NSW reporting period, including large areas of NSW experiencing unprecedented bushfires between October 2019 and March 2020, and in February 2020 some areas of NSW experienced flooding.

During 2023, there was a transition between data warehouses, this may have impacted the data for the 2022-23 period.

South Australia

South Australia reported a high proportion of episodes of treatment where amphetamines are the principal drug of concern and assessment only is the main treatment type. This is related to assessments provided under the Police Drug Diversion Initiative. This program is legislated in South Australia, unlike other jurisdictions, and therefore results in a higher percentage of assessment only services with high rates of engagement with methamphetamine users. In addition, due to the Cannabis Expiation Notice legislation in South Australia, adult simple cannabis offences are not diverted to treatment and so are excluded from the data.

The South Australian Police Drug Diversion initiative also saw a change in legislation from April 2019 [Statutes Amendment (Drug Offences) Bill 2018, where youth are no longer diverted immediately for an Assessment. Adults who have been apprehended twice in four years are no longer eligible for an Assessment.

Northern Territory

As of 2018 all agencies; regardless of setting, are instructed to complete a separate assessment only episode prior to the commencement of treatment. This policy relates to monitoring the volume of assessment work performed by agencies, particularly in relation to certain alcohol-related legislatively-based programs such as the Banned Drinker Register (BDR).

Key terminology and glossary

Key terminology

Closed treatment episode

An episode of treatment for alcohol and other drugs is the period of contact, with defined dates of commencement and cessation (start and end date), between a client and a treatment provider or team of providers in which there is no change in the main treatment type or the principal drug of concern, and there has not been a non-planned absence of contact for greater than 3 months.

A treatment episode is considered **closed** where any of the following occurs:

- treatment is completed or has ceased
- there has been no contact between the client and treatment provider for 3 months, or
- there is a change in the main treatment type, principal drug of concern or delivery setting.

Treatment episodes are **excluded** from the AODTS NMDS for a reporting year if they:

- are not closed in the relevant financial year
- are for clients who are receiving pharmacotherapy (through an opioid substitution therapy program) and not receiving any other form of treatment that falls within the scope of the collection
- include only activities relating to needle and syringe exchange, or
- are for a person aged under 10.

The Alcohol and Other Drug Treatment Services National Minimum Data set is a service-based collection and not a demand-based collection.

Drugs of concern

The **principal drug of concern** is the main substance that the client stated led them to receive treatment from the AOD treatment agency. In this report, only clients who received treatment for their own substance use are included in analyses of principal drug of concern. It is assumed that only the person using the substance themselves can accurately report principal drug of concern; therefore, these data are not collected from those who received treatment for someone else's drug use.

Additional drugs of concern refers to any other drugs the client reports using in addition to the principal drug of concern. Clients can nominate up to 5 additional drugs of concern, but these drugs are not necessarily the subject of any treatment within the episode.

All drugs of concern refers to all drugs reported by clients, including the principal drug of concern and any additional drugs of concern.

Reasons for cessation

The reasons for a client ceasing to receive a treatment episode from an AOD treatment service include:

- **expected/planned completion:** episodes where the treatment was completed, or where the client ceased to participate at expiation or by mutual agreement
- **ended due to unplanned completion:** episodes where the client ceased to participate against advice, without notice or due to non-compliance
- **referred to another service/change in treatment mode:** episodes that ended due to a change in main treatment type, delivery setting or principal drug of concern, or where the client was transferred to another service provider.
- **other**: episodes that ended due to the client returning to court or jail due to non-compliance with a drug court program or sanctioned by court diversion service, imprisoned (other than drug court sanctioned), died, or reasons not elsewhere classified**.**

Treatment types

Treatment type refers to the type of activity used to treat the client's alcohol or other drug use. Rehabilitation, withdrawal management (detoxification) and pharmacotherapy are not available for client's who received treatment for someone else's drug use. See glossary for more information on treatment types and definitions.

The **main treatment type** is the principal activity that is determined at assessment by the treatment provider to be necessary for the completion of the treatment plan for the client's alcohol or other drug use for their principal drug of concern. One main treatment type is reported for each treatment episode. 'Assessment only', 'support and case management' and 'information and education' can be reported only as main treatment types.

In 2019–20, changes were made to categories under Main Treatment; the word 'only' was removed from support and case management and information and education. The removal of the word 'only' from support and case management and information and education, changed reporting rules for agencies; allowing agencies to be able to report and more accurately capture these items as an additional treatment in conjunction with a main treatment type.

Additional treatment types refer to other treatment types provided to the client, in addition to their main treatment type. Up to 4 additional treatment types can be reported. For example, a client may receive counselling as their main treatment and support and case management as an additional treatment. Up to four additional treatment types can be recorded for each client.

Note that Victoria and Western Australia do not supply data on additional treatment types. In these jurisdictions, each type of treatment (main or additional) results in a separate episode.

Glossary

additional drugs: Clients receiving treatment for their own drug use nominate a principal drug of concern that has led them to receive treatment and additional drugs of concern, of which up to 5 are recorded in the AODTS NMDS. Clients receiving treatment for someone else's drug use do not nominate drugs of concern.

additional treatment type: Clients receive 1 main treatment type in each episode and additional treatment types as appropriate, of which up to 4 are recorded in the AODTS NMDS.

agency: agencies included in the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) are publicly funded (at state, territory, or Australian Government level) government and non-government agencies that provide one or more specialist alcohol and other drug treatment services, whether residential or non-residential. Acute care hospitals or psychiatric hospitals are also included if they have specialist alcohol and other drug units that provide treatment to non-admitted patients (for example, outpatient services), as are Indigenous or mental health services if they provide specialist alcohol and other drug treatment.

alcohol: A central nervous system depressant made from fermented starches. Alcohol inhibits brain functions, dampens the motor and sensory centres and makes judgement, coordination and balance more difficult (NDARC 2016).

amphetamines: Stimulants that include methamphetamine, also known as methylamphetamine. Amphetamines speed up the messages going between the brain and the body. Common names are speed, fast, up, uppers, louee, goey and whiz. Crystal methamphetamine is also known as ice, shabu, crystal meth, base, whiz, goey or glass.

Australian Standard Geographical Classification (ASGC): Common framework defined by the Australian Bureau of Statistics for collection and dissemination of geographically classified statistics. The ASGC was implemented in 1984 and the final release was in 2011. It has been replaced by the Australian Statistical Geography Standard (ASGS) see below:

Australian Statistical Geography Standard (ASGS): Common framework defined by the Australian Bureau of Statistics for collection and dissemination of geographically classified statistics. The ASGS replaced the ASGC in July 2011.

benzodiazepines: Also known as minor tranquillisers, these drugs are most commonly prescribed by doctors to relieve stress and anxiety, and to help people sleep. Common names include benzos, tranx, sleepers, downers, pills, serras (Serepax®), moggies (Mogadon®) and normies (Normison®).

client: an individual who is assessed and/or accepted for treatment for their own or someone else's alcohol or other drug use from an in-scope agency and who is aged 10 or older at the start of the treatment episode.

client type: The status of a person in terms of whether the treatment episode concerns their own alcohol or other drug use or that of another person. Clients may receive treatment or assistance concerning their own alcohol or other drug use, or treatment and/or assistance in relation to the alcohol or other drug use of another person.

client counts:

Every client in the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) is assigned a statistical linkage key (SLK-581).

Clients are counted based on the number of SLK-581s in the AODTS NMDS.

National counts are based on the first time a client's SLK-581 appears in the AODTS NMDS. All clients are counted once.

State and territory counts are based on counting the occurrence of SLK-581s for each client in the AODTS NMDS in each jurisdiction. This may result in clients being counted more than once. This is most common among clients who travel interstate for treatment. For example, clients who reside in Queanbeyan, NSW and travel to Canberra, ACT for treatment. This means that the sum of clients at the state and territory level can be greater than the national total.

This report uses both national and state and territory counts to describe trends at both national and jurisdictional levels, as well as movements between jurisdictions. For more information, refer to the supplementary table footnotes and the SLK-581 guide for use [PDF 96kB].

closed treatment episode: A period of contact between a client and a treatment provider, or team of providers. All information included in the AODTS NMDS regarding clients and treatment services are based on a closed treatment episode (there is an end date which falls within the reporting period). An episode is closed when treatment is completed, there has been no further contact between the client and the treatment provider for 3 months, or when treatment is ceased (see reason for cessation).

cocaine: A drug that belongs to a group of drugs known as stimulants. Cocaine is extracted from the leaves of the coca bush (*Erythroxylum coca*). Some of the common names for cocaine include C, coke, nose candy, snow, white lady, toot, Charlie, blow, white dust and stardust.

diversion client type: Clients who received at least 1 AOD treatment episode during a collection year resulting from a referral by a police or court diversion program. The 2 subtypes in this group are:

- diversion only clients – received treatment as a result of diversion referrals only
- diversion client with non-diversion episodes – received at least 1 treatment episode resulting from a diversion referral, but also received at least 1 treatment episode resulting from a non-diversion referral in a collection year.

ecstasy (MDMA): The popular street name for a range of drugs containing the substance 3, 4-methylenedioxymethamphetamine (MDMA) – a stimulant with hallucinogenic properties. Common names for ecstasy include Adam, Eve, MDMA, X, E, the X, XTC and the love drug.

GHB: stands for gamma hydroxybutyrate, which is a central nervous system depressant. Common names for GHB include, G, Grievous Bodily Harm, fantasy, liquid E, liquid ecstasy and blue nitro.

government agency: An agency that operates from the public accounts of the Australian Government or a state or territory government, is part of the general government sector and is financed mainly from taxation.

heroin: One of a group of drugs known as opioids, which are strong painkillers with addictive properties. Heroin and other opioids are classified as depressant drugs. Common names for heroin include smack, skag, dope, H, junk, hammer, slow, gear, harry, big harry, horse, black tar, China white, Chinese H, white dynamite, dragon, elephant, boy, home-bake or poison.

illicit drug use: Includes:

- the use of illegal drugs – drugs that are prohibited from manufacture, sale or possession in Australia, such as cannabis, cocaine, heroin and MDMA (ecstasy)
- misuse, non-medical or extra-medical use of pharmaceuticals – drugs that are available from a pharmacy, over-the-counter or by prescription, which may be subject to misuse, such as opioid-based pain relief medications, opioid substitution therapies, benzodiazepines, over-the-counter codeine and steroids
- use of other psychoactive substances – legal or illegal, potentially used in a harmful way, such as kava, or inhalants such as petrol, paint or glue (but not including tobacco or alcohol).

licit drug use: The use of legal drugs in a legal manner, including tobacco smoking and alcohol consumption.

main treatment type: The principal activity that is determined at assessment by the treatment provider to treat the client's alcohol or other drug use for the principal drug of concern.

median: The midpoint of a list of observations ranked from the smallest to the largest.

method of use for principal drug of concern: The client's usual method of administering the principal drug of concern as stated by the client. Includes: ingests, smokes, injects, sniffs (powder), inhales (vapour), other and not stated.

new client: Clients who have received treatment from a publicly funded AOD agency in the financial year for the first time, having never received treatment in any previous year. This is based on if a client's Statistical Linkage Key-581 has not appeared previously in the data collection since 2013-14. This does not account for miscoding of, or changes to, client name, date of birth or sex.

nicotine: The highly addictive stimulant drug in tobacco.

non-government agency: An agency that receives some government funding, but is not controlled by the government, and is directed by a group of officers or an executive committee. A non-government agency may be an income tax-exempt charity.

principal drug of concern: The main substance that the client stated led them to receive treatment from an alcohol and drug treatment agency.

reason for cessation: The reason the client ceased to receive a treatment episode from an alcohol and other drug treatment service. The client can have:

- completed treatment – where the treatment was completed as planned
- a change in the main treatment type
- a change in the delivery setting
- a change in the principal drug of concern
- been transferred to another service provider – including where the service provider is no longer the most appropriate, and the client is transferred or referred to another service. For example, transfers could occur for clients between non-residential and residential services, or between residential services and a hospital – excludes situations where the original treatment was completed before the client transferred to a different provider for other treatment
- ceased to participate against advice – here the service provider is aware of the client's intention to stop participating in treatment, and the client ceases despite advice from staff that such action is against the client's best interest
- ceased to participate without notice
- ceased to participate involuntarily – where the service provider stops the treatment due to non-compliance with the rules or conditions of the program
- ceased to participate at expiation – where the client has fulfilled their obligation to satisfy expiation requirements (for example, participation in a treatment program to avoid having a criminal conviction being recorded against them) as part of a police or court diversion scheme and chooses not to continue with further treatment
- ceased to participate by mutual agreement – where the client ceases participation by mutual agreement with the service provider, even though the treatment plan has not been completed. This may include situations where the client has moved out of the area
- been to a drug court or sanctioned by court diversion service – where the client is returned to court or jail due to non-compliance with the program
- been imprisoned (other than sanctioned by a drug court or diversion service)
- died.

The grouped categories used in the report for **reason for cessation**:

- referred to another service/change in treatment mode: includes episodes that ended due to a change in main treatment type, delivery setting or principal drug of concern, or where the client was transferred to another service provider
- ended due to planned completion: Includes episodes where the client completed treatment–ceased to participate at expiation or by mutual agreement
- ended due to unplanned completion: Includes episodes where the client ceased to participate against advice, without notice, or due to non-compliance.

referral source: The source from which the client was transferred or referred to the alcohol and other drug treatment service.

returning client: Clients who have received treatment from a publicly funded AOD agency in the financial year plus at least 1 previous year since 2013–14. This is based on if a client's Statistical Linkage Key-581 has appeared previously in the data collection since 2013-14. This does not account for miscoding of, or changes to, client name, date of birth or sex.

standard drink: Contains 10 grams of alcohol (equivalent to 12.5 millilitres of alcohol). Also referred to as a full serve.

tobacco: A plant, *Nicotiana tabacum*, whose leaves are dried and used for smoking and chewing and in snuff. Its major pharmacologically active substance is the alkaloid nicotine (see nicotine).

treatment delivery setting: The main physical setting in which the type of treatment that is the principal focus of a client's alcohol and other drug treatment episode is actually delivered to a client (irrespective of whether or not this is the same as the usual location of the service provider).

treatment episode: The period of contact between a client and a treatment provider or a team of providers. Each treatment episode has 1 principal drug of concern and 1 main treatment type. If the principal drug or main treatment changes, then a new episode is recorded.

treatment delivery setting: The main physical setting in which the type of treatment that is the principal focus of a client's alcohol and other drug treatment episode is actually delivered to a client (irrespective of whether or not this is the same as the usual location of the service provider).

treatment episode: The period of contact between a client and a treatment provider or a team of providers. All information included in the AODTS NMDS regarding clients and treatment services are based on a closed treatment episode (there is an end date which falls within the reporting period). Each treatment episode has 1 principal drug of concern and 1 main treatment type. If the principal drug or main treatment changes, then a new episode is recorded.

treatment type: The type of activity that is used to treat the client's alcohol or other drug use, which includes:

- assessment only – where only assessment is provided to the client (service providers would normally include an assessment component in all treatment types)
- counselling – can include cognitive behaviour therapy, brief intervention, relapse intervention and motivational interviewing
- information and education – where information and education is provided to the client (service providers would normally include an information and education component in all treatment types)
- pharmacotherapy – where the client receives another type of treatment in the same treatment episode and includes drugs such as naltrexone, buprenorphine and methadone used as maintenance therapies or relapse prevention for people who experience dependence on certain types of opioids. Where a pharmacotherapy is used for withdrawal, it is included in the withdrawal category. Due to the complexity of the pharmacotherapy sector, this report provides only limited information on agencies whose sole function is to provide pharmacotherapy
- rehabilitation – focuses on supporting clients in stopping their drug use, and to prevent psychological, legal, financial, social and physical consequences of problematic drug use. Rehabilitation can be delivered in several ways, including residential treatment services, therapeutic communities and community-based rehabilitation services
- support and case management – support includes helping a client who occasionally calls an agency worker for emotional support, while case management is usually more structured than 'support'. It can assume a more holistic approach, taking into account all client needs (including general welfare needs) and it includes assessment, planning, linking, monitoring and advocacy
- withdrawal management (detoxification) – includes medicated and non-medicated treatment to help manage, reduce or stop the use of a drug of concern.

Acronyms

Acronym	Full name
ABS	Australian Bureau of Statistics
ACT	Australian Capital Territory
AIHW	Australian Institute of Health and Welfare
AOD	Alcohol and other drugs
AODTS NMDS	Alcohol and Other Drug Treatment Services National Minimum Data Set
ASCDC	Australian Standard Classification of Drugs of Concern
ASGC	Australian Standard Geographical Classification
ASGS	Australian Statistical Geography Standard
GHB	gamma hydroxybutyrate
MDMA	3, 4-methylenedioxymethamphetamine
NA	Not applicable
NDS	National Drug Strategy
NDSHS	National Drug Strategy Household Survey
NGOs	Non-Government Organisations
NSW	New South Wales
NT	Northern Territory
Qld	Queensland
SA	South Australia
SLK	statistical linkage key
Tas	Tasmania
Vic	Victoria
WA	Western Australia

Primary Health Network (PHN)

General notes:

- The Australian Government commissioned Primary Health Networks (PHNs) from 1 July 2015, to provide funding for locally based AOD treatment services in line with community need. This funding is delivered through the Australian Government's *Drug and Alcohol Program,* and aims to improve the access to, and effectiveness of drug and alcohol treatment services in the community.
- Data presented in the dashboards are from all publicly funded alcohol and other drug (AOD) treatment services (which include PHN-commissioned services) that have reported to the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS).
- AOD treatment agencies funded by their PHN under the Australian Government Department of Health's Drug and Alcohol Program (DAP) submitted data to the AODTS NMDS for the first time in 2016–17.
- In these dashboards, data are presented from the 2017–18 collection year to show the trends in each PHN prior to the establishment of the boundaries.
- Financial year data from agencies include treatment episodes that ended within the period (closed treatment episodes) and excludes those that were ongoing or new (not closed) within the reporting year.

Agencies dashboard:

- The PHN of the agency was assigned based on the Statistical Area Level 2 (SA2) of the treatment agency using the Australian Bureau of Statistics' (ABS) SA2 2016 to Primary Health Network 2017 concordance file.
- As SA2 2016 boundaries may not correspond to PHN 2017 boundaries, some agencies may be captured in a neighbouring PHN including those in a neighbouring jurisdiction.

Main treatment for client dashboards:

- The PHN of the client was based on the postcode of the client using the Australian Bureau of Statistics' (ABS) Postal Area 2021 to Primary Health Network 2017 concordance file. Clients reporting an invalid postcode were assigned: 'PHN Unallocated' and removed from analysis. In 2021–22, 6,922 records contained invalid postcodes. Correspondence mappings may change over time and data may differ from what was previously published. The numbers presented here may also not correspond to those presented elsewhere based on this correspondence.
- Results with cell sizes less than 5 have been presented as '<5' (in some cases the value is null), due to this adjustment some values may not sum to the total or 100%.
- Data collection and reporting practices in Western Australia and Victoria are not directly comparable with data for other jurisdictions because every treatment type provided is reported as a separate episode.

Client demographics dashboard:

- Client numbers are based on records with a valid statistical linkage key (SLK-581).
- Client numbers are not comparable to client data published in the AODTS in Australia 2022–23 report. These dashboards include clients who attended treatment in multiple PHN locations in the collection year. The sum of clients across the 31 PHN levels is greater than the state/territory results due to finer geographic granularity of PHNs compared to the state/territory level. The sum of clients across PHNs is also greater than the national distinct client total for 2022–23, which reflects the number of clients treated, irrespective of whether they received treatment in multiple locations.

Principal drug of concern dashboards:

- The PHN of the client was based on the postcode of the client using the Australian Bureau of Statistics' (ABS) Postal Area 2021 to Primary Health Network 2017 concordance file. Clients reporting an invalid postcode were assigned: 'PHN Unallocated' and removed from analysis. In 2021–22, 6,393 records contained invalid postcodes. Correspondence mappings may change over time and data may differ from what was previously published. The numbers presented here may also not correspond to those presented elsewhere based on this correspondence.
- Results with cell sizes less than 5 have been presented as '<5' (in some cases the value is null), due to this adjustment some values may not sum to the total or 100%.

Jurisdiction-specific notes:

- Victoria reported comparatively high incidences of 'Not stated drugs' (15%) as the drug of concern. This is in part due to service providers adjusting to changes in reporting practices associated with the implementation of a new data collection system in 2019–20. In 2020–21, these drugs of concern were coded as 'Other drugs of concern' (14%) to realign with previous coding practices for Victoria. Victoria is working with service providers to encourage more specific reporting of drug of concern.
- In Queensland, the proportion of cannabis episodes reported as the principal drug of concern is a result of the Police Drug Diversion Program, Illicit Drugs Court Diversion Program and Drug and Alcohol Assessment Referral Program (DAAR) operating in the state.
- South Australia reports a high proportion of treatment episodes where amphetamines are the principal drug of concern due to the SA Police Drug Diversion Initiative (PDDI). In addition, adult cannabis offences are not included in the PDDI due to the SA Cannabis Expiation Notice legislation.
- In the Australian Capital Territory, removal of criminal penalties for possession of small quantities of cannabis in the ACT at the end of January 2020 reduced the number of cannabis-related diversions recorded as treatment episodes to low levels (mainly under-18s). Data collection improvements at government-operated services resulted in fewer 'not stated' responses in the 2022–23 collection.

Australian Government
Australian Institute of Health and Welfare

Pharmacotherapy in Australia

AODTS NMDS

The Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) visualisations are based on episode data reported during the 2022–23 collection cycle and contains information on treatment provided to clients by publicly funded alcohol and other drug (AOD) treatment services. Only episodes where pharmacotherapy was an additional treatment, or a main treatment with an additional treatment provided are included in the AODTS NMDS. Episodes where pharmacotherapy and no additional treatment was provided are excluded.

NOPSAD collection

The National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD) Collection visualisations are based on client data reported on a snapshot day in June 2023. This collection contains information on clients receiving opioid pharmacotherapy treatment, prescribers of opioid drugs and the dosing points that clients attend to receive their medication.

Notes

Amendments

4 October 2024

Footnotes have been amended in *Data tables: 2022–23 SCR.Clients rates and multiple years* (specifically *Tables SCR.26a-c*), found on the Data page and in *Figure FIRST NATIONS 1* and *Figure FIRST NATIONS 3*, found on the Aboriginal and Torres Strait Islander (First Nations) people page. This was done to note that 2016 Census was used to derive population rates for First Nations and Non-Indigenous Australians (not the 2021 Census).

8 July 2024

In *Data tables: 2022–23 Primary Health Network (PHN) geography (episodes),* the column width has been expanded in table *PHN AODTS NMDS Clients 7*, so that the 'Non-Indigenous Australians' column title displays correctly.

Acknowledgements

The authors of this report were Jennifer Zhou, Owen Croker, Willow Bryant and Kristina Da Silva from the Tobacco, Alcohol and Other Drugs Unit of the Australian Institute of Health and Welfare (AIHW).

The authors gratefully acknowledge the contributions, comments and advice of the Alcohol and Other Drug Treatment Services National Minimum Data Set Working Group.

The AIHW thanks the numerous alcohol and other drug treatment service agencies that provided data for this report. Without the cooperation of the staff in these agencies in each state and territory, this data collection and report would not be possible.

The Department of Health and Aged Care provided funding for this report.

Thanks are extended to the data managers and staff in the following departments:

- Department of Health and Aged Care, Australian Government
- Ministry of Health, New South Wales
- Department of Health, Victoria
- Department of Health, Queensland
- Mental Health Commission, Western Australia
- Department of Health and Wellbeing, South Australia
- Department of Health, Tasmania
- Health Directorate, Australian Capital Territory
- NT Health, Northern Territory

Data quality statement

AODTS NMDS 2022–23 Data quality Statement - external site opens in new window

Data

Data cubes (*Alcohol and other drug treatment services in Australia: early insights*)

Data tables: 2022–23 Agcy.Agency (episodes)

Data
XLS 112kB

Data tables: 2022–23 SC.Clients (national)

Data
XLS 219kB

Data tables: 2022–23 SC.Clients (state and territories)

Data
XLS 1.1MB

Data tables: 2022–23 SCR.Clients rates and multiple years

Data
XLS 147kB

Data tables: 2022–23 Drg.Drugs (episodes)

Data
XLS 4.1MB

Data tables: 2022–23 OV.Overview (episodes)

Data
XLS 177kB

Data tables: 2022–23 ST.State and territories (episodes)

Data
XLS 6.6MB

Data tables: 2022–23 Trt.Treatment (episodes)

Data
XLS 2.9MB

Data tables: 2022–23 Primary Health Network (PHN) geography (episodes)

Data
XLS 340kB

Data tables: 2022–23 SCR.Clients (state and territories numbers)

Data
XLS 2.6MB

Report editions

This release

Alcohol and other drug treatment services in Australia annual report | 14 Jun 2024

Previous releases

- Alcohol and other drug treatment services in Australia 2018–19 | **Publication** | 26 Jun 2020
- Alcohol and other drug treatment services in Australia 2017–18 | **Publication** | 25 Jul 2019
- Alcohol and other drug treatment services in Australia 2016–17 | **Publication** | 22 Jun 2018
- Alcohol and other drug treatment services in Australia 2015–16 | **Publication** | 28 Jun 2017
- Alcohol and other drug treatment services in Australia 2014–15 | **Publication** | 15 Jun 2016
- Alcohol and other drug treatment services in Australia 2013–14 | **Publication** | 18 Jun 2015
- Alcohol and other drug treatment services in Australia 2012-13 | **Publication** | 12 Aug 2014
- Alcohol and other drug treatment services in Australia 2011-12 | **Publication** | 28 Aug 2013
- Alcohol and other drug treatment services in Australia 2010-11: report on the National Minimum Data Set | **Publication** | 16 Nov 2012

Related material

Resources

Alcohol and other drug treatment services in Australia: early insights

Resource

High-level information for 2022–23 about publicly funded AOD treatment services, the people they treated, and the treatment provided. This report includes data cubes.

Alcohol, tobacco & other drugs in Australia

Resource

Key trends in availability, consumption, harms and treatment of alcohol, tobacco and other drug use for vulnerable populations.

National Opioid Pharmacotherapy Statistics Annual Data collection

Resource

Information about the clients who access opioid pharmacotherapy, the health professionals who provide pharmacotherapy, and dosing points.

National Drug Strategy Household Survey 2022–2023

Resource

Information about drug use trends over time, how these patterns have changed over time and opinions on a range of initiatives designed to reduce the harm caused by tobacco, alcohol and illicit drug use.

Trends in cannabis availability, use, and treatment in Australia, 2013–14 to 2021–22

Resource

Cannabis is the most widely used illegal drug in Australia, with 2.5 million people in 2022–2023 having used it in the previous 12 months. Between 2013–14 and 2021–22, 221,000 clients received treatment for their cannabis use from publicly-funded drug treatment agencies. This report draws together data from multiple sources to describe trends in cannabis availability, use and treatment in Australia, including the characteristics of people who use or receive treatment for cannabis.

Completion of alcohol and drug treatment in Australia, 2011–12 to 2020–21: differences by drugs of concern and treatment characteristics

Resource

Understanding how clients leave specialist alcohol and other drug (AOD) treatment provides insights into how clients and AOD services engage with each other. Between 1 July 2013 and 30 June 2021, 228,500 people sought specialist AOD treatment for either alcohol or amphetamines. Of the 648,400 treatment episodes provided to these clients across this 8 year period, 1 in 4 episodes did not end as planned. This report examines how the likelihood of planned completion varies by treatment characteristics such as drug type (alcohol compared to amphetamines), main treatment and client remoteness.

Patterns of intensive alcohol and other drug treatment service use in Australia, 1 July 2014 to 30 June 2019

Resource

Clients accessing alcohol and other drug treatment services often receive multiple episodes of treatment, with some clients requiring more intensive treatment to achieve their goals. This report describes 3 distinct client cohorts based on their patterns of treatment service use between 1 July 2014 and 30 June 2019. Clients who received intensive treatment were more likely than other cohorts to report receiving treatment for multiple principal drugs of concern and for more main treatment types across episodes.

Patterns of alcohol and other drug treatment service use in Australia, 1 July 2014 to 30 June 2018

Resource

Clients accessing alcohol and other drug treatment services across Australia commonly have multiple episodes of treatment spanning several years. This report categorises 3 client groups based on their patterns of service use between 1 July 2014 and 30 June 2018. While there were subtle differences in principal drug of concern and some aspects of service use between the 3 groups, overall there were many similarities. This highlights the complexities of characterising alcohol and other drug service users.

Alcohol and other drug use in regional and remote Australia: consumption, harms and access to treatment 2016–17

Resource

This report identifies trends and differences in alcohol and other drug use, harms and treatment in Major cities and Regional and remote Australia. The consumption of alcohol at levels placing people at risk of alcohol-related harm was higher for clients in Regional and remote Australia compared with those in Major cities. While the consumption of illicit drugs was similar for clients in Major cities and Regional and remote areas, the type of illicit drug used varied. Clients in Regional and remote areas were more likely than those in Major cities to travel 1 hour or longer to access services.

Trends in methylamphetamine availability, use and treatment, 2003–04 to 2013–14

Resource

There have been several corresponding trends in the availability, use and treatment of methylamphetamines since 2003–04. Following a decline between 2006–07 and 2009–10, there have been increases across many factors relating to methylamphetamines to 2013–14. Arrests, seizures and detections have all increased. Users are now favouring the crystal form of methylamphetamine. They are using it more frequently, and, there appear to be more new users of crystal. There are more people in treatment reporting smoking as their usual method of use for amphetamines than previously.

Related topics

- Alcohol & other drug treatment services

Archived content

Alcohol and other drug treatment services in Australia annual report 2021–22

Resource from report: Alcohol and other drug treatment services in Australia annual report | *14 Jun 2024*

In 2021–22, around 131,000 people aged 10 and over received treatment from alcohol and other drug treatment services. The four most common drugs that led clients to seek treatment were alcohol (42% of episodes), amphetamines (24%), cannabis (19%) and heroin (4.5%). The median age of clients was 37 years.
PDF 12.7MB

Alcohol and other drug treatment services in Australia annual report 2020–21

Resource from report: Alcohol and other drug treatment services in Australia annual report | *14 Jun 2024*

In 2020–21, around 139,300 clients aged 10 and over received AOD treatment. The four most common drugs that led clients to seek treatment were alcohol (37%), amphetamines (24%), cannabis (19%) and heroin (4.6%). The median age of clients was 35 years.
PDF 10MB

Alcohol and other drug treatment services in Australia annual report 2019-20

Resource from report: Alcohol and other drug treatment services in Australia annual report | *14 Jun 2024*

In 2019–20, around 139,300 clients aged 10 and over received AOD treatment. The four most common drugs that led clients to seek treatment were alcohol (34%), amphetamines (28%), cannabis (18%) and heroin (5.1%). The median age of clients was 35 years. Early responses of AOD services to the COVID-19 pandemic are seen in the last quarter of 2019–20, impacting some treatment types and service delivery settings.
PDF 3.9MB